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Summary 
 
I 
Summary 
 
Buruli ulcer (BU) is a neglected tropical disease of the skin and subcutaneous tissue 
caused by infection with Mycobacterium ulcerans. The disease has been reported from 
over 30 countries worldwide with the highest prevalence in rural areas of West African 
countries. Clinically, M. ulcerans disease presents in different forms, ranging from small 
non-ulcerative nodules to large ulcers. The pathology of BU is largely attributable to the 
production of mycolactone, a lipid-like macrolide exotoxin with cytotoxic and 
immunosuppressive characteristics. Although mycolactone-induced cytotoxicity and 
tissue necrosis are the key elements of BU pathogenesis, the molecular mechanisms 
underlying these processes remained to be elucidated.  
Within the framework of this PhD thesis, we could show that mycolactone binds to the 
12-kDa FK506-binding protein and acts as a potent inhibitor of both mTORC1 and 
mTORC2. Inhibition of mTORC2 results in inactivation of Akt and dephosphorylation 
and activation of the Akt-targeted transcription factor FoxO3. Subsequent up-regulation 
of the FoxO3 target gene Bim, a pro-apoptotic member of the Bcl-2 protein family, was 
observed both in vitro and in human BU lesions. Moreover, Bim knockout mice were able 
to contain M. ulcerans infection and did not develop necrotic lesions with large clusters 
of extracellular bacilli typical for BU, highlighting the pivotal role of Bim-promoted 
apoptosis for BU pathogenesis.  
In addition, we aimed at characterizing the nature of immune defense mechanisms 
conferring protection against BU. Specifically, we focused on the role of interferon-γ and 
of cellular immune effector mechanisms during the early intracellular stage of M. 
ulcerans infection. We could show that interferon-γ is critical for early host immunity 
against M. ulcerans, since mice lacking this cytokine showed a faster increase in bacterial 
burden and an accelerated pathogenesis, indicative of a reduced capacity to kill the 
bacilli during the early intracellular stage of the infection.  
Finally, we evaluated the activity of the new tuberculosis drug candidate Q203 against 
M. ulcerans using the BU mouse foot pad infection model. In this project, we were able to 
demonstrate that Q203 has a higher activity against M. ulcerans than rifampicin, and 
might therefore be suited to replace rifampicin as the first line therapeutic option in the 
future.
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Zusammenfassung 
 
Buruli Ulkus (BU) ist eine vernachlässigte Erkrankung der Haut und des 
Unterhautgewebes, welche durch Infektion mit Mycobakterium ulcerans verursacht 
wird. Die Tropenkrankheit wurde weltweit in über 30 Ländern nachgewiesen, mit der 
höchsten Prävalenz in ländlichen Gebieten einiger westafrikanischer Länder. Klinisch 
präsentiert sich BU mit einem breiten Spektrum an Krankheitsbildern, welche von 
geschlossenen Läsionen bis hin zu offenen Ulzera reichen. Die Pathologie der Krankheit 
ist eng assoziiert mit der Produktion von Mykolacton, einem fettähnlichen 
Makrolidtoxin, welches zytotoxische und immunsuppressive Eigenschaften besitzt. 
Obwohl die Mykolacton-induzierte Zytotoxizität und die daraus resultierende 
Gewebenekrose für die Pathogenese der Krankheit von zentraler Bedeutung sind, 
mussten die zugrundeliegenden molekularen Mechanismen erst noch entschlüsselt 
werden.     
Im Rahmen der vorliegenden Doktorarbeit konnten wir zeigen, dass Mykolacton an das 
12-kDa FK506 Bindungsprotein bindet und dabei als potenter Inhibitor der beiden 
mTOR Komplexe wirkt. Die Inhibition vom mTOR Komplex 2 resultiert in der 
Inaktivierung der Kinase Akt und in der anschliessenden Dephosphorylierung und 
Aktivierung des von Akt regulierten Transkriptionsfaktors FoxO3. Die darauffolgende 
Hochregulation der Expression des FoxO3-regulierten Genes Bim, einem pro-
apoptotischen Mitglied der Bcl-2 Proteinfamilie, wurde sowohl in vitro als auch in 
humanen BU Läsionen beobachtet. Des Weiteren konnten wir zeigen, dass Bim 
Knockout Mäuse fähig sind, Infektionen mit M. ulcerans zu kontrollieren und dass sie 
keine der für BU typischen nekrotischen Läsionen mit grossen Akkumulationen von 
extrazellulären Bakterien entwickeln, was die entscheidende Rolle der Bim-abhängigen 
Apoptose für die Pathogenese von BU unterstreicht.  
Ein zusätzliches Ziel dieser Doktorarbeit war es, die Immunabwehr-Mechanismen, 
welche zum Schutz vor BU beitragen, genauer zu charakterisieren. Ein spezifischer 
Fokus lag dabei auf der Rolle von Interferon-γ und auf den zellulären 
Immuneffektormechanismen während der frühen intrazellulären Phase der Infektion 
mit M. ulcerans. Dabei konnten wir zeigen, dass Interferon-γ für die frühe Immunabwehr 
gegen M. ulcerans wichtig ist, da wir bei Interferon-γ-defizienten Mäusen eine schnellere 
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Zunahme der Bakterienlast und einen beschleunigten Krankheitsverlauf beobachtet 
haben, was darauf hinweist, dass die Fähigkeit dieser Tiere, intrazelluläre Bakterien 
während des frühen Stadiums der Infektion zu bekämpfen, reduziert ist.   
Des Weiteren testeten wir die Aktivität von Q203, einem möglichen neuen Medikament 
zur Behandlung der Tuberkulose, in einem BU Mausmodell. Hierbei konnten wir zeigen, 
dass Q203 eine höhere Aktivität gegen M. ulcerans besitzt als Rifampicin und daher 
geeignet sein könnte, Rifampicin in der Zukunft als Primärtherapie zu ersetzen. 
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Introduction 
 
Buruli ulcer (BU) is a chronic necrotizing disease of the skin and subcutaneous tissue 
caused by infection with Mycobacterium ulcerans (M. ulcerans), a relative of 
Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium leprae (M. leprae), the 
two causative pathogens of tuberculosis and leprosy, respectively. M. ulcerans is unique 
in the sense that it produces mycolactone, a cytotoxic and immunosuppressive lipid-like 
macrolide exotoxin responsible for the pathophysiology of the disease [1,2]. After a long 
time of disregard, the World Health Organization (WHO) recognized BU in 1998 as an 
emerging health problem and consequently launched the Global Buruli Ulcer Initiative 
(GBUI) aiming to intensify and coordinate the control and research activities of this 
devastating skin disease [3]. 
Despite intensified research efforts during the last 15 years, many of the central 
molecular mechanisms underlying the pathogenesis of BU still remain obscure and a 
practical and well-tolerated anti-BU treatment is not available.   
 
 
History and epidemiology of Buruli ulcer 
The first report on BU was published in 1948 by MacCallum et al. describing the clinical 
symptoms of six patients with ulcerative lesions of the skin in the Bairnsdale district in 
Australia. In the same study, the disease causing pathogen, later referred to as 
Mycobacterium ulcerans (M. ulcerans), was isolated from one of the lesions and 
described as a bacterium with a lower optimal growth temperature than M. tuberculosis 
[4]. A few years later, the Buruli County in Uganda was identified as a hot-spot of the 
disease and from this time onwards the disease became more generally known as Buruli 
ulcer (BU) [5]. In the 1970’s, cases were also reported from various other places in 
Africa including regions that nowadays belong to Cameroon, Nigeria and the Democratic 
Republic of the Congo [6–8]. Since then, BU has been widely distributed and is today 
reported from over thirty countries worldwide. It affects South East Asian countries 
such as Indonesia, Papa New Guinea and Malaysia as well as countries in Central and 
South America including Mexico, Peru or Suriname [9,10]. After tuberculosis and 
leprosy, BU is considered to be the third most common mycobacterial disease 
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worldwide, however, in some high burden West African countries, the disease is more 
prevalent than leprosy [11,12]. In 2014, there were 2200 new cases of BU worldwide 
which is most likely an underestimation of the exact numbers since only 12 of the 
affected 33 countries reported data to the WHO (Figure 1) [13]. In addition, the remote 
locations of most endemic areas and as a consequence the limited access of many of the 
patients to the health care systems may potentiate this underestimation [11]. 
 
 
 
Figure 1: Geographical distribution of BU in 2014 [13]. 
 
Although BU affects people at all ages, most of the patients are children between the age 
of 4 and 15 years [9]. No gender differences in BU incidence have been observed among 
children and adults [14]. About 80 % of the ulcers are found on the limbs, most of them 
are located on the lower extremities [9]. 
In BU endemic countries, the disease mostly occurs close to wetlands with slow-flowing 
water courses or stagnant water. In several countries including Nigeria, Liberia or 
Australia, the emergence of the disease has been attributed to environmental 
disturbances in water management, for example for energy production, agriculture or 
mining [14]. 
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Evolution, reservoir and transmission of M. ulcerans 
It is assumed that M. ulcerans has evolved from a common progenitor of Mycobacterium 
marinum (M. marinum), an intracellular environmental bacterium living in aquatic 
niches, occasionally causing relatively minor granulomatous skin lesions in humans 
[15,16]. Like M. ulcerans, M. marinum optimally grows at 28 °C – 32 °C but only poorly at 
37 °C [16]. The close relationship of M. ulcerans and M. marinum was identified using 
comparative genomics showing that the two species share over 98 % of genomic DNA 
sequence identity. Moreover, it was proposed that all M. ulcerans strains diverged from a 
common M. marinum progenitor [15,17]. During the evolutionary divergence from M. 
marinum, M. ulcerans has undergone some major genetic changes. Firstly and probably 
most importantly, M. ulcerans has acquired a 174 kb virulence plasmid called pMUM 
through horizontal gene transfer. This plasmid encodes the polyketide synthases 
required for the production of the macrolide exotoxin mycolactone, the only virulence 
factor of M. ulcerans identified to date [18,19]. Secondly, M. ulcerans has integrated the 
two insertion sequence elements IS2404 and IS2606 into its genome. While these two 
elements are absent in M. marinum, they have been expanded to high copy numbers in 
the genome of M. ulcerans, constituting the molecular target for the most sensitive 
method of BU diagnosis, the polymerase chain reaction (PCR) [20]. The genomic 
expansion of IS2404 to 213 copies and of IS2606 to 91 copies resulted in the disruption 
of over 110 genes, extensive pseudogene formation, genomic rearrangement and 
genome reduction [2,21]. The evolution of the M. ulcerans genome indicates that this 
pathogen underwent a series of adaptions allowing its transition from an environmental 
to a host-adapted niche [21]. For example, the acquisition of the immunosuppressive 
toxin mycolactone, the loss or modification of cell wall antigens, the slow replication 
time of around 72 hours as well as the thermosensitivity of M. ulcerans altogether favor 
a long-term survival in a mammalian host [21–23]. 
During the evolution, two different but closely related lineages of M. ulcerans causing 
human disease have emerged. The so-called ancestral lineage of is more closely related 
to M. marinum and causes only sporadic disease in China, Japan, Mexico and South 
America. In contrast, BU in Africa, Australia and South East Asia is primarily caused by 
the classical lineage of M. ulcerans containing the most pathogenic genotypes, resulting 
in a higher prevalence in these countries [24]. Strains of these two lineages are, together 
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with the few other mycolactone-producing mycobacteria (MPM) including the fish and 
frog pathogens, commonly known as M. ulcerans [25]. 
Despite intensive research in the last few years, the reservoir and the exact mode of 
transmission of M. ulcerans still remain unclear [9]. Like its progenitor M. marinum, M. 
ulcerans is considered as an environmental bacterium and its DNA has been detected in 
the environment [26,27]. In addition, research has focused on invertebrates or 
vertebrates as potential animal reservoirs and indeed M. ulcerans DNA has been 
detected in animals such as water bugs and aquatic snails [9,23]. Since then, mainly 
water bugs were suspected to play a major role in the transmission of BU, however, their 
role still remains questionable as these insects rarely bite humans [9,28,29]. In 
Australia, possums with skin lesions caused by M. ulcerans have recently been identified 
as a potential mammalian reservoir and mosquitos as possible vectors [30,31]. While 
possums represent a potential animal reservoir for M. ulcerans in Australia, a 
comparable animal reservoir could not be identified in Africa [32,33]. Furthermore, the 
mode of transmission from a potential animal reservoir or from the environment to 
humans is still unclear and several possibilities such as an involvement of insect bites or 
a direct transmission from an environmental reservoir to humans, for example after skin 
trauma, have been discussed [9].  
 
 
Pathogenesis of Buruli ulcer 
The pathogenesis of BU entirely relies on the presence of the cytotoxic and 
immunosuppressive macrolide toxin mycolactone [1]. Due to the low optimal growth 
temperature of the bacteria and hence a strong tropism for the skin, BU is 
predominantly a disease of the skin and the subcutaneous fat tissue with very restricted 
systemic dissemination. Furthermore, the disease progresses only slowly, probably as a 
result of the long generation time of M. ulcerans [34].  
The first clinical sign of the disease is typically a movable, subcutaneous nodule which 
can be observed after an estimated incubation time of 2 to 3 months (Figure 2, A). From 
this initial nodular stage, the disease may develop into a non-ulcerative plaque or 
oedema (Figure 2, B and C, respectively). As the infection progresses, a massive 
destruction of the subcutaneous adipose tissue can be observed, resulting in the collapse 
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of the epidermis and the formation of characteristic ulcers with undermined edges 
(Figure 2, D) [2,34]. Complementary to these descriptions, the WHO introduced a 
classification system which is primarily based on the size of the lesions. Lesions grouped 
into category I are smaller than 5 cm in diameter whereas lesions with a diameter of 5 – 
15 cm are classified into category II. Category III finally contains lesions with a diameter 
of over 15 cm, lesions in the region of head and neck, mixed forms such as osteomyelitis, 
lesions with involvement of joints and disseminated forms of the disease [35]. 
Interestingly, BU lesions are often described as painless and it was speculated for a long 
time whether this analgesic effect might be the result of the local destruction of nerve 
fibers [36]. However, a recent study indicates the painless nature of BU lesions most 
likely comes from mycolactone-induced signaling through angiotensin type II receptors 
(AT2R), resulting in neuronal hyperpolarization and analgesia [37]. 
 
 
Figure 2: Illustration of the typical clinical presentations of the three non-ulcerative BU 
forms, the nodule (A), the plaque (B) and the oedema (C). In (D), a medium sized ulcer is 
shown as an example for the open forms of BU [35]. 
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After the infection and an early intramacrophage growth phase, it is assumed that small 
clusters of acid-fast bacilli (AFB) are formed which produce a protective cloud of 
mycolactone, preventing their elimination by infiltrating immune cells. With the 
proliferation of the AFB and increasing mycolactone concentrations, a central necrotic 
area  develops and infiltrating immune cells are killed by the toxin [34,38–41]. 
Additional histopathological hallmarks of BU are the presence of fat cell ghosts, 
epidermal hyperplasia and the absence of significant cellular infiltration [34,42]. 
However, this immunosuppressive phenotype of active BU lesions is reverted during 
antibiotic treatment into an inflammatory phenotype characterized by extensive 
infiltration of lymphocytes, macrophages and Langhans’ giant cells as well as by the 
presence of intracellular bacteria and of bacterial debris in phagocytic cells. In addition, 
the formation of granulomatous and organized lymphoid structures can be observed 
during antibiotic treatment [11,14,40]. 
 
 
Cellular effects of mycolactone 
The existence of a virulence factor produced by M. ulcerans was already postulated in 
the 1960’s, however, it was not until 1999 that mycolactone could be isolated by the 
group of Pamela Small [1,43]. Mycolactone is a polyketide macrolide-lipid like molecule 
and the only virulence factor identified of this pathogen to date [2]. In the last few years, 
the availability of synthetic mycolactone, which seems to have identical biological 
properties as the natural A/B forms purified from bacterial cultures, has facilitated the 
research on this molecule [44–47]. 
The production of mycolactone is essential to the pathophysiology of BU as it causes the 
two determining characteristics of the ulcers: extensive cytotoxicity and pronounced 
immunosuppression [2]. The prominent role of mycolactone for BU pathogenesis is 
further supported by studies showing that intradermal injection of the toxin is sufficient 
to induce the formation of BU-like lesions in animal models and that mycolactone-
deficient M. ulcerans mutants are not virulent [1,41]. 
Mycolactone consists of a 12-membered lactone core and an upper and a lower 
polyketide side chain (Figure 3) [1], rendering the molecule highly hydrophobic and 
thus it is thought that mycolactone enters mammalian cells by passive diffusion [48]. 
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Using a fluorescent mycolactone derivative it was demonstrated that the toxin localizes 
to the cytosol, pointing to the presence of a cytosolic receptor for mycolactone [48]. In 
active BU lesions, it is assumed that mycolactone is largely retained in the extracellular 
matrix formed around the bacterial colonies [49]. 
 
 
 
Figure 3: Chemical structure of the M. ulcerans virulence factor mycolactone A/B. 
 
The production of mycolactone is dependent on the 174 kb virulence plasmid pMUM 
that is present in all MPM. This plasmid encodes the polyketide synthases required for 
the synthesis of the toxin [18]. Six different variants of mycolactones named A to F have 
been described so far which differ in their potency and their geographical distribution. 
The most virulent M. ulcerans strains from Africa mainly produce mycolactone A/B, the 
most potent form of the toxin. Mycolactone A/B is composed of a 3:2 ratio of the Z-/E- 
isomers of the C-4-C-5 bond in the lower side chain. Mycolactone C and D on the other 
hand are less potent and the predominant mycolactone species produced by the 
Australian and Asian strains, respectively [47,50]. In addition to these variants produced 
by the human pathogenic strains of M. ulcerans, mycolactone E and F are produced by 
the fish pathogen and frog pathogens which have been previously also referred to as M. 
pseudoshottsii and M. liflandii [51–53]. Importantly, all of these mycolactones contain the 
same lactone core but possess a lower side chain that varies in length, position of the 
double bonds and in the number and position of hydroxyl groups, resulting in different 
cytotoxicities [53,54]. This suggests that the lower side chain of mycolactone is largely 
responsible for the biological activity of the molecule, which was recently confirmed in 
structure-activity relationship studies using different synthetic mycolactones [47].  
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Although mycolactone was not yet identified in the late 1970’s, it was already known at 
this time that sterile filtrates of M. ulcerans cultures contained a highly cytotoxic 
substance that induced the rounding up, detachment and cell death of L929 fibroblasts 
[55]. Today, L929 fibroblasts are still the most sensitive cell type identified and are 
frequently used as a reporter cells. Furthermore, it was shown for the same cell line that 
mycolactone induces cell cycle arrest at the G1/G0 phase [1]. Interestingly, different cell 
types show different susceptibilities to mycolactone-induced cytotoxicity and die after 
different times of exposure. For instance, while immature dendritic cells are rather 
sensitive and die within the first 48 hours of mycolactone treatment, J774 macrophages 
and Jurkat T-cells are more resistant and only die after prolonged incubation times [56–
58]. Although mycolactone cytotoxicity is absolutely central for the pathogenesis of BU, 
the molecular mechanisms underlying this process still remain obscure. 
In contrast to mycolactone-induced cytotoxicity, much more is known about the 
mycolactone-mediated immunosuppression, the second functional feature of the toxin. 
It is known that mycolactone modulates local and systemic immune responses [59,60], 
for example by blocking the activation of different immune cells including T-cells, 
dendritic cells, monocytes and macrophages [56,58,61,62], by interfering with T-cell 
homing [63], or by reducing the expression of T-cell receptors as well as co-stimulatory 
molecules including CD40 and CD86 [56,58]. Furthermore, mycolactone interferes with 
the phagocytic activity of macrophages [59,60] and the ability of monocytes, 
macrophages and dendritic cells to produce the cytokine tumor necrosis factor alpha 
(TNFα) [61,62,64,65]. Additionally, the production of various other cytokines including 
interleukin (IL)-6, IL-8 and IL-10 is strongly reduced in both primary human monocytes 
and macrophages as result of mycolactone exposure [61]. Interestingly, this almost 
complete loss of proteins responsible for a proper functioning of immune system might 
be explained by a recent study showing that mycolactone interferes with protein 
translocation into the endoplasmatic reticulum (ER), leading to the degradation of 
nearly all glycosylated and secreted proteins [66].    
Finally, the well-characterized cytoskeletal rearrangements observed in mycolactone-
treated cells have recently been associated with uncontrolled ARP2/3-mediated actin 
polymerization as a result of mycolactone-induced activation of members from the 
Wiskott-Aldrich syndrome protein family (WASP) of actin regulators [67]. 
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Immune responses against M. ulcerans 
There is only limited data on the development of immune responses against M. ulcerans 
and it is not entirely clear to which extent mycolactone might interfere. In Tuberculosis 
(TB) endemic areas where Bacille Calmette-Guérin (BCG) vaccination is frequent, the 
analysis of M. ulcerans-specific immune responses is further complicated by the broad 
cross-reactivity of M. ulcerans antigens with antigens from M. tuberculosis and M. bovis  
[40]. In studies using filtrates from M. ulcerans cultures Immunoglobulin (Ig) G and IgM 
antibody responses were found in sera of BU patients. However, they could also be 
identified in TB patients as well as in BCG-vaccinated individuals [68,69]. In BU non-
endemic areas, the highly immunogenic 18 kDa small heat shock protein of M. ulcerans 
which has also a homologue in M. leprae but not in M. tuberculosis and M. bovis was 
successfully used in seroepidemiological studies to distinguish between BU patients and 
healthy household contacts [70]. However, the sera from some people living in BU 
endemic areas who did not develop active disease also contained M. ulcerans-specific 
IgG, indicating the generation of protective humoral responses in exposed, but 
otherwise healthy individuals [70–72]. This is in line with findings from reports on 
spontaneous healing of BU patients [73,74]. 
On the other hand, it was reported that the control of M. ulcerans infection may be 
predominantly dependent on a TH1 cellular immune response [2,40]. Indeed, the TH1-
specific cytokine interferon-γ (IFNγ) was found to be strongly expressed in both nodules 
and ulcers of human BU patients, suggesting that a TH1 response might be induced at an 
early stage of infection [75]. Furthermore, spontaneous healing is often correlated with 
a positive delayed hypersensitivity against M. ulcerans antigens, indicative of cell-
mediated immunity [68,76]. 
 
 
Diagnosis and Treatment 
For the laboratory diagnosis of BU, there are currently four methods available. At rural 
treatment centers, microscopy can be used for direct smear examination from wound 
exudates stained with Ziehl-Neelsen/Methylene blue (ZN) to detect AFB. This method is 
easily applicable and delivers rapid results. However, it has a low sensitivity, does not 
show whether the bacilli are viable or not and cannot discriminate between BU and 
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cutaneous tuberculosis [77,78]. The other three methods require more sophisticated 
equipment which is often only available in bigger hospitals or in reference laboratories. 
Today, the gold standard for BU diagnosis is a polymerase chain reaction (PCR) 
targeting the genomic multi-copy insertional sequence 2404 (IS2404), since it has the 
highest sensitivity and specificity of all four methods [77]. However, stringent quality 
control measures should be implemented on a regular basis to ensure the accuracy of 
the obtained PCR results as issues with false-positivity or false-negativity have been 
raised [20,79]. 
In vitro cultivation of M. ulcerans is the only possibility allowing the discrimination 
between viable and non-viable organisms and can additionally be used for monitoring 
the treatment efficiency and the development of drug resistance. However, the slow 
growth of the bacteria and the low sensitivity restrict the use of this method for 
immediate patient care [77]. 
Histopathology requires highly trained personnel performing invasive sampling 
procedures in the form of patient biopsies. In addition to supporting the diagnosis, this 
technique can be used for studying treatment response and wound healing and can 
provide new mechanistic insights into disease pathogenesis by answering basic 
biological questions [20,40,41,80–82].  
According to the latest recommendations by the WHO, suspected BU cases should be 
laboratory confirmed by at least one of the four methods introduced above. Preferably, 
positive results from two different tests should be obtained to minimize misdiagnosis 
based on false-positivity or false-negativity and it is recommended that at least 70 % of 
all reported cases should be laboratory confirmed by PCR [20]. 
Typical indications used for the differential diagnosis of BU are the presence of 
ulcerative lesions with undermined edges, lymphadenopathy as well as the absence of 
fever and pain [11].  
For the laboratory confirmation of BU, different sampling methods exist depending on 
the nature of the lesion (open or closed) and the diagnosis method of choice. For early 
and closed lesions, fine-needle aspiration is commonly used whereas open, ulcerative 
lesions can be swabbed with a cotton swab [20,83]. Both of these sample types can be 
used for diagnosis by microscopy, PCR and cultivation. In order to perform 
histopathological analysis, punch biopsies or surgical excisions are however required 
[20]. 
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Because of the difficult diagnosis of BU in rural settings, there is a strong need for new 
point-of-care diagnostic tests [20]. In particular, the detection of mycolactone in human 
lesions or M. ulcerans-specific antibodies would be promising approaches for the 
development of a new highly specific and easily applicable diagnostic test [84]. 
Until the implementation of antibiotic therapy in 2004 by the WHO, surgical removal of 
the infected tissue including a wide margin of healthy tissue was considered to be the 
most effective treatment of BU [35,85]. However, surgery followed by skin grafting can 
involve multiple operations and resulted in an average hospitalization of more than 3 
months [86]. Furthermore, the relapse rates after surgery without the combination of 
antibiotic therapy were still in the range of 20 % [87].  
It was already known from studies performed in the 1970’s that rifampicin can be used 
to effectively treat small BU lesions [11]. However, it was not before 2004 when the 
WHO started to recommend antibiotic therapy to effectively treat BU. The antibiotic 
regimen recommended by the WHO is based on a combination of oral rifampicin (10 
mg/kg) and intramuscular streptomycin (15 mg/kg) (R/S) daily during a period of 8 
weeks [88]. As a direct consequence of the introduction of the antibiotic therapy, relapse 
rates could be reduced to around 2 % and the requirement for surgical interventions has 
diminished [89,90]. However, despite the effectivity of the R/S treatment there is still a 
strong need for intensive wound care, surgical removal of necrotic tissue, for covering of 
large parts of damaged skin by skin grafting as well as for correcting deformities in 
order to prevent disabilities [11]. Although the use of R/S combination therapy seems to 
be well tolerated by the majority of patients, the therapy has the disadvantage of a daily 
need for intramuscular injections of streptomycin [85]. Hence, research efforts are 
driven towards a replacement of streptomycin with clarithromycin, a less toxic drug that 
can be orally delivered [91–94].   
Histopathological studies indicate that the production of mycolactone declines early 
after start of R/S treatment [95]. This leads to a rapid onset of local cellular immune 
responses defined by chronic leukocyte infiltration, formation of defined granulomas, 
efficient phagocytosis of extracellular bacilli and finally to clearance of the infection. 
After eight weeks of R/S treatment, most of the bacteria display a beaded appearance, 
reflecting their killing  [40,95–97]. As a consequence of the massive activation of the 
immune system during the course of antibiotic therapy, a temporary worsening of the 
status of the lesions or the development of new lesions may occur, a phenomenon called 
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“paradoxical reaction”. This can be resolved by simple wound care and does not need 
additional treatment [40,80].   
It was already noticed in the 1970`s that the application of heat might be an attractive 
approach to treat BU as M. ulcerans grows optimally at temperatures between 28 °C – 32 
°C and does not grow at temperatures above 37 °C [98,99]. This so-called thermotherapy 
has been proven an attractive and cheap alternative to the antibiotic treatment since 
application of heat is nowadays easily possible by using bags filled with phase change 
material [100]. By performing a follow-up clinical trial these promising results of the 
thermotherapy were confirmed in a larger patient cohort carried out in Cameroon [101]. 
Finally, major efforts have been undertaken for the development of a vaccine against BU 
[102,103].  
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Apoptosis   
The process of cell death is a fundamental part of life and is of great importance for the 
development of organisms as well as for the regulation of the immune system and for 
host defense against bacterial or viral infections [104]. However, excessive cell death is 
also responsible for several pathological conditions, including Parkinson’s, Alzheimer’s 
or Huntington’s disease [105].   
On account of this, it is not surprising that several forms of genetically programmed cell 
death mechanisms, so-called programmed cell death (PCD), exist. The most intensively 
studied form of PCD is apoptosis and knowledge of the mechanisms involved in this 
process was first gained during studies of the cell death occurring during the 
development of the nematode Caenorhabditis elegans [106,107].  
During apoptosis, cells undergo several biochemical and morphological changes. A key 
event happening during the onset of apoptosis is the activation of a family of cysteine 
aspartyl proteases, so-called caspases, whose proteolytic activities are essential for this 
process. Caspases are further subdivided into initiator caspases that cleave the inactive 
pro-forms of effector caspases, thereby activating them. Effector caspases cleave other 
protein substrates in the cell and are responsible for the cellular degradation [108]. 
Additionally, when undergoing apoptosis, cells start to shrink, lose their attachment to 
the surrounding, their chromatin condenses and the plasma membrane starts blebbing. 
These blebs are the progenitors of apoptotic bodies, small cytoplasmic fragments 
encapsulated in cell membranes which may contain functional organelles surrounded by 
intact plasma membranes [109–111]. Another biochemical feature of apoptotic cells is 
the presentation of phosphatidylserine, a normally inward-facing phospholipid of the 
plasma membrane, as a cell surface marker that results in efficient phagocytosis of the 
dying cell by recruited macrophages, thereby minimizing the damage to the surrounding 
tissue [112].  
Apoptosis can be triggered by two different cellular pathways, the extrinsic (death 
receptor) or the intrinsic (mitochondrial) apoptosis pathway [113,114].  
Extrinsic apoptosis is activated by clustering and binding of transmembrane receptors 
such as CD95/APO-1/Fas with its corresponding trimeric ligands, in this case APO-
1/FasL. This results in the recruitment of the adaptor molecule Fas-Associated protein 
with Death Domain (FADD) to the Fas receptor. FADD then associates with procaspase-8 
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via dimerization of the death effector domain (DED), resulting in the formation of a 
death-inducing signaling complex (DISC) and auto-catalytic cleavage of procaspase-8. 
Activated caspase-8 in turn activates other downstream caspases including caspase-3 
and caspase-7, finally leading to the destruction of the cell [110,115].  
In contrast, the intrinsic apoptosis pathway is directly activated at the mitochondria by 
non-receptor-mediated stimuli such as radiation, hypoxia or toxins that cause changes in 
the inner mitochondrial membrane resulting in an opening of the mitochondrial 
permeability transition (MPT) pore, loss of the mitochondrial membrane potential and 
release of the pro-apoptotic cytochrome c into the cytosol [116]. Cytosolic cytochrome c 
binds and activates Apaf-1, leading to the recruitment of procaspase-9 and the formation 
of an apoptosis inducing complex named apoptosome. As a consequence, procaspase-9 
is activated, resulting in the recruitment and activation of the downstream caspase-3 
and subsequent cleavage of a number of key substrates responsible for the execution of 
apoptosis [117–119].    
The mitochondrial apoptosis pathway is regulated by members of the Bcl-2 family of 
proteins which are either pro- or anti-apoptotic. For instance, Bmf, Bak and Bak are pro-
apoptotic Bcl-2 family members and Bcl-2, Bcl-xL and Bcl-w are anti-apoptotic. These 
proteins are of special relevance for the intrinsic apoptosis, as they can directly control 
the mitochondrial membrane permeability for cytochrome c, thereby determining 
whether a cell is committed to apoptosis or not [120]. 
The Bcl-2 interacting mediator of cell death (Bim), an important member of the pro-
apoptotic Bcl-2 family proteins, is alternatively spliced and as a consequence exists in a 
variety of different isoforms [121,122]. The most prominent splice variants of Bim are 
Bim-short, Bim-long and Bim-extra-long (BimS, BimL and BimEL) that are all cytotoxic 
[123]. Bim acts by binding in a heterodimeric complex to anti-apoptotic Bcl-2 family 
proteins, thereby allowing the pro-apoptotic proteins Bax and Bak to form an oligomeric 
pore in the outer mitochondrial membrane, the so-called mitochondrial apoptosis-
inducing channel (MAC) [114,124]. Furthermore, a direct interaction of Bim with Bax 
and Bak has been demonstrated, suggesting that Bim can directly activate these two 
proteins to form a MAC [125–127]. MAC formation leads to mitochondrial cytochrome c 
release, the formation of the apoptosome, activation of the initiator caspase-9, 
subsequent activation of the effector caspases-3, -6, and -7 and finally to cellular 
degradation [114].  
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The mTOR signaling pathway and its role in apoptosis 
The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine 
kinase belonging to the family of the phosphoinositide 3-kinase (PI3K)-related protein 
kinases (PIKK) [128]. mTOR is a master regulator of a number of important cellular 
processes including cell growth, metabolism, cytoskeletal organization and survival 
[129]. As such, mTOR is implicated in various disease states where cellular growth and 
homeostasis are deregulated, for example in cancer, metabolic disorders or ageing 
[128].  
mTOR interacts with several proteins to form two distinct multi-protein complexes 
named mTOR complex 1 (mTORC1) and 2 (mTORC2) (Figure 4). mTORC1 is composed 
of the catalytic subunit mTOR, the regulatory-associated protein of mTOR (Raptor), 
mLST8/GβL, Deptor and proline-rich Akt substrate 40 [130]. This complex is regulated 
by various environmental signals such as growth factors, nutrients and cellular stress 
[128]. The PI3K/Akt pathway is an important up-stream mediator of mTORC1, since it is 
the central pathway integrating external growth factors through PI3K-dependent 
activation of Akt [131]. mTORC1 controls cellular proliferation and growth by 
promoting the biosynthesis of proteins, lipids and organelles and it inhibits catabolic 
processes such as autophagy [129]. The biosynthesis of proteins is controlled by 
mTORC1 through phosphorylation of the ribosomal protein S6 kinase 1 (S6K1) and of 
the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) [132]. When 
4E-BP1 is phosphorylated by mTORC1, it dissociates from the eukaryotic translation 
initiation factor 4E, thereby allowing for the recruitment of the translation initiation 
factor to the 5’ end of the mRNAs, resulting in the start of protein translation [133]. In 
addition, phosphorylation of S6K1 by mTORC1 results in the activation of multiple 
proteins that promote translation initiation and elongation [128]. Furthermore, active 
mTORC1 signaling inhibits macroautophagy, a catabolic process induced by starvation, 
which eventually results in the destruction of the whole cell [134].  
The second complex, mTORC2, is composed of mTOR, the rapamycin-insensitive 
companion of mTOR (Rictor), mLST8/GβL, Protor, Deptor, and mammalian stress-
activated protein kinase interacting protein (mSIN1) [129]. In contrast to mTORC1, little 
is known about the up-stream regulation of mTORC2. Generally, it is thought that 
growth factors stimulate mTORC2, either directly or indirectly [128]. Originally, 
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mTORC2 was identified in Saccharomyces cerevisiae as a regulator of actin cytoskeleton 
organization, which was later also confirmed in mammalian cells [135–137]. In these 
studies it has been observed that knocking down mTORC2 components results in 
perturbed actin polymerization and cell morphology. The underlying molecular 
mechanisms are not yet fully understood, however, it is though that mTORC2 regulates 
these mechanisms by phosphorylation of the protein kinase Cα (PKCα), phosphorylation 
and relocalization of the focal adhesion-associated adaptor protein paxillin, and by the 
loading of the two Rho-GTPases RhoA and Rac1 with GTP [135,137].  
Beside the regulation of the cytoskeletal organization, mTORC2 has been implicated in 
the control of cell survival, cell proliferation and metabolism [128,129]. These processes 
are all highly dependent on the activation state of Akt, which positively regulates them 
through phosphorylation of a set of diverse proteins [138]. The activity of Akt is 
determined by the phosphorylation status at two specific sites: Ser308, which is 
targeted by phosphoinositide-dependent kinase 1 (PDK1) and Ser473, a site that has 
been demonstrated to be specifically phosphorylated by mTORC2 and required for full 
activation of this kinase [139–141]. Subsequently, several reports reconfirmed that 
mTORC2 specifically phosphorylates Akt at Ser473 by showing that ablation of mTORC2 
components blocks Akt phosphorylation at this site, resulting in impairment of the 
phosphorylation of some, but not all, Akt targets [142,143]. For instance, the 
transcription factors forkhead box O1 and 3 (FoxO1, FoxO3) are dephosphorylated upon 
depletion of mTORC2 [144]. These transcription factors are normally excluded from the 
nucleus upon phosphorylation by Akt, followed by ubiquitination and proteolytic 
degradation. In mTORC2 depleted cells, FoxO transcription factors are devoid of 
phosphorylation and as a results retained in the nucleus where they can promote 
apoptosis by inducing the expression of pro-apoptotic Bcl-2 family proteins such as Bim 
or by activating cell-extrinsic apoptosis pathways including Fas receptor signaling [145].  
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Figure 4: Overview of the mTOR signaling pathway. mTOR exists in two different multi-
protein complexes named mTORC1 and mTORC2 that are both activated in response to 
growth factor stimulation. mTOR is essential for the regulation of multiple cellular 
functions, including proliferation, actin remodeling and survival. Adapted from [146].       
 
 
Rapamycin and its derivatives 
The natural mTOR inhibitor rapamycin (Sirolimus), a macrolide produced by the 
bacterium Streptomyces hydroscopius, was originally used as an antifungal and 
immunosuppressive agent. The discovery of mTOR as the target of rapamycin and the 
compound’s inherent anti-proliferative characteristics have led to the discovery of 
rapamycin as a potential anti-cancer agent [147]. Upon entering the cells, rapamycin 
forms a complex with the intracellular 12-kDa FK506-binding protein (FKBP12) and this 
complex interacts with the FKBP12-rapamycin binding domain (FRB) of mTOR, thus 
inhibiting the kinase activity of mTORC1. In contrast, FKBP12/rapamycin cannot 
physically interact with mTORC2 and as a consequence does not inhibit its functions 
[129,135,137]. However, prolonged exposure to rapamycin has been shown to inhibit 
mTORC2 in some cell types by blocking the assembly of the complex, leading to 
inhibition of Akt signaling [148,149]. This indirect inhibition of mTORC2 can be 
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explained by a progressive sequestration of mTOR in a complex with 
FKPB12/rapamycin, reducing its availability for the formation of mTORC2 [128].   
The poor water solubility and limitations in the bioavailability of rapamycin have driven 
efforts to improve these characteristics and have resulted in the generation of the first 
rapamycin analogs (rapalogs), including everolimus (RADD001, Novartis, Basel) and 
temsirolimus (CCI-779, Wyeth, NJ) (Figure 5) [150,151]. Despite the introduction of 
chemical modifications during the generation of rapalogs, these compounds preserve 
their binding to FKBP12 and subsequent interaction with mTOR, thus maintaining a 
conserved mode of action [149]. 
 
 
 
Figure 5: Chemical structure of Rapamycin (left) and of its derivatives Everolimus 
(middle) and Temsirolimus (right).  
 
  
ATP-competitive mTOR kinase inhibitors 
Limitations in the success of rapamycin-based therapies in the clinics have led to the 
development of a second generation of mTOR inhibitors that are known as ATP-
competitive mTOR kinase inhibitors (TKIs). As the name already says, this class of 
mTOR inhibitors directly targets the kinase domain of mTOR, thereby inhibiting its 
catalytic activity. The mechanistic advantage of this class of inhibitors is the blockage of 
the kinase activity of both mTOR complexes, resulting in the inhibition of mTORC1 and 
mTORC2 [128,152]. In the last few years, numerous TKIs have been developed, 
including PP242, WAY-600 and AZD-8055 (Figure 6) [153]. The therapeutic benefit of 
TKIs over rapalogs for the treatment of cancer originates from their ability to block 
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mTORC2-dependent phosphorylation of Akt [154]. However, the major disadvantage of 
TKIs restricting their use in the clinics is their potential toxicity as it has been 
anticipated that global inhibition of mTOR results in higher levels of toxicity in non-
diseased tissue [149]. For instance, the dual mTOR inhibitor PP242 has recently been 
shown to promote mTORC2-specific apoptosis in arteries in a rat model of pulmonary 
arterial hypertension due to increased levels of the pro-apoptotic protein Bim [155]. 
Nevertheless, TKIs have a great potential for the treatment of many different cancers 
and some of them are already successfully used in the clinics as illustrated by the 
example of Imatinib (Gleevec), a TKI administered for the treatment of chronic myeloid 
leukemia [156].  
 
 
 
Figure 6: Chemical structures of the TKIs PP242 (left), WAY-600 (middle) and AZD-
8055 (right).  
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Objectives 
 
Within the framework of this thesis, specific objectives were: 
1. to unravel the molecular mechanisms underlying the cytotoxic activity of 
mycolactone by making use of cellular systems, the BU mouse foot pad model as 
well as biopsies from human BU patients. 
2. to contribute to the understanding of the nature of immune effector mechanisms 
conferring protection against BU with a focus on the role of interferon-γ and of 
cellular immune defense mechanisms during the early intracellular stage of M. 
ulcerans infection. 
3. to evaluate the activity of a new tuberculosis drug candidate against M. ulcerans. 
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Abstract 
Mycolactone, the macrolide exotoxin produced by Mycobacterium ulcerans, is central to 
the pathogenesis of the necrotic skin disease Buruli ulcer (BU). Using two complex 
synthetic probe molecules, we demonstrate that mycolactone binds to the 12-kDa 
FK506-binding protein and acts as a potent mTOR inhibitor. In contrast to the 
immunosuppressive drug rapamycin, a non-cytotoxic inhibitor of mTORC1, mycolactone 
also shows powerful inhibition of mTORC2 activity, resulting in inactivation of Akt and 
dephosphorylation and activation of the Akt-targeted transcription factor FoxO3. 
Subsequent up-regulation of the FoxO3 target gene Bim was observed both in vitro and 
in human BU lesions. Further highlighting the key role of Bim-dependent apoptosis in 
BU pathogenesis, Bim knockout mice were able to contain M. ulcerans infections and did 
not develop any of the typical necrotic BU lesions with large clusters of extracellular 
bacteria. 
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Introduction 
The cytotoxic and immunosuppressive macrolide exotoxin mycolactone A/B (in the 
following simply referred to as “mycolactone”) (Fig. 1) is the key virulence factor of 
Mycobacterium ulcerans (M. ulcerans), the causative pathogen of the chronic necrotizing 
skin disease Buruli ulcer (BU). After tuberculosis and leprosy, BU is the third most 
common mycobacterial disease in humans and leads to massive subcutaneous tissue 
destruction and the formation of ulcers with characteristic undermined edges [1–3]. 
Mycolactone is regarded as essential for BU pathogenesis, as  mycolactone-deficient M. 
ulcerans mutants are avirulent and intradermal injection of the toxin in animal models is 
sufficient to induce the formation of BU-like lesions [4]. Despite the severity of the 
disease, the formation of extensive skin lesions is not accompanied by pain, since 
mycolactone induces analgesia by targeting the angiotensin pathways [5].  
Mycolactone has been shown to have pleiotropic cellular effects. It is highly cytotoxic 
and immunosuppressive, induces cytoskeletal rearrangements and blocks protein 
translocation to the ER [1,6–8].  
Mycolactone-induced cytoskeletal rearrangements have been recently associated with 
mycolactone binding to the Wiskott-Aldrich syndrome protein family (WASP) regulators 
of actin polymerization, resulting in blockade of WASP autoinhibition and uncontrolled 
ARP2/3-mediated actin polymerization, a process that was partly suppressed by co-
administration of the N-WASP inhibitor Wiskostatin [7]. 
Like rapamycin, an immunosuppressant produced by Streptomyces hygroscopicus, 
mycolactone belongs to the group of natural macrolides. Rapamycin acts as inhibitor of 
the mammalian target of rapamycin (mTOR), a serine/threonine protein kinase involved 
in the regulation of cell fate decisions including cell proliferation, cell survival, 
transcription and translation. mTOR interacts with several proteins to form two 
different complexes named mTOR complex 1 (mTORC1) and 2 (mTORC2). These two 
mTOR complexes have distinct sensitivities to rapamycin and different downstream 
outputs. Rapamycin forms a complex with the intracellular 12-kDa FK506-binding 
protein (FKBP12), which directly interacts and inhibits mTORC1, but not mTORC2. 
Short-term rapamycin treatment does not inhibit mTORC2 because the FKBP12-
rapamycin complex cannot bind to intact mTORC2. However, it was shown that long-
term treatment reduces mTORC2 signaling in some cell types by suppressing mTORC2 
assembly [9–12]. One of the main targets of mTORC2 is Akt, a serine/threonine protein 
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kinase controlling cellular survival processes and inhibiting apoptosis pathways through 
phosphorylation of different target proteins. Most importantly, mTORC2  
phosphorylates Akt  at Ser473, which is  required for maximal Akt activation [13]. 
Defective phosphorylation of Akt associated with depletion or inhibition of mTORC2 has 
been demonstrated to impair phosphorylation of several Akt targets including the two 
transcription factors forkhead box O1 and 3 (FoxO1, FoxO3) [14,15]. These transcription 
factors are normally excluded from the nucleus through phosphorylation by Akt, 
resulting in their ubiquitination and proteolytic degradation. In contrast, nuclear FoxOs 
are devoid of phosphorylation and can promote apoptosis by inducing the expression of 
the pro-apoptotic Bcl-2 family member Bim. Additionally, they can activate cell-extrinsic 
apoptosis pathways such as Fas receptor signaling [16].  
Despite the fact that mycolactone-induced cell death is the central element of BU 
pathogenesis, the molecular mechanisms underlying this process are still completely 
unknown.  
In the present study we have used well-defined synthetic mycolactone and mycolactone 
derivatives in order to decipher the molecular mechanisms of mycolactone cytotoxicity. 
Two distinct biotin-tagged mycolactone analogs were designed and used as molecular 
probes for target identification. By applying several complementary approaches, we 
show that the toxin acts as a potent mTOR inhibitor, thus causing up-regulation of the 
FoxO3 target gene Bim via the mTORC2-Akt-FoxO3 axis and finally Bim-dependent 
apoptosis.   
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Results 
 
Synthesis of Mycolactone and Mycolactone Derivatives 
The synthesis of mycolactone and a truncated derivative 1 has been described 
previously by our group [17,18]. For target identification, biotin tags were introduced as 
an extension of the upper side chain (2) or as a replacement of the lower polyene side 
chain (3). In both cases, a diethylenglycol carbamoyl spacer was used for connecting 
biotin to the mycolactone scaffold. As for the natural product, the synthesis of 
mycolactone derivatives 1-3 proceeded through macrocyclic alkyl iodide 4 as a common 
advanced intermediate (Fig 1). The syntheses of these derivatives are summarized in 
Supplementary Schemes S1 – S3 (Appendix Chapter 1).  
 
 
Mycolactone treatment results in up-regulation of Bim and Bim-dependent 
apoptosis 
To investigate whether mycolactone-exposed mammalian cells die by apoptosis, 
programmed necrosis or autophagy, L929 fibroblasts were treated with 80 nM (60 
ng/ml) synthetic mycolactone [18]. Treatment was in the presence of either the pan-
caspase inhibitor zVAD.fmk (zVAD) [19], the autophagy inhibitor 3-methyladenine (3-
MA) [20] or necrostatin-1 (Nec-1), a selective inhibitor of programmed necrosis 
targeting the central RIP-1 kinase [21]. Since mycolactone has recently been 
demonstrated to bind to and activate the Wiskott-Aldrich syndrome protein family 
(WASP) of actin regulators [7], the effect of the WASP inhibitor wiskostatin (Wisko) on 
mycolactone-induced cytotoxicity was also assessed [22]. While mycolactone-treated 
L929 fibroblasts showed no signs of cell death after 24 hours of mycolactone exposure, 
about 75 % of the cells had died after 48 hours (Fig. 2a). Only the pan-caspase inhibitor 
zVAD significantly reduced mycolactone-induced cytotoxicity (Fig. 2a), demonstrating 
that mycolactone-treated cells die by apoptosis. Surprisingly, co-administration of the N-
WASP inhibitor Wiskostatin did not decrease, but even enhance mycolactone 
cytotoxicity (Fig. 2a).  
To dissect the molecular mechanism of mycolactone-mediated cytotoxicity, we 
performed a quantitative RT-PCR screen of 84 genes involved in the regulation of 
apoptosis, necrosis and autophagy. Expression of these genes was profiled in L929 
Results Chapter 1 
 
35 
fibroblasts at different times after the start of mycolactone treatment. While the 
expression of genes involved in the regulation of necrosis or autophagy was not or only 
marginally affected by the toxin, mycolactone treatment resulted in a strong up-
regulation of the transcription of the genes encoding the pro-apoptotic BH3-only protein 
Bim (BimEL isoform) and the Fas death receptor (Supplementary Table 1, Appendix 
Chapter 1). The pro-apoptotic BH-3 only protein Bim binds to anti-apoptotic Bcl-2 
family proteins, thereby allowing the pro-apoptotic proteins Bax and Bak to form 
oligomeric pores, the so-called mitochondrial apoptosis-induced channels (MAC), in the 
outer mitochondrial membrane. As a result, cytochrome c is released into the cytoplasm 
and the initiator caspase-9 as well as the downstream effector caspases-3, -6, and -7 are 
activated, which ultimately leads to cellular demolition [23,24]. 
Experiments with a second set of primers reconfirmed up-regulation of Bim and Fas 
receptor mRNA levels in L929 fibroblasts treated for 24 hours with mycolactone (18- 
and 9-fold increase, respectively; Fig. 2b). No changes were observed for DMSO control 
cells (Supplementary Fig. 1a). When expression of these two highly regulated genes was 
analyzed at the protein level by Western blot analysis of whole cell lysates, a good 
correlation between the increase in mRNA and protein levels was observed (Fig. 2c). 
In addition to the up-regulation of Bim and Fas, cleaved caspase-8 emerged in L929 
fibroblasts after 24 hours of mycolactone treatment (Fig. 2c), suggesting activation of 
the extrinsic apoptotic pathway in association with the up-regulation of the Fas 
receptor. Detection of Bim, Fas and cleaved caspase-8 thus immediately preceded the 
onset of apoptosis (Fig. 2a). Additional markers, such as cleavage of caspase-3, cleavage 
of the caspase-3 target nuclear Poly(ADP-ribose) polymerase-1 (PARP-1) [21,25] (Fig. 
2c), as well as the release of mitochondrial cytochrome c (Fig. 2d) provided further 
evidence for the induction of apoptosis. 
Next, we assessed whether mycolactone-induced apoptosis is dependent on the 
observed induced expression of Fas and/or Bim. Therefore, we silenced these factors 
through RNA interference. Bim and Fas knockdown efficiencies in transfected cells were 
monitored by quantitative RT-PCR (Supplementary Fig. 1b) and Western blot analysis 
(Fig. 2e). While knockdown of Bim completely protected L929 fibroblasts from 
mycolactone-induced apoptosis, ablation of Fas did not diminish cell death significantly 
compared to untransfected cells or to cells transfected with a non-targeting control 
short interfering RNA (siRNA) (Fig. 2f).  
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Mycolactone is a natural mTORC1/2 inhibitor 
It has been suggested that mycolactone shares structural features with the 
immunosuppressive macrolide rapamycin [1]. We therefore hypothesized that 
mycolactone might also act as an mTOR inhibitor and that the mode of action may be 
comparable to that of cytotoxic mTORC1/2 inhibitors, such as PP242 and WAY-600 
[15,26], which induce Bim-dependent apoptosis. To verify this hypothesis, we tested, 
whether mycolactone treatment has an effect on the phosphorylation of the mTORC1 
targeted ribosomal protein S6 at residue Ser235/236 (pS6 (Ser235/236)) and the 
mTORC2 targeted protein kinase Akt at residue Ser473 (pAkt (Ser473)) [9]. Western 
Blot analysis of whole cell lysates of mycolactone- or rapamycin-treated L929 
fibroblasts showed that mycolactone treatment completely abolished phosphorylation 
of both S6 and Akt (Fig. 3a). As expected, rapamycin was found to have a strong effect on 
S6 phosphorylation due to inhibition of mTORC1, while it is a weaker inhibitor of 
mTORC2, as shown by its less pronounced effects on Akt phosphorylation (Fig. 3a). No 
changes in the phosphorylation of the S6 protein and Akt were found in the DMSO 
controls. Neither mycolactone nor rapamycin treatment affected total expression of the 
S6 and Akt proteins (Fig. 3a).  
Qualitatively similar effects as for L929 fibroblasts were also observed with Jurkat cells, 
a non-adherent human T lymphocyte cell line. However, Jurkat cells died 24 hours later 
than L929 fibroblasts and mycolactone-induced effects were generally delayed and less 
pronounced for this cell line (Supplementary Fig. 2). These results are consistent with 
previous findings on the lower sensitivity of Jurkat cells towards mycolactone compared 
to L929 fibroblasts [27,28]. Collectively, however, the results obtained for both, L929 
fibroblasts and Jurkat cells, identified mycolactone as a potent inhibitor of mTORC1 and 
mTORC2, which causes dephosphorylation and inactivation of the Akt kinase. 
 
 
Mycolactone induces Bim-dependent apoptosis via the mTORC2-Akt-FoxO3 
signaling axis 
In a next step we investigated whether the mycolactone-induced mTORC2-dependent 
inactivation of Akt results in dephosphorylation and transcriptional activation of the 
directly Akt-targeted transcription factor FoxO3 [14–16], thus potentially leading to the 
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up-regulation of the FoxO3 target genes Bim and Fas [16] and ultimately to Bim-
dependent apoptosis.  
Western blot analysis of whole cell lysates revealed complete dephosphorylation of 
FoxO3 at the Akt target site Thr32 after 12 hours of mycolactone treatment of  L929 
fibroblasts (Fig. 3b) [15], which correlates well  with the time course of Akt inactivation 
(Fig. 3a), but also with the up-regulation of Bim and Fas and the induction of Bim-
dependent apoptosis (Fig. 2a-c). Dephosphorylation of FoxO3 was also observed to a 
weaker extent for rapamycin-treated L929 fibroblasts, but not for untreated control 
cells (Fig. 3b). Neither mycolactone nor rapamycin affected expression of the FoxO3 
protein itself (Fig. 3b).  
In RNA interference experiments knockdown of FoxO3 significantly reduced 
mycolactone-induced apoptosis (Fig. 3c). Since FoxO3 seemed to play a pivotal role in 
mycolactone-mediated cytotoxicity, we next investigated whether transcriptional 
activity of FoxO3 in fact constitutes the molecular basis for the observed mycolactone-
mediated up-regulation of Bim and Fas (Fig. 2b,c). To this end, we analyzed the 
expression levels of FoxO3, Bim and Fas in FoxO3 knockdown cells by quantitative RT-
PCR and by Western blot analysis. Intriguingly, the massive up-regulation of Bim and 
Fas upon mycolactone treatment was strongly reduced in FoxO3 knockdown cells, thus 
confirming that FoxO3 is the main transcriptional regulator of Bim-dependent apoptosis 
in mycolactone-treated cells (Fig. 3d and Supplementary Fig. 1c).  
 
 
The lower (C5) side chain of mycolactone is required for mTOR inhibition and 
Bim-dependent apoptosis 
Our previous structure-activity relationship studies with synthetic mycolactone 
derivatives have demonstrated that the lower (C5) side chain of mycolactone is crucial 
to its cytotoxic activity [18]. To test whether this side chain is required for the mTOR 
inhibitory activity and the subsequent induction of Bim-dependent apoptosis, L929 
fibroblasts were treated with either mycolactone or compound 1 (Fig. 1), a mycolactone 
derivative with a truncated lower side chain [18]. Whole cell lysates were analyzed by 
Western blotting for phosphorylation of S6 and Akt proteins, as well as for the levels of 
Bim. As expected, mycolactone-treated L929 fibroblasts displayed a complete inhibition 
of mTORC1/2 followed by a massive up-regulation of Bim (Fig. 4a). In contrast, no 
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inhibition of mTORC1/2 and no up-regulation of Bim was observed for 1-treated cells 
(Fig. 4a), confirming that the lower side chain of mycolactone is indeed required for 
mTOR inhibition and subsequent induction of Bim-dependent apoptosis.  
 
 
Mycolactone acts through binding to the 12-kDa FK506-binding protein (FKBP12) 
Since mycolactone showed potent mTOR inhibitory activity and is known to be highly 
immunosuppressive [1], we next investigated whether it binds, like rapamycin, to the 
intracellular 12-kDa FK506-binding protein (FKBP12). Streptavidin-coated ELISA plates 
were incubated with synthetic biotinylated mycolactone derivatives 2 or 3 (Fig. 1). 
Compound 2 has a biotin tag attached to the upper side chain via a diethylenglycol-
carbamoyl linker while compound 3 incorporates a biotinylated diethylenglycol-based 
replacement of the lower side chain of the toxin. It should be noted that we had 
previously found a butyl-carbamoyl analog of 2 (containing a butyl residue instead of a 
biotinylated diethylenglycol extension) to be only marginally less cytotoxic than natural 
mycolactone [18]. After compound treatment, plates were incubated with recombinant 
FKBP12 protein and bound FKBP12 protein was detected using anti-FKBP12 antibodies. 
While compound 2, the derivative with an unmodified O-linked polyunsaturated lower 
side chain, displayed binding to FKBP12 (Fig. 4b), 3, which contains the biotin label 
attached to a substitute of the lower side chain, showed only background binding to 
FKBP12 (Fig. 4c).  
To analyze whether mycolactone binding to FKBP12 is in fact relevant for the cytotoxic 
activity of mycolactone, we performed a competition assay using FK506 (Tacrolimus), 
an immunosuppressive drug binding to the conserved active site of FKBP12 [29–31]. 
Strikingly, we found that administration of a 1000-fold excess of FK506 completely 
protected L929 fibroblasts from mycolactone-induced apoptosis. A significant level of 
protection from mycolactone cytotoxicity was already achieved at a molar ratio of 10 
(Fig. 4d).  
Taken together, our data show that mycolactone binds to FKBP12 and that this complex 
induces Bim-dependent apoptosis via the mTORC2-Akt-FoxO3 signaling axis. The model 
of the mode of action of mycolactone inferred from these experiments is depicted in 
Figure 4e. 
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Up-regulation of Bim in human BU lesions  
One of the main features of the pathogenesis of BU is the destruction of subcutaneous 
adipose tissue, leading to the collapse of the epidermis and the formation of 
characteristic ulcers with undermined edges [1]. To reconfirm that these events are 
triggered by mycolactone via the mTORC2-Akt-FoxO3-Bim axis, we performed further 
analyses with primary human adipocytes and clinical specimens from BU patients.  
We found that the sensitivity of primary human adipocytes to mycolactone was 
comparable to that of L929 fibroblasts. However, adipocytes died later and only started 
to undergo apoptosis after five days of mycolactone treatment (Supplementary Fig. 3a). 
As for L929 fibroblasts, a complete inhibition of mTORC1/2 (Supplementary Fig. 3b) as 
well as a massive up-regulation of Bim was observed for adipocytes treated with 16 nM 
or 80 nM mycolactone both at mRNA (8-fold up-regulation, Supplementary Fig. 3c) and 
at protein levels (Supplementary Fig. 3b). 
Immunohistochemical staining of tissue specimens from BU patients revealed up-
regulation of Bim in BU lesions (Fig. 5). Punch biopsies taken at the border of ulcerative 
BU lesions comprising epidermis, dermis and subcutis showed characteristic 
histopathological hallmarks of BU, including the presence of epidermal hyperplasia, fat 
cell ghosts and extensive necrosis. Small clusters of solid stained acid-fast bacilli (Fig. 
5b,c) were dispersed in the necrotic areas (Region 2 in Fig. 5a). In this region consisting 
of completely necrotic tissue devoid of living and infiltrating cells, no Bim-staining was 
observed (Fig. 5e). However, in the neighboring layers with better preserved tissue 
infiltrated by immune cells (Regions 1 and 3 in Fig. 5a), a substantial number of cells 
expressing high levels of Bim were found (Fig. 5d,f).  
 
 
Containment of infection and lack of tissue necrosis in M. ulcerans-infected Bim 
knockout mice 
To confirm that Bim-mediated apoptosis plays a key role in the pathogenesis of BU, we 
infected C57Bl/6 wild-type (WT) and homozygous Bim knockout mice (Bim-/-) by 
injection of M. ulcerans bacteria into the left hind foot pad. Additionally, homozygous Fas 
(Fas-/-) knockout mice were included in the experiment to reconfirm the results of the in 
vitro knockdown analyses (Fig. 2f) that suggested no involvement of the Fas pathway in 
mycolactone cytotoxicity. Disease progression was monitored by weekly measurements 
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of the foot pad thickness using a caliper. In contrast to the Bim-/- mice, all WT and Fas-/- 
mice started to show swelling of feet and reddening of the skin four weeks after 
infection (Fig. 6a,b). Histopathologically, these macroscopic signs in the susceptible mice 
correlated with edema formation and massive tissue necrosis (Fig. 6c,d). Quantitative 
IS2404 RT-PCR analysis [32] of footpad lysates revealed that bacterial multiplication 
was significantly impaired in the Bim-/- mice (Fig. 6f). As expected for active BU lesions, 
large numbers of extracellular acid-fast bacilli were found throughout the infected 
footpads of WT and Fas-/- mice (Fig. 6e). In contrast, only small numbers of acid-fast 
bacilli were found in the footpads of the Bim-/- mice, primarily at the injection sites (Fig. 
6e). Close vicinity of these small bacterial clusters to nuclei were indicative of uptake of 
the acid-fast bacteria by phagocytes (Fig. 6e).  
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Discussion 
Cytotoxicity and immunosuppression mediated by mycolactone, the macrolide exotoxin 
produced by M. ulcerans, play key roles in the pathogenesis of BU. Using structurally 
well-defined synthetic mycolactone and mycolactone derivatives, we show that the toxin 
is an mTOR inhibitor that binds to the 12-kDa FK506-binding protein (FKBP12). In 
contrast to the non-cytotoxic rapamycin, which primarily acts as an inhibitor of mTORC1 
and therefore only marginally interferes with the pro-survival Akt signaling, 
mycolactone also efficiently inhibits mTORC2, thereby activating a cytotoxic program via 
the mTORC2-Akt-FoxO3-Bim axis. For all mammalian cell types studied here, the 
sequence of events leading from the inhibition of mTORC2 to Bim-promoted apoptosis 
took at least 24 hours. This time lapse between the start of exposure to mycolactone and 
the onset of apoptosis has prevented recognition of the involvement of mTOR inhibition 
in mycolactone-mediated apoptosis in previous short time experiments [33]. For the 
same reason the potency of mycolactone has been often underestimated and the 
concentrations employed in some of the published studies on the activities of 
mycolactone at ‘non-toxic’ concentrations were in fact performed at toxic mycolactone 
concentrations.  
In vitro, ablation of Bim expression by siRNA completely protected cells from 
mycolactone-induced cell death. Bim is also of fundamental importance for BU 
pathogenesis in vivo, as demonstrated by its high level of expression in cells surrounding 
the necrotic core of human BU lesions. Furthermore, Bim-deficient mice were 
completely resistant to tissue necrosis induced by infection with M. ulcerans. As a 
consequence of the resistance to mycolactone-mediated apoptosis, bacterial 
multiplication was significantly reduced in the Bim-deficient mice. This finding indicates 
that infiltrating phagocytes can contain the infection if they are not killed by the toxin 
produced by the internalized bacilli. While knockdown of Bim led to a complete 
protection from mycolactone cytotoxicity, ablation of FoxO3 had only a partial 
protective effect. This may be due to compensating functions by other FoxO family 
members. 
The rather uncommon observation of a concomitant activation of cell-extrinsic (Fas, 
caspase-8) and cell-intrinsic (Bim) apoptosis pathways could possibly be a passive side-
effect of FoxO3 activation by mycolactone. However, cooperation between these two 
pathways in terminating immune responses by efficiently deleting activated T-cells has 
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been demonstrated in vivo [34,35], possibly contributing to the immunosuppressive 
properties of mycolactone. 
A recent study showed that mycolactone induces cytoskeletal rearrangement via 
blockage of WASP autoinhibition, leading to uncontrolled ARP2/3-mediated actin 
polymerization [7]. In our experiments the N-WASP inhibitor wiskostatin failed to block 
mycolactone-mediated cell death and even enhanced apoptosis. Cytoskeletal 
rearrangements might as well be triggered  by the inhibition of mTORC2, since it has 
been demonstrated that the ablation of mTORC2 components affects actin 
polymerization, resulting in perturbed cell morphology [36]. 
Beyond the identification of the signaling cascade underlying mycolactone cytotoxicity, 
the results presented here also have major implications for mycolactone-induced 
immunosuppression, the second key feature of BU pathogenesis. The almost identical 
kinetics of mTOR inhibition in mycolactone- and rapamycin-treated cells as well as the 
demonstration of mycolactone binding to FKBP12 suggests that mycolactone and 
rapamycin might mediate systemic immunosuppression by similar pathways. This 
hypothesis is supported by studies showing that mycolactone can be traced in 
peripheral blood and peripheral lymph nodes of M. ulcerans infected mice, leading to a 
substantial down-regulation of T cell responses [37–39]. Since rapamycin-FKBP12 
cannot directly bind and inhibit fully assembled mTORC2 [9], these similarities between 
rapamycin and mycolactone may suggest that mycolactone interferes with mTORC2 
signaling by suppressing mTORC2 assembly, as previously demonstrated for rapamycin 
[9–12]. 
Our finding that the diffusible macrolide toxin mycolactone is a highly potent natural 
mTOR inhibitor does not only explain the molecular basis of mycolactone-mediated local 
pathogenesis and systemic immunosuppression, but may also open new perspectives for 
the development of a novel class of mTOR inhibitors with potential applications for the 
treatment of autoimmune diseases, organ graft rejection or cancer. 
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Figures  
 
 
 
Figure 1: Structures of mycolactone A/B and of synthetic mycolactone derivatives 
1-3. 
Chemical structures of mycolactone A/B, truncated derivative 1 and biotin-tagged 
analogs 2 and 3. All compounds were prepared from key intermediate 4. 
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Figure 2: Mycolactone up-regulates Bim and induces Bim-dependent apoptosis in 
L929 fibroblasts.  
(a) Mycolactone-treated L929 fibroblasts die by apoptosis. Cells were pre-treated for 1 h 
with 10 μM zVAD, 200 μM 3-MA, 10 μM Nec-1 or 1 μM Wisko prior to the addition of 
mycolactone. Cell viability was assessed by FACS analysis after 24 (left), 48 (middle), 
and 72 (right) hours. (b) Up-regulation of Bim and Fas mRNA expression as determined 
by qRT-PCR. Values are displayed as log2 (fold change). Mean values across duplicate 
samples are shown, and error bars represent the s.d. (c) Up-regulation of Bim and Fas 
protein levels, and the presence of cleaved caspase-8, downstream caspase-3 and PARP-
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1 as determined by Western blot. (d) Cytochrome c release from mitochondria as 
determined by Western blot using cytoplasmic fractions of mycolactone- or DMSO-
treated L929 fibroblasts. (e) Protein levels of Bim and Fas in transfected L929 
fibroblasts. (f) Knockdown of Bim – but not Fas - completely protects L929 fibroblasts 
from mycolactone-induced cytotoxicity. Cells were transfected with 10 nM siRNA 
control (si ctrl), siFas, siBim or siFas+ siBim 6 h prior to mycolactone addition and cell 
viability was assessed by FACS. Western blot data in (c-e) are representative of three 
independent experiments. α-Tubulin served as loading control. The bar graphs in a and f 
show mean values across duplicate samples, and the error bars represent the s.d. of 
three independent experiments. Two-tailed Student’s t test. ****, P ≤ 0.0001, ***, P ≤ 
0.001, **, P ≤ 0.01, n. s., not significant. 
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Figure 3: Mycolactone is an mTOR inhibitor and induces Bim-dependent apoptosis 
via the mTORC2-Akt-FoxO3 signaling axis.  
(a) Mycolactone is a potent mTORC1/2 inhibitor. Western blot analysis for phospho-S6 
ribosomal protein (Ser235/236) (pS6 (Ser235/36)), total S6 ribosomal protein (total 
S6), phospho-Akt (Ser473) (pAkt (Ser473)) and total Akt in L929 fibroblasts treated 
with 80 nM mycolactone (left), 80 nM rapamycin- (middle) or DMSO (right). (b-d) 
Mycolactone-induced mTORC2 inhibition results in dephosphorylation and activation of 
the transcription factor FoxO3, subsequent up-regulation of Bim and Fas and finally in 
Bim-dependent apoptosis. (b) Akt-dependent phosphorylation of the transcription 
factor FoxO3 is inhibited in mycolactone-treated cells, resulting in its transcriptional 
activation. Western blot analysis for phospho-FoxO3 (Thr32) (pFoxO3 (Thr32)) and 
total FoxO3 in L929 fibroblasts treated with 80 nM mycolactone (left), 80 nM rapamycin 
(middle) or DMSO (right). (c) Knockdown of FoxO3 protects L929 fibroblasts from 
mycolactone-induced apoptosis. Cells were transfected with 30 nM siRNA control (si 
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ctrl) or siFoxO3 6 h prior to mycolactone treatment and cell viability was assessed by 
FACS. Mean values across duplicate samples are shown, and the error bars represent the 
s.d. of three independent experiments. Two-tailed Student’s t test. ****, P ≤ 0.0001. (d) 
Knockdown of FoxO3 in L929 fibroblasts resulted in a strong decrease of the two FoxO3 
targets Fas and Bim as demonstrated by Western blot for total FoxO3, Fas and Bim 24 h 
after addition of 80 nM mycolactone or DMSO. Western blot data in (a,b,d) are 
representative of three independent experiments. α-Tubulin served as loading control.  
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Figure 4: Mycolactone-induced apoptosis is dependent on the interaction with the 
12-kDa FK506-binding protein (FKBP12).  
(a) Cells treated with compound 1 showed no mTORC1/2 inhibition and no up-
regulation of Bim. Western blot analysis for pS6 (Ser235/236), total S6, pAkt (Ser473), 
total Akt and Bim in L929 fibroblasts treated with 80 nM mycolactone or 1. α-Tubulin 
served as loading control. Western blot data are representative of three independent 
experiments. (b,c) Recombinant human FKPB12 protein binds to compound 2 (b), but 
not to compound 3 (c) as shown by ELISA. The graphs show mean values across 
duplicate samples, and the error bars represent the s.d. of three independent 
experiments. (d) Treatment with the FKBP12 binding competitor FK506 (Tacrolimus) 
protects L929 fibroblasts from mycolactone-induced apoptosis. Cells were treated with 
mycolactone in combination with FK506 at a molar ratio of 1/1000 (1000x), 1/100 
(100x), 1/10 (10x) and 1/1 (1x) and cell viability was assessed by FACS analysis. Mean 
values across duplicate samples are shown, and the error bars represent the s.d. of three 
independent experiments. Two-tailed Student’s t test. ****, P ≤ 0.0001, **, P ≤ 0.01, n. s., 
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not significant. (e) Model of the mycolactone-induced apoptosis pathway. FKBP12, 12-
kDa FK506-binding protein; mTORC1, 2, mammalian target of rapamycin complex 1, 2; 
AKT, serine/threonine protein kinase AKT (protein kinase B); FoxO3, Forkhead box O3; 
Bim, Bcl-2-like protein 11; PI3K, Phosphatidylinositol-4,5-bisphosphate 3-kinase; PDK1, 
3-Phosphoinositide-dependent protein kinase-1; S6K1, ribosomal protein S6 kinase 
beta-1; S6, ribosomal protein S6.  
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Figure 5: High expression levels of Bim in human BU lesions. 
(a-f) Histological sections of a punch biopsy were either stained with Haematoxylin-
Eosin (HE) (a), Ziehl-Neelsen (ZN) to stain for mycobacteria (b,c) or with an anti-Bim 
antibody (d-f), counterstain Haematoxylin. (a) Punch biopsy of a lesion with typical 
histopathological hallmarks of a BU infection: large necrotic areas, fat cell ghosts, 
absence of infiltration (Region 2) in the necrotic core and the presence of solid stained 
acid-fast bacilli (b,c). The necrotic core is surrounded by infiltrating immune cells 
(Region 1, Region 3). No intact (and no Bim-positive) cells are present in the necrotic 
core (Region 2, e).  Bim-positive cells were found in large numbers in the infiltrated 
regions (d,e). Scale bars, 350 μm (a), 40 μm (b, d-f), 11 μm (c). 
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Figure 6: Bim knockout mice are resistant to the pathogenesis of BU. 
(a-f) Left hind foot pads of 8 week old female C57Bl/6 wild-type (WT), Fas homozygous 
knockout (Fas-/-) and Bim homozygous knockout (Bim-/-) mice were infected with M. 
ulcerans. (a) Progression of the infection as determined by weekly measurements of the 
foot pad thickness. Mean values are shown; the error bars represent the s.d.  (n = 6 per 
genotype). (b) Representative images of a WT (left), Fas-/- (middle) and Bim-/- (right) 
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mouse 5 weeks after infection. Scale bars, 1 cm. (c-e) Histologic sections of foot pads 
from mice infected with M. ulcerans stained with Hematoxylin/Eosin (HE) (c,d) or Ziehl-
Neelsen/Methylene blue (ZN) to stain for mycobacteria (e). (f) Quantification of M. 
ulcerans in foot pad lysates by quantitative RT-PCR for the insertion sequence IS2404. 
Genomes per foot pad are shown. Values are displayed as mean, the error bars represent 
the s.d. (n = 3 per genotype). Scale bars, 1 cm (b), 3 mm (c), 160 μm (d), 20 μm (e). P 
values in a and f were calculated using two-tailed Student’s t test. ****, P ≤ 0.0001, **, P ≤ 
0.01.  
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Supplementary Figure 1: Mycolactone up-regulates Bim and Fas mRNA expression 
via activation of FoxO3.  
(a) Stable Bim and Fas mRNA expression levels in DMSO control L929 fibroblasts. mRNA 
expression was assessed over time by qRT-PCR. Values are displayed as log2 (fold 
change). Mean values across duplicate samples are displayed, and error bars represent 
the s.d. (b) Determination of Fas and Bim knockdown efficiencies in transfected L929 
fibroblasts by qRT-PCR. Fas and Bim mRNA expression levels were assessed 24 h after 
treatment with 80 nM mycolactone or DMSO. (c) Knockdown of FoxO3 in L929 
fibroblasts results in a strong decrease of Fas and Bim. FoxO3, Fas and Bim mRNA 
expression 24 h after addition of 80 nM mycolactone or DMSO as determined by qRT-
PCR. Values in (b,c) are shown as fold change, one of two independent similar 
experiment is shown. 
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Supplementary Figure 2: Mycolactone is an mTORC1/2 inhibitor and induces 
FoxO3- and Bim-dependent apoptosis in the more resistant Jurkat cells.  
(a) Mycolactone-treated Jurkat cells die by apoptosis. Jurkat cells were pre-treated for 1 
h with 10 μM zVAD, 200 μM 3-MA, 10 μM Nec-1 or 1 μM Wisko prior to the addition 
mycolactone. Cell viability was assessed by FACS analysis after 24 (left), 48 (middle) and 
72 (right) hours. The bar graphs display mean values across duplicate samples, and the 
error bars represent the s.d. of three independent experiments. Two-tailed Student’s t 
test. **, P ≤ 0.01; ***, P ≤ 0.001. (b,c) Mycolactone up-regulates Bim and Fas in Jurkat 
cells. (b) Up-regulation of Bim and Fas mRNA expression in mycolactone-treated (left) 
but not in DMSO-treated (right) cells as determined by qRT-PCR. Values are displayed as 
log2 (fold change). Mean values across duplicate samples are shown, and error bars 
represent the s.d. (c) Up-regulation of Bim and Fas protein levels, and the detection of 
cleaved caspase-8, downstream caspase-3 and PARP-1 as determined by Western blot. 
(d) Cytochrome c release from mitochondria in Jurkat cells. Cytochrome c levels were 
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analyzed by Western blot using cytoplasmic fractions of Jurkat cells treated with 
mycolactone or DMSO. Whole cell lysates of mycolactone-treated Jurkat cells (48 h) 
served as positive control (+ ctrl). (e) Mycolactone acts as an mTORC1/2 inhibitor in 
Jurkat cells. Western blot analysis for phospho-S6 ribosomal protein (Ser235/236) (pS6 
(Ser235/36)), total S6 ribosomal protein (total S6), phospho-Akt (Ser473) (pAkt 
(Ser473)) and total Akt in Jurkat cells treated with 80 nM mycolactone (left), 80 nM 
rapamycin (middle) or DMSO (right). Western blots in (c-e) are representative of three 
independent experiments. α-Tubulin served as loading control. 
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Supplementary Figure 3: Treatment of primary human adipocytes with 
mycolactone results in complete inhibition of mTORC1/2 and the up-regulation of 
Bim.  
(a) Phase contrast microscopy images of primary human adipocytes treated for 1, 5 or 7 
days with 16 nM mycolactone or DMSO. Bars, 100 μm. (b) Mycolactone treatment of 
primary human adipocytes induces complete mTORC1/2 inhibition and a strong up-
regulation of Bim. Western blot analysis of primary human adipocytes whole cell lysates 
for pS6 (Ser235/236), total S6, pAkt (Ser473), total Akt and Bim after 5 days treatment 
with 16 nM or 80 nM mycolactone or DMSO control. α-Tubulin served as loading control. 
(c) Up-regulation of Bim mRNA expression levels by mycolactone in primary human 
adipocytes as determined by qRT-PCR. Cells were either treated with 16 nM or 80 nM 
mycolactone or DMSO. Values are displayed as log2 (fold change). One of two 
independent similar experiments is shown. 
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Methods 
 
Compounds 
The synthesis of mycolactone A/B, compound 1 and key intermediate 4 have been 
described previously [17,18]. The synthesis of biotin conjugates 2 and 3 starting from 4 
is described in detail in Supplementary Schemes S1 – S3 (Appendix Chapter 1). All 
intermediates were fully characterized and all final compounds were purified by 
preparative HPLC. 
 
 
Cell culture, flow cytometric analysis, siRNA transfection and competition with 
FK506 
L929 fibroblasts were purchased from ATCC and Jurkat cells were a kind gift from J.-P. 
Bourquin’s laboratory (University of Zurich). Cells were grown in RPMI 1640 medium 
supplemented with 10 % heat-inactivated FCS (Sigma) and 2 mM glutamine and 
incubated at 37 °C and 5 % CO2.  
For all experiments, highly defined synthetic mycolactone A/B (mycolactone) [17] 
dissolved in DMSO was used, an attractive alternative to the commonly used 
heterogeneous extracts purified by lipid chromatography. For all experiments, toxin-free 
DMSO at a concentration of 0.012 % served as solvent control.  
For flow cytometric analysis, 24’000 L929 fibroblasts or 100’000 Jurkat cells were 
seeded into 24-well plates. L929 cells were allowed to adhere overnight, whereas Jurkat 
cells were plated directly prior to mycolactone treatment. Synthetic mycolactone (80 
nM) or DMSO (control) were added in a volume of 600 µl medium. For experiments 
involving additional inhibitors, cells were pre-treated for 1 h with indicated 
concentrations of zVAD.fmk (Promega), 3-Methyladenine (Sigma), Necrostatin-1 
(Sigma) or wiskostatin (Sigma) prior to mycolactone addition. Inhibitors were re-fed 
every 24 h. For flow cytometric analysis, cells were stained with Annexin V-FITC and PI 
(AnnexinV kit, Calbiochem) according to the manufacturer’s recommendations. Stained 
cells were analyzed by flow cytometry using a BD FACS Calibur Flow Cytometer at 
indicated times and cell death was quantified using the CellQuest Pro Software (Becton 
Dickinson).  
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For the generation of transient knockdowns, L929 fibroblasts were transfected with si 
ctrl (ON-TARGETplus Non-targeting Pool, Thermo Scientific), siFas, siBim or siFoxO3 
(ON-TARGETplus SMART Pool siRNAs, Thermo Scientific) with a final concentration of 
10 nM using HiPerFect® Transfection Reagent (Qiagen) following the manufacturer’s 
instructions. Six hours after transfection, cells were adherent and mycolactone was 
added. Cell death was quantified 48 h after transfection by Annexin V / PI staining and 
flow cytometric analysis as described above. Fas, Bim and FoxO3 expression levels of 
transfected cells were analyzed by quantitative RT-PCR and by Western Blot. 
siRNA target sequences used: siFas: 5’-GUAAAUACAUCCCGAGAAU-3’, 5’-
CGAUGAAGAGCAUGGUUUA-3’, 5’-GAAAUCGCCUAUGGUUGUU-3’ and 5’-
GUGAAACCAUACCAAUGAA-3’, siBim: 5’-GGAGACGAGUUCAACGAAA-3’, 5’-
UUACAACUGUUACGCUUUA-3’, 5’-GAAGACCACCCUCAAAUGG-3’ and 5’-
GCAACCUUCUGAUGUAAGU-3’ and siFoxO3: 5’-UCGCAACGAUCCAAUGAUG-3’, 5’-
CCACAGCGACGUCAUGAUG-3’, 5’-GGAGUUUGGUCAAUCAGAA-3’ and 5’-
GUGCAAACCUUCCCGUCAU-3’. 
For the FK506 competition experiments, cells were pre-treated for 1 h with indicated 
concentrations of FK506 (Invivogen) or DMSO solvent control before addition of 20 nM 
mycolactone. FK506 was re-fed every 12 h and cell viability was assessed after 36 h by 
Annexin V / PI staining and flow cytometric analysis as described above. 
 
 
Quantitative RT-PCR 
For the quantitative RT-PCR screen, L929 fibroblasts were treated for indicated times 
with 80 nM mycolactone followed by total RNA extraction from cells using the RNeasy® 
Mini Kit (Qiagen), and reverse-transcribed in cDNA with the RT2 First Strand Kit 
(Qiagen) according to the manufacturer’s instructions. While extracting RNA, DNase 
treatment was performed using the RNase-Free DNase Set (Qiagen). The initial 
screening experiment (Supplementary Table 1, Appendix Chapter 1) was performed two 
times independently using the RT2 ProfilerTM PCR array system (Qiagen, Mouse Cell 
Death PathwayFinderTM) on a StepOnePlus Real Time PCR System (Applied Biosystems) 
with RT2 SYBR® green ROXTM qPCR Mastermix (Qiagen) according to the manufacturer’s 
protocol. Transcript expression levels were normalized against the housekeeping genes 
actin beta (Actb), hypoxanthine-guanine phosphoribosyltransferase (Hprt) and heat 
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shock protein 90 kDa alpha, class B member 1 (Hsp90ab1) and displayed as fold changes 
or log2 (fold change). Up-regulation of Bcl2l11 (Bim) and Fas gene transcription in L929 
fibroblasts was reconfirmed in a second step using newly designed primers and also 
assessed in Jurkat cells and primary human adipocytes. The following primers were 
used: mActb: fwd: 5’- CTCTGGCTCCTAGCACCATGAAGA-3’, rev: 5’-
GTAAAACGCAGCTCAGTAACAGTCCG-3’, mHprt: fwd: 5’- TCCTCCTCAGACCGCTTTT-3’, 
rev: 5’-CCTGGTTCATCATCGCTAATC-3’, mHsp90ab1: fwd: 5’-TACTCGGCTTTCCCGTCA-3’, 
rev: 5’-GCCTGAAAGGCAAAGGTCT-3’, mFas: fwd: 5’- AAACCAGACTTCTACTGCGATTCT-3’, 
rev: 5’- GGGTTCCATGTTCACACGA-3’, mBim: fwd: 5’-GGAGACGAGTTCAACGAAACTT-3’, 
rev: 5’-AACAGTTGTAAGATAACCATTTGAGG-3’, hActb: fwd: 5’-GCACAGAGCCTCGCCTT-
3’, rev: 5’-CCTTGCACATGCCGGAG-3’, hHprt: fwd: 5’-TGACCTTGATTTATTTTGCATACC-3’, 
rev: 5’-CGAGCAAGACGTTCAGTCCT-3, hHsp90ab1: fwd: 5’-AACCGCATCTATCGCATGA-3’, 
rev: 5’-CATCAGGAACTGCAGCATTG-3’, hFas: 5’-GTGGACCCGCTCAGTACG-3’, rev: 5’-
TCTAGCAACAGACGTAAGAACCA-3’, hBim: fwd: 5’-CATCGCGGTATTCGGTTC-3’, rev: 5’-
GCTTTGCCATTTGGTCTTTTT-3’. For determination of expression levels of transfected 
cells, the following primers were used: mFas, mBim (described above) and mFoxO3: 
fwd: 5’-GATAAGGGCGACAGCAACAG-3’, rev: 5’-CATTCTGAACGCGCATGA-3’. 
 
 
Western Blot 
Cells were treated with indicated concentrations of mycolactone, rapamycin, compound 
1 or DMSO and cell lysates were prepared at indicated time points in ice-cold RIPA-plus 
buffer (Sigma) complemented with 1 mM DTT, 1 mM NaF, 2 mM NaVO4 and protease 
inhibitor cocktail (Sigma). Cell fractionation was performed using the Cell Fractionation 
Kit Standard (ab109719, abcam®). 
For SDS-PAGE, equal amounts of cell lysates were loaded on precast 10 % Bis-Tris Gels 
(NuPAGE Novex®, Life Technologies) with MES running buffer and transferred to 
nitrocellulose membranes using the iBlot dry-blotting system (Novex®, Life 
Technologies) according to the manufacturer’s recommendations. Membranes were 
blocked in 5 % milk in PBS/Tween-20 overnight at 4 °C and incubated with specific 
primary antibodies in 5 % BSA in TBS/Tween-20 overnight at 4 °C. Membranes were 
washed and incubated with peroxidase-conjugated secondary antibodies in 5 % milk 
PBS/Tween-20 for 1 h at room temperature. Blots were developed using the ECL 
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Western Blotting Substrate (Pierce). For phospho antibodies, the LumiGLO Reserve 
Substrate (KPL) was used. Antibodies used: Fas (AP00027PU-N, Acris), FasL (sc-6237, 
Santa Cruz Biotechnology), Bim (♯2819, Cell Signaling), mouse Cleaved Caspase-8 
(♯8592, Cell Signaling), human Cleaved Caspase-8 (♯9496, Cell Signaling), Cytochrome C 
(ab133504, abcam®), Caspase-3 (♯9662, Cell Signaling), PARP-1 (sc-7150, Santa Cruz 
Biotechnology), pS6 (Ser235/236) (♯2211, Cell Signaling), total S6 (♯2217, Cell 
Signaling), pAkt (Ser473) (♯9271, Cell Signaling), total Akt (♯9272, Cell Signaling), 
pFoxO1 (Thr24) / pFoxO3  (Thr32) (♯9464, Cell Signaling), total FoxO3 (♯2497, Cell 
Signaling) and alpha-Tubulin (T9026, Sigma).  
 
 
ELISA 
NeutrAvidin Coated High Capacity Plates (Thermo Scientific) were blocked for 1 h with 
SuperBlock® T20 (TBS) Blocking Buffer (Thermo Scientific) and incubated for 2 h with 2 
μg/ml compound 2 or 3 / TBS-T. Plates were subsequently washed with TBS-T, 
incubated for 1 h with recombinant human FKPB12 protein (Cayman Chemical) diluted 
in blocking buffer at indicated concentrations, washed again with TBS-T and incubated 
for 1 h with 0.33 μg/ml mouse anti-FKBP antibody (Sino Biological) diluted in blocking 
buffer. Plates were washed again with TBS-T and bound FKBP12 antibodies were 
detected using an Alkaline Phosphatase (AP) conjugated goat anti-mouse IgG antibody 
(Sigma) diluted 1:20’000 in blocking buffer and the Alkaline Phosphatase Yellow (pNPP) 
Liquid Substrate System (Sigma). The whole ELISA was performed at 37 °C and under 
light-protection. 
 
 
Primary human adipocytes 
Pools of subcutaneous human pre-adipocytes were purchased from Zen-Bio. Cells were 
expanded in vitro in DMEM / F12 (Sigma) containing 10 % heat-inactivated FBS, 1 % 
HEPES, 1 % sodium pyruvate, 1 % penicillin-streptomycin solution (Invitrogen) and 5 
ng/ml bFGF (Sigma). When the pre-adipocytes reached confluence, cells were drifted to 
adipogenic differentiation by cultivating them for 14 days in DMEM / F12 medium 
supplemented with 10 % FBS, 1 % penicillin-streptomycin solution, 1 μM 
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Dexamethasone (Sigma), 0.5 mM 3-Isobutyl-1-Methylxanthine (Sigma), 100 μM 
Indomethacin (Sigma) and 10 μg/ml Actrapid HM (Novo Nordisk). 
After 14 days, adipogenic differentiation was checked by performing an Oil Red O 
staining and cells were analyzed by quantitative RT-PCR, Western Blot and phase 
contrast microscopy.  
For phase contrast microscopy, cells were treated for indicated times with 16 nM 
mycolactone or DMSO solvent control and analyzed at room temperature with an 
Olympus IX50 Osiris Microscope equipped with a LCPlanFL (40x/0.6) Objective 
(Olympus). Pictures were taken with a Colorview III camera (Olympus) and the CellSens 
1.9 software (Olympus). For adjustment of brightness and contrast levels, Adobe 
Photoshop CS6 was used. 
 
 
Immunohistochemistry  
Punch biopsies of untreated laboratory reconfirmed Buruli ulcer patients were analyzed. 
The tissue was surgically removed and immediately transferred into 10 % neutral 
buffered formalin solution (4 % paraformaldehyde) for 24 h at room temperature 
(tissue fixation). Afterwards samples were stored and transported in 70 % ethanol, 
embedded into paraffin and cut into 5 µm sections with a microtome.  
After deparaffinization and rehydration sections were either directly stained with 
Haematoxylin/Eosin (HE) or Ziehl-Neelsen/Methylenblue (ZN) according to WHO 
standard protocols (see reference WHO diagnosis booklet) or further processed for 
immunohistochemistry (IHC). For IHC, antigen retrieval was performed with citrate 
buffer, pH 6.0, (Dako® Education guide: Immunohistochemical Staining methods). 
Endogenous peroxidase was inactivated by applying 0.3 % H202 for 20 min and 
prevention of unspecific binding was achieved by incubation with 1.5 % goat serum 
(Vectorlabs) for 30 min. Primary antibodies specific for Bim (♯2933, Cell Signaling, 
1:100) were diluted in phosphate buffered saline (PBS) containing 0.1 % Tween-20 and 
added to the slides for 1 h at room temperature. After incubation with a matching biotin-
conjugated secondary antibody (goat anti-rabbit, ♯BA1000, Vectorlabs, 1:200) staining 
was performed using the Vector ABC elite and the NovaRED system (Vectorlabs). 
Haematoxylin (Sigma) was used as a counter stain.  
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Slides were analyzed at room temperature with a DM2500 Microscope (Leica) equipped 
with the Leica Okular HC Plan s (10x/25) and the Leica Objective HC PL Fluotar 
(20x/0.5) or the Leica Objective HCX PL Fluotar (100x/1.3, Leica Type N Immersion 
liquid). Pictures were taken either with an Aperio scanner or with a Leica DFC 420 
camera and the Leica application Suite 4.3.0 software. For adjustment of brightness 
levels, Adobe Photoshop CS6 was used. 
 
 
Mouse procedures 
Mice were maintained in specific pathogen-free facilities at the école polytechnique 
fédérale de Lausanne (EPFL, Switzerland). All studies were performed under BSL-3 
conditions either in 8 weeks old female C57Bl/6 wild type mice or mice homozygous for 
the lymphproliferation spontaneous mutation (Faslpr) or homozygous Bim knockout 
mice (Bcl2l11tm1.1Ast), respectively (Jackson Laboratory). For the infection of mice, the M. 
ulcerans strain S1013 isolated in 2010 from the ulcerative lesion of a Cameroonian BU 
patient was used [40]. Bacteria were grown for 6 weeks in Bac/T medium (Biomerieux, 
251011), pelleted by centrifugation and resuspended in sterile PBS to a stock 
concentration of 125 mg/ml wet weight corresponding to 2.20 x 105 CFU/ml as 
determined by plating serial dilutions on 7H9 agar plates (Difco, 271310). Mice were 
subcutaneously infected with 30 µl of a 1/100 dilution of the stock solution in sterile 
PBS into the hind left foot pad. Progression of the infection was followed by weekly 
measurements of the foot pad thickness using a caliper. At week 5, mice were 
euthanized and pictures of the feet were taken using a compact camera (WG-20, RICOH). 
Afterwards, foot pads were aseptically removed for determination of bacterial load by 
quantitative RT-PCR or for histopathological analysis.  
 
 
Determination of bacterial load by quantitative RT-PCR  
For preparation of foot pad lysates, mouse feet designated for quantification of M. 
ulcerans bacteria were removed above the ankle after euthanasia, cut into 4 pieces with 
a scalpel and transferred to hard tissue grinding tubes (MK28-R, Precellys, KT03961-1-
008.2). Afterwards, 750 µl sterile PBS was added and homogenization was performed 
using a Precellys 24-Dual tissue homogenizer (3 x 20 s at 5000 rpm with 30 s break). 
Results Chapter 1 
 
64 
The lysate was transferred into a new tube and the remaining, still intact tissue was 
homogenized for a second time after adding 750 µl of sterile PBS. After homogenization, 
the two lysates were pooled and used for DNA extraction. 
DNA was isolated from 100 µl of a 1/20 dilution of the foot pad lysate as described by 
Lavender and Fyfe [32]. Isolated DNA was analyzed for IS2404 by quantitative RT-PCR 
as previously described [32]. Ct values were converted into number of genomes per foot 
pad by using the standard curve established by Fyfe et al. [41]. 
 
 
Histopathology  
Mouse feet designated for histopathological analysis were removed above the ankle and 
transferred to 10 % neutral-buffered Formalin solution (4 % formaldehyde, Sigma, 
HT501128-4L) and fixed during 24 hours at room temperature. Afterwards, the feet 
were decalcified in 0.6 M EDTA and 0.25 M citric acid for 14 days at 37 °C and 
transferred to 70 % ETOH for storage. After dehydration and paraffin embedding, 5 μm 
thin sections were cut, de-paraffinised, rehydrated, and stained with 
Haematoxylin/Eosin (HE, Sigma, 51275-500ML, J.T. Baker, 3874) or Ziehl-
Neelsen/Methylene blue (ZN, Sigma, 21820-1L and 03978-250ML) to stain for 
mycobacteria according to WHO standard protocols. Stained sections were mounted 
using Eukitt® mounting medium (Fluka, 03989) and pictures were taken with a Leica® 
DM2500B microscope or with an Aperio scanner.     
 
 
Statistics 
Two-sided Student’s t test was used for statistical analysis (Prism GraphPad). We 
assumed normality and equal distribution of variance between the different groups 
compared. 
 
 
Study approval  
Analyzed human tissue samples were collected during another trial (ISRCTN72102977) 
and were reanalysed for the current purpose. Ethical approval for analyzing patient 
specimens was obtained from the National Ethics Committee of Cameroon and the 
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Ethics Committee of the Heidelberg University Hospital, Germany. Written informed 
consent from the patients or the guardians of the patients exists. 
All animal experiments were approved by and performed according to the guidelines 
and regulations of the local animal welfare committee of the Canton of Vaud, 
Switzerland (authorization number 2657). 
 
Results Chapter 1 
 
66 
References 
1.  Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of 
Mycobacterium ulcerans. Nat Rev Microbiol. 2009;7: 50–60. doi:10.1038/nrmicro2077 
2.  Guarner J, Bartlett J, Whitney EAS, Raghunathan PL, Stienstra Y, Asamoa K, et al. Histopathologic 
features of Mycobacterium ulcerans infection. Emerg Infect Dis. 2003;9: 651–656.  
3.  Junghanss T, Johnson RC, Pluschke G. 42 - Mycobacterium ulcerans Disease. Manson’s Tropical 
Infectious Diseases (Twenty-Third Edition). London: W.B. Saunders; 2014. pp. 519–531.e2. Available: 
http://www.sciencedirect.com/science/article/pii/B9780702051012000431. Accessed 9 November 
2015. 
4.  George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, et al. Mycolactone: a polyketide 
toxin from Mycobacterium ulcerans required for virulence. Science. 1999;283: 854–857.  
5.  Marion E, Song O-R, Christophe T, Babonneau J, Fenistein D, Eyer J, et al. Mycobacterial toxin induces 
analgesia in buruli ulcer by targeting the angiotensin pathways. Cell. 2014;157: 1565–1576. 
doi:10.1016/j.cell.2014.04.040 
6.  Gama JB, Ohlmeier S, Martins TG, Fraga AG, Sampaio-Marques B, Carvalho MA, et al. Proteomic 
analysis of the action of the Mycobacterium ulcerans toxin mycolactone: targeting host cells 
cytoskeleton and collagen. PLoS Negl Trop Dis. 2014;8: e3066. doi:10.1371/journal.pntd.0003066 
7.  Guenin-Macé L, Veyron-Churlet R, Thoulouze M-I, Romet-Lemonne G, Hong H, Leadlay PF, et al. 
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin 
Invest. 2013;123: 1501–1512. doi:10.1172/JCI66576 
8.  Hall BS, Hill K, McKenna M, Ogbechi J, High S, Willis AE, et al. The Pathogenic Mechanism of the 
Mycobacterium ulcerans Virulence Factor, Mycolactone, Depends on Blockade of Protein 
Translocation into the ER. PLoS Pathog. 2014;10: e1004061. doi:10.1371/journal.ppat.1004061 
9.  Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149: 274–293. 
doi:10.1016/j.cell.2012.03.017 
10.  Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011;23: 744–755. 
doi:10.1016/j.ceb.2011.09.003 
11.  Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, et al. Pathological angiogenesis 
is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10: 159–170. 
doi:10.1016/j.ccr.2006.07.003 
12.  Sarbassov DD, Ali SM, Sengupta S, Sheen J-H, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment 
inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22: 159–168. 
doi:10.1016/j.molcel.2006.03.029 
13.  Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the 
rictor-mTOR complex. Science. 2005;307: 1098–1101. doi:10.1126/science.1106148 
14.  Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the 
mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-
FOXO and PKCalpha, but not S6K1. Dev Cell. 2006;11: 859–871. doi:10.1016/j.devcel.2006.10.007 
15.  Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, et al. Effective and selective targeting of leukemia 
cells using a TORC1/2 kinase inhibitor. Nat Med. 2010;16: 205–213. doi:10.1038/nm.2091 
16.  Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene. 2008;27: 2312–2319. 
doi:10.1038/onc.2008.24 
17.  Gersbach P, Jantsch A, Feyen F, Scherr N, Dangy J-P, Pluschke G, et al. A ring-closing metathesis 
(RCM)-based approach to mycolactones A/B. Chem Weinh Bergstr Ger. 2011;17: 13017–13031. 
doi:10.1002/chem.201101799 
18.  Scherr N, Gersbach P, Dangy J-P, Bomio C, Li J, Altmann K-H, et al. Structure-Activity Relationship 
Studies on the Macrolide Exotoxin Mycolactone of Mycobacterium ulcerans. PLoS Negl Trop Dis. 
2013;7: e2143. doi:10.1371/journal.pntd.0002143 
19.  Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-Val-Ala-Asp 
(OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. 
Biochem J. 1996;315: 21–24.  
Results Chapter 1 
 
67 
20.  Wu Y-T, Tan H-L, Shui G, Bauvy C, Huang Q, Wenk MR, et al. Dual role of 3-methyladenine in 
modulation of autophagy via different temporal patterns of inhibition on class I and III 
phosphoinositide 3-kinase. J Biol Chem. 2010;285: 10850–10861. doi:10.1074/jbc.M109.080796 
21.  Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) 
polymerase by a proteinase with properties like ICE. Nature. 1994;371: 346–347. 
doi:10.1038/371346a0 
22.  Peterson JR, Lokey RS, Mitchison TJ, Kirschner MW. A chemical inhibitor of N-WASP reveals a new 
mechanism for targeting protein interactions. Proc Natl Acad Sci. 2001;98: 10624–10629. 
doi:10.1073/pnas.201393198 
23.  Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, et al. Apoptosis initiated when 
BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315: 856–859. 
doi:10.1126/science.1133289 
24.  Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003;17: 2481–2495. 
doi:10.1101/gad.1126903 
25.  Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a 
mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate 
poly(ADP-ribose) polymerase. Cell. 1995;81: 801–809.  
26.  Yu K, Toral-Barza L, Shi C, Zhang W-G, Lucas J, Shor B, et al. Biochemical, cellular, and in vivo activity 
of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 
2009;69: 6232–6240. doi:10.1158/0008-5472.CAN-09-0299 
27.  Boulkroun S, Guenin-Macé L, Thoulouze M-I, Monot M, Merckx A, Langsley G, et al. Mycolactone 
suppresses T cell responsiveness by altering both early signaling and posttranslational events. J 
Immunol Baltim Md 1950. 2010;184: 1436–1444. doi:10.4049/jimmunol.0902854 
28.  Guenin-Macé L, Carrette F, Asperti-Boursin F, Bon AL, Caleechurn L, Bartolo VD, et al. Mycolactone 
impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci. 
2011;108: 12833–12838. doi:10.1073/pnas.1016496108 
29.  Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-
trans peptidyl-prolyl isomerase. Nature. 1989;341: 758–760. doi:10.1038/341758a0 
30.  Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant 
FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341: 755–
757. doi:10.1038/341755a0 
31.  Galat A. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity--targets--functions. 
Curr Top Med Chem. 2003;3: 1315–1347.  
32.  Lavender CJ, Fyfe JAM. Direct detection of Mycobacterium ulcerans in clinical specimens and 
environmental samples. Methods Mol Biol Clifton NJ. 2013;943: 201–216. doi:10.1007/978-1-60327-
353-4_13 
33.  Simmonds RE, Lali FV, Smallie T, Small PLC, Foxwell BM. Mycolactone inhibits monocyte cytokine 
production by a posttranscriptional mechanism. J Immunol Baltim Md 1950. 2009;182: 2194–2202. 
doi:10.4049/jimmunol.0802294 
34.  Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P. Apoptosis regulators Fas and Bim 
cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity. 
2008;28: 197–205. doi:10.1016/j.immuni.2007.12.017 
35.  Weant AE, Michalek RD, Khan IU, Holbrook BC, Willingham MC, Grayson JM. Apoptosis regulators Bim 
and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. Immunity. 
2008;28: 218–230. doi:10.1016/j.immuni.2007.12.014 
36.  Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122: 3589–3594. 
doi:10.1242/jcs.051011 
37.  Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, Boneca IG, et al. Mycolactone diffuses into the 
peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring. PLoS 
Negl Trop Dis. 2011;5: e1237. doi:10.1371/journal.pntd.0001237 
Results Chapter 1 
 
68 
38.  Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, et al. Selective suppression of dendritic 
cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med. 2007;204: 1395–1403. 
doi:10.1084/jem.20070234 
39.  Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei D, Pluschke G, et al. 
Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical 
excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol. 
2006;79: 1150–1156. doi:10.1189/jlb.1005581 
40.  Bratschi MW, Bolz M, Minyem JC, Grize L, Wantong FG, Kerber S, et al. Geographic distribution, age 
pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. 
PLoS Negl Trop Dis. 2013;7: e2252. doi:10.1371/journal.pntd.0002252 
41.  Fyfe JAM, Lavender CJ, Johnson PDR, Globan M, Sievers A, Azuolas J, et al. Development and 
application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in 
clinical and environmental samples. Appl Environ Microbiol. 2007;73: 4733–4740. 
doi:10.1128/AEM.02971-06 
 
Results Chapter 2 
 
69 
 
Results Chapter 2 
 
 
Interferon-γ is a Crucial Activator of Early Host Immune Defense 
against Mycobacterium ulcerans Infection in Mice 
 
 
 
Raphael Bieri1,2, Miriam Bolz1,2, Marie-Thérèse Ruf1,2 and Gerd Pluschke1,2* 
 
 
1Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland 
2University of Basel, Petersplatz 1, 4003 Basel, Switzerland 
 
 
* Corresponding author 
 
 
 
 
 
 
 
 
 
 
 
 
Article published in: 
PLOS Neglected Tropical Diseases 
Results Chapter 2 
 
70 
Abstract 
Buruli ulcer (BU), caused by infection with Mycobacterium ulcerans, is a chronic 
necrotizing human skin disease associated with the production of the cytotoxic 
macrolide exotoxin mycolactone. Little is known about the type of immune responses 
elicited against this pathogen and the effector functions conferring protection against 
BU. While histopathological analyses of advanced BU lesions have demonstrated a 
mainly extracellular localization of the toxin producing acid fast bacilli, there is growing 
evidence for an early intra-macrophage growth phase of M. ulcerans. This has led us to 
investigate whether interferon-γ might play an important role in containing M. ulcerans 
infections. In an experimental Buruli ulcer mouse model we found that interferon-γ is 
indeed a critical regulator of early host immune defense against M. ulcerans infections. 
Interferon-γ knockout mice displayed a faster progression of the infection compared to 
wild-type mice. This accelerated progression was reflected in faster and more extensive 
tissue necrosis and oedema formation, as well as in a significantly higher bacterial 
burden after five weeks of infection, indicating that mice lacking interferon-γ have a 
reduced capacity to kill intracellular bacilli during the early intra-macrophage growth 
phase of M. ulcerans.  
This data demonstrates a prominent role of interferon-γ in early defense against M. 
ulcerans infection and supports the view that concepts for vaccine development against 
tuberculosis may also be valid for BU.  
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Author Summary 
Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU), a slow progressing 
ulcerative skin disease. The mode of transmission of M. ulcerans remains unknown and 
only little is known about the early stages of the disease and the nature of protective 
immune responses against this pathogen. 
Given the increasing evidence for an early intracellular growth phase of M. ulcerans, we 
aimed at evaluating the impact of cell-mediated immunity for immunological defense 
against M. ulcerans infections. By comparing wild-type and interferon-γ-deficient mice in 
a BU mouse model, we could demonstrate that interferon-γ is a critical regulator of early 
host immune defense against M. ulcerans infections, indicative of an important role of 
early intracellular multiplication of the pathogen. In mice lacking interferon-γ the 
bacterial burden increased faster, resulting in accelerated pathogenesis. The observed 
differences between the two mouse strains were most likely due to differences in the 
capacity of macrophages to kill intracellular bacilli during the early stages of infection.  
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Introduction 
Buruli ulcer (BU), caused by infection with Mycobacterium ulcerans (M. ulcerans), is a 
progressive disease of the skin and subcutaneous tissue. The disease is primarily 
affecting West African rural communities, but has also been reported from America, 
Australia and Asia. The pathogenesis of BU is mainly attributed to mycolactone, a 
macrolide exotoxin produced by M. ulcerans [1]. Mycolactone is essential for bacterial 
virulence and is highly cytotoxic for a wide range of mammalian cell types in vitro and in 
vivo, including fibroblasts, keratinocytes and adipocytes [1–4]. Injection of the toxin 
induces the formation of necrotic non-inflammatory lesions similar to BU lesions. 
Additionally to the induction of apoptosis, mycolactone possesses immunosuppressive 
characteristics and has been demonstrated to downregulate local and systemic immune 
responses [5,6], by interfering with the activation of immune cells such as T-cells, 
dendritic cells, monocytes and macrophages [7–10]. Furthermore, exposure to 
mycolactone results in complete inhibition of tumor necrosis factor alpha (TNFα) 
production by monocytes and macrophages, affects T-cell homing and interferes with 
the expression of T-cell receptors as well as co-stimulatory molecules including CD40 
and CD86 [6–12].  
Despite these immunosuppressive features of mycolactone, sera of individuals living in 
BU endemic regions frequently contain M. ulcerans-specific antibodies, demonstrating 
that many individuals develop immune responses associated with exposure to M. 
ulcerans without developing clinical disease [13,14]. Moreover, high mRNA levels for the 
cytokines interferon-γ (IFNγ), interleukin-1β and TNF-α were found in human BU 
lesions, indicating that the innate immune system is activated at the site of infection 
[15]. Reports on spontaneous healing of BU [16,17], and a partial protective effect of 
Bacille Calmette-Guérin (BCG) vaccination in humans and experimentally infected mice 
[18–21] are all factors indicating that clearance of the M. ulcerans infection by the 
immune system is possible, in particular before large clusters of mycolactone producing 
extracellular bacteria have formed. These clusters are located in necrotic subcutaneous 
tissue of advanced BU lesions and are no longer reached by infiltrating leukocytes.   
Antibodies against surface antigens of M. ulcerans do not seem to have a protective effect 
[22], indicating that cellular, and in particular type 1 helper (TH1) cell responses [1,23] 
are more important in immune defense against BU than humoral responses.  
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IFNγ is critical for host defense against intracellular pathogens. In Mycobacterium 
tuberculosis (M. tuberculosis) infections, IFNγ produced by TH1 cells, but also CD8 
cytotoxic T (Tc) cells and NK cells, renders the macrophage competent to kill 
intracellular bacteria by overcoming the pathogen-induced block in phagosome-
lysosome fusion and by producing microbicidal effectors such as nitric oxide (NO), 
resulting in host cell apoptosis and clearance of the bacteria [24–27]. In the early phase 
of an M. ulcerans infection an intra-macrophage growth phase seems to play an 
important role [6,28]. Protection mediated by IFNγ stimulated macrophages seems to be 
impaired by the suppression of IFNγ production after local build-up of mycolactone [29].  
Here we have re-evaluated the role of IFNγ for host immune defense against M. ulcerans 
by comparing progression of the infection in IFNγ knockout and wild-type mice 
experimentally challenged with a fully virulent M. ulcerans isolate. 
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Methods 
 
Ethical statement 
This study was carried out in strict accordance with the Rules and Regulations for the 
Protection of Animal Rights (Tierschutzverordnung) of the Swiss Federal Food Safety 
and Veterinary Office. The protocol was granted ethical approval by the Veterinary 
Office of the county of Vaud, Switzerland (Authorization Number: 2657). 
 
 
Mouse procedures  
Mice were kept in specific pathogen-free facilities at the Ecole Polytechnique Fédérale 
de Lausanne (EPFL), Switzerland. All experiments were performed under BSL-3 
conditions either in 8 weeks old female C57Bl/6 wild type mice or mice homozygous for 
the Ifngtm1Ts targeted mutation (IFNγ-/-, B6.129S7-Ifngtm1Ts/J, Jackson Laboratory). 
Animals were infected with the M. ulcerans strain S1013 isolated in 2010 from the 
ulcerative lesion of a BU patient from Cameroon [30]. The bacteria were cultivated from 
a low passage cell bank for six weeks in Bac/T medium (Biomerieux, 251011), pelleted 
by centrifugation and diluted in sterile PBS to a stock concentration of 125 mg/ml wet 
weight. Mice were infected subcutaneously into the hind left foot pad with 30 µl (about 1 
x 104 bacilli) of an appropriate dilution of the stock suspension in sterile PBS. 
Progression of the infection was followed by weekly measurements of the food pad 
thickness using a caliper. At weeks 1, 3, 5 and 8, groups of mice were euthanized and 
pictures of the feet were taken using a compact camera (WG-20, RICOH). The food pads 
were aseptically removed for determination of the bacterial load by quantitative real-
time PCR (qPCR) or for histopathological analysis.  
 
 
Determination of bacterial load by qPCR 
Feet designated for the quantification of M. ulcerans were cut into 4 pieces using a 
scalpel and transferred to hard tissue grinding tubes (MK28-R, Precellys, KT03961-1-
008.2). Next, 750 µl sterile PBS was added and feet were homogenized using a Precellys 
24-Dual tissue homogenizer (3 x 20 s at 5000 rpm with 30 s break). The lysates were 
transferred into new tubes and the remaining tissues were homogenized for a second 
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time after adding 750 µl of sterile PBS. The two lysates were pooled and used for DNA 
isolation. The DNA was extracted from 100 µl of a 1/20 dilution of the foot pad lysates as 
described by Lavender and Fyfe [31] and the isolated DNA was analyzed for insertion 
sequence (IS) 2404 by qPCR as previously described [31]. The number of genomes per 
foot pad was calculated according to the standard curve established by Fyfe et al. [32]. 
 
 
Histopathology 
Mouse feet used for histopathological analysis were fixed in 10 % neutral-buffered 
formalin solution (4 % formaldehyde, Sigma, HT501128-4L) for 24 hours at room 
temperature, decalcified in 0.6 M EDTA and 0.25 M citric acid for 14 days at 37 °C and 
transferred to 70 % EtOH for storage. After dehydration and embedding in paraffin, 5 
μm thin sections were cut. Sections were then deparaffinised, rehydrated, and stained 
with Haematoxylin/Eosin (HE, Sigma, 51275-500ML, J.T. Baker, 3874) or Ziehl-
Neelsen/Methylene blue (ZN, Sigma, 21820-1L and 03978-250ML) to stain for 
mycobacteria according to WHO standard protocols [33]. Finally, the sections were 
mounted with Eukitt mounting medium (Fluka, 03989) and pictures were taken with an 
Aperio scanner or with a Leica DM2500B microscope. 
 
 
Western Blot analysis 
10 μg of M. ulcerans whole cell lysate was resolved on a 1-well 4-12 % gradient gel 
(NuPAGE Novex 4-12 % Bis-Tris Gel, Invitrogen, NP0330BOX) using MES running buffer 
and transferred to nitrocellulose membranes with the iBlot dry-blotting system (Novex, 
Life Technologies) according to the manufacturer’s recommendations. The membrane 
was blocked in 5 % skim milk / PBS overnight at 4 °C, cut into thin strips and incubated 
with the indicated sera diluted 1:400 in 1 % skim milk / PBS-Tween-20 for 1.5 hours. 
After washing in 1 % skim milk / PBS-Tween-20, the membrane was incubated for 1 
hour with HRP-conjugated goat anti-mouse IgG γ-chain secondary antibody (Southern 
Biotech, 1030-05) diluted 1:4000 in 1 % skim milk / PBS-Tween-20. Blots were 
developed using the ECL Western Blotting Substrate (Pierce, 32106). 
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Statistics 
For statistical analysis, Student’s t test was used (Prism GraphPad). We assumed 
normality and equal distribution of variance between the different groups analyzed. 
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Results 
 
M. ulcerans infections progress faster in mice lacking IFNγ 
In order to evaluate the role of IFNγ in host immune defense against M. ulcerans 
infections, we infected 8 weeks old female C57Bl/6 wild-type (WT) mice and mice 
homozygous for the Ifngtm1Ts targeted mutation (IFNγ-/-) into the left hind foot pad with 
1 x 104 M. ulcerans bacilli. Progression of the disease was followed by weekly 
measurements of the foot pad thickness with a caliper. While all IFNγ-/- mice displayed 
strong swelling of the infected foot pads after 5 weeks of infection, no swelling was 
observed for the WT animals (Fig 1A). Six weeks after infection, some of the WT animals 
also started to show swelling of the infected feet. However, there was still a significant 
difference in foot pad thickness between the two different groups, which only resolved 
by week 8 (Fig 1A).  
Complementary to the determination of the foot pad thickness, we documented the 
disease progression with pictures of the infected feet at 1, 3, 5 and 8 weeks after 
infection (Fig 1B). At week 5 infected foot pads of the WT mice did not show any 
macroscopic difference to the non-infected right control foot pads (Fig 1B). In contrast, 
the infected feet of the IFNγ-/- mice were swollen and showed signs of inflammation (Fig 
1B). Although the difference in the food pad thickness resolved after 8 weeks of 
infection, the infected feet of the IFNγ-/- animals were more inflamed and clearly more 
ravaged at this time point (Fig 1B).  
 
 
IFNγ-deficient mice display more extensive tissue necrosis and oedema formation 
than WT mice 
Histopathological analysis of representative foot pads was performed to evaluate 
whether the increased foot pad thickness in IFNγ-/- mice at week 5 was caused by 
cellular infiltration or mainly by oedema formation. While no changes in tissue integrity 
were observed after 1 week of infection in both groups (Fig 2, A1-A3 and B1-B3), IFNγ-/- 
mice displayed massive oedema formation and tissue necrosis after 5 weeks of infection 
(Fig 2, B5, B4 and B6, respectively). Both are typical hallmarks of BU pathogenesis 
[34,35]. In contrast, the foot pads of the WT animals were devoid of oedema formation 
or tissue necrosis at this time point (Fig 2, A4-A6). Eight weeks after infection the foot 
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pads of the IFNγ-/- mice were still more oedematous and necrotic than those of the WT 
animals and the infection even affected the adjacent joints and legs (Fig 2, A7-A9 and B7-
B9).     
 
 
Enhanced bacterial multiplication in IFNγ-deficient mice 
Next, we assessed whether the more severe course of M. ulcerans infection in the IFNγ-/- 
mice was associated with a higher bacterial burden in these animals. The bacterial load 
in footpads of WT and mutant mice was determined 1, 3, 5 and 8 weeks after infection 
by qPCR [22,31,32]. Strikingly, the bacterial load in the mice lacking IFNγ was 
significantly (3.5 fold) higher after 5 weeks of infection than in WT mice (Fig 3A), 
correlating with the strong foot pad swelling observed at this time point in only the 
mutant mice (Fig 1, A and B). As for the foot pad thickness, the differences in the 
bacterial load had resolved 8 weeks after infection (Fig 3A). 
To reconfirm the qPCR results we stained tissue sections of whole foot pads with ZN to 
detect AFB. After 3 weeks of infection, only few AFB were found which were 
predominantly intracellular (Fig 3, B1 and B2). As for the qPCR analysis (Fig 3A), no 
difference in the total number of AFB was observed between the two groups at this time 
point. However, a trend to less extracellular bacterial debris and more viable 
extracellular bacilli was observed for IFNγ-/- foot pads at this time (S1 Fig).   
In contrast, more AFB were detected in the IFNγ-/- mice 5 weeks after infection (Fig 3, C3 
and C4), as compared to the WT controls (Fig 3, C1 and C2), which was again correlating 
with the results of the qPCR analysis (Fig 3A). At this time point, AFB were present as a 
mix of intra- and extracellular bacteria (Fig 3C). Interestingly, while the bacterial load 
was different for the two groups at this time point, no marked differences in the total 
cell infiltration was observed (Fig 3C). In line with the findings from the qPCR analysis 
(Fig 3A), the differences in the bacterial load had resolved 8 weeks after infection (S2 
Fig).   
 
 
Lack of antibody responses against M. ulcerans after 5 and 8 weeks of infection 
To evaluate whether the stronger increase in the bacterial load between weeks 3 and 5 
in the IFNγ-/- mice (Fig 3A) was caused by a diminished innate immune response as a 
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result of the lack activating IFNγ or rather by reduced antibody-mediated immune 
responses against M. ulcerans, we tested the reactivity of sera of infected mice with M. 
ulcerans whole cell lysates by Western Blot analysis. A complete absence of specific 
antibodies was observed both for WT and IFNγ-/- mice after 5 and 8 weeks of infection 
(Fig 4). Together with the observed presence of less extracellular debris in IFNγ-/- mice 
during the early phase of the infection (S1 Fig), this indicates that CMI is critical for host 
immunity against M. ulcerans infections.  
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Discussion 
Evidence for an early intra-macrophage growth phase of M. ulcerans has led to the 
suggestion that the immune effector mechanisms protecting against M. ulcerans 
infection are similar to those active against M. tuberculosis [36–38]. However, in contrast 
to this closely related pathogen, M. ulcerans has the capacity to produce the cytotoxic 
macrolide mycolactone, which eventually kills the host cells and causes the 
characteristic necrotizing pathology of BU [1,35]. In the case of M. tuberculosis infection, 
the host immune response involves cell-mediated immunity (CMI) accompanied by a 
delayed type hypersensitivity (DTH) reaction [39]. Similarly, several reports showed 
that CMI and DTH responses are frequently induced in BU patients [38,40–45].  
If CMI is required for immunological defense against M. ulcerans infections, IFNγ which 
is produced primarily by TH1, but also by TC and NK cells, is likely to play a critical role in 
this process by activating macrophages to kill intracellular bacteria at an early stage of 
infection. To test this hypothesis, we have used an experimental BU mouse model and 
compared the disease progression in WT and IFNγ-/- mice during active infection with a 
highly virulent M. ulcerans strain recently isolated from the lesion of a BU patient [30]. 
Our study conclusively demonstrates a key role of IFNγ for early immune defense 
against M. ulcerans infection in vivo, as mice lacking this cytokine suffered from an 
accelerated and more severe pathology associated with a significantly higher bacterial 
burden after 5 weeks of infection. These results indicate that CMI and IFNγ-dependent 
activation of the bactericidal activity of macrophages helps to contain the infection 
during its largely intracellular early stages. Further support for this hypothesis came 
from our histopathological analysis, where a trend to lower levels of extracellular acid-
fast debris was found in the IFNγ-/- mice at the early intracellular stages of the infection. 
Moreover, these findings are in line with the observation of Torrado et al. who have 
reported that IFNγ-dependent phagosome maturation and NO production are required 
to control the intracellular proliferation of M. ulcerans in vitro [29]. In the same report, it 
is described, that IFNγ-deficient mice show increased susceptibility only for 
mycolactone-negative or intermediate virulent, but not for highly virulent M. ulcerans 
strains [29]. However, these at first view contradictory results can be explained by the 
fact that the mice infected by Torrado et al. with a highly virulent M. ulcerans strain were 
only monitored over a period of 20 days post infection, a time frame that is too narrow 
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to detect the differences between WT and IFNγ-/- mice, as we did not observed them 
before 5 weeks of infection. 
In conclusion, our results indicate that the outcome of an infection with M. ulcerans may 
depend strongly on cellular immune defense mechanisms. IFNγ is likely to play an 
important role both as an element of innate immunity in the very early phase of host-
pathogen interaction after inoculation and also in the subsequent development of 
protective adaptive cellular immune responses. Innate and adaptive immune defense 
mechanisms seem to be strong enough in the majority of exposed individuals living in 
BU endemic areas to protect them from developing clinical disease [13,14]. However, 
when the immune response of an individual is too weak to kill the intracellular bacteria, 
BU disease may develop. Intracellular multiplication of the bacteria may take place and 
small accumulations of bacteria found as globus-like structures [46,47] may represent 
the origin for the formation of large clusters of mycolactone producing M. ulcerans 
bacteria. As a result of mycolactone-induced host cell apoptosis, necrotic areas are 
forming around the bacteria. Furthermore, in the advanced BU lesions viable leukocyte 
infiltrates are no longer found close to the infection foci in the necrotic subcutaneous 
tissue, indicating that the accumulation of mycolactone is preventing macrophages and 
other defense cells from reaching the now extracellular pathogens before they are killed. 
As a result, a chronic M. ulcerans infection may develop, leading to the formation of large 
BU lesions, often resulting in severe morbidity and disability and requiring long and 
costly hospitalization [35]. 
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Figures 
 
 
 
Fig 1. Faster progression of M. ulcerans infection in IFNγ-deficient mice.  
WT and IFNγ-/- mice were infected into the left hind foot pad with M. ulcerans and the 
progression of the disease was followed by weekly measurements of the food pad 
thickness (A) and documented with pictures of the infected feet (B). (A) IFNγ-/- mice 
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exhibited an accelerated progression of M. ulcerans infection. At weeks 5 and 6, the foot 
pad thickness was significantly higher in IFNγ-/- mice than in WT animals. Mean values 
of the foot pad thickness (mm) are shown, the error bars represent the S.D.. P values 
were calculated using two-tailed Student’s t test. ****, P ≤ 0.0001, **, P ≤ 0.01, n.s., not 
significant. (B) Pictures of representative feet taken 1, 3, 5 and 8 weeks after infection. 
At week 5, all mice deficient for IFNγ-/- had swollen feet. No swelling was observed in 
WT mice at this time point. Eight weeks after infection, foot pad swelling was observed 
for both WT and IFNγ-/- mice but the macroscopic disease symptoms were more severe 
in mice lacking IFNγ. Scale bars represent 5 mm. 
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Fig 2. Extensive tissue necrosis and oedema formation in mice lacking IFNγ.  
HE stained histologic sections of foot pads from representative WT (A) and IFNγ-/- (B) 
mice 1, 5 and 8 weeks after infection with M. ulcerans. Scale bars represent 5 mm (A1, 
A4, A7, B1, B4 and B7, left), 1 mm (A1, A4, A7, B1, B4 and B7, box), 150 µm (A2, A5, A8, 
B2, B5 and B8) and 80 µm (A3, A6, A9, B3, B6 and B9).   
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Fig 3. IFNγ-deficient mice have a significantly higher bacterial burden 5 weeks 
after infection.  
WT and IFNγ-/- mice were infected with M. ulcerans and the bacterial load was 
determined by IS2404-specific qPCR (A). The distribution of AFB in the footpads was 
assessed by histopathological analysis at week 3 (B) and week 5 (C). (A) IFNγ-/- mice had 
a significantly higher bacterial burden as compared to WT animals 5 weeks after 
infection with M. ulcerans. Values are displayed as mean, the error bars represent the 
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S.D. (n = 3 per genotype). P values were calculated using two-tailed Student’s t test. *, P ≤ 
0.05. (B and C) 5 μm tissue sections of foot pads from representative WT (left) and IFNγ-
/- (right) mice stained with ZN for visualization of AFB after 3 (B) or 5 (C) weeks of 
infection. AFB were predominantly intracellular at week 3 (B1 and B2, black arrows) 
whereas a mix of intra- and extracellular bacilli was found after 5 weeks of infection (C). 
At week 5, more AFB were present in IFNγ-/- foot pads (C2 and C4), no difference in the 
total immune cell infiltration between the two groups was observed (C1 and C3). Scale 
bars represent 8 µm (B1 and B2), 160 µm (C1 and C3) and 40 µm (C2 and C4). 
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Fig 4. Absence of specific antibody responses against M. ulcerans in infected WT 
and IFNγ-/- mice.  
Sera of WT and IFNγ-/- mice were analyzed 5 and 8 weeks after infection for the 
presence of specific IgG antibody responses against M. ulcerans by Western blotting on 
M. ulcerans whole cell lysate. A monoclonal antibody specific for the M. ulcerans antigen 
MUL3720 served as positive control.  
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S1 Fig. IFNγ-deficient mice show lower amounts of bacterial debris and higher 
numbers of intact extracellular bacteria 3 weeks after infection.  
Histologic analysis of foot pad sections from representative WT (left) and IFNγ-/- (right) 
infected for 3 weeks of infection with M. ulcerans. Arrows indicate bacterial debris (left) 
or intact AFB (right). Scale bars, 8 µm. 
 
 
 
 
S2 Fig. No differences in the amount of AFB after 8 weeks of infection.  
Histologic sections of foot pads from representative WT (left) and IFNγ-/- (right) mice 
infected for 8 weeks with M. ulcerans stained with ZN for AFB visualization. Scale bars, 
30 µm.  
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Abstract 
Imidazo(1,2-α)pyridine amines (IPA) represent one of the novel classes of compounds 
exhibiting high potency against M. tuberculosis. Among them, the TB drug candidate 
Q203 has outstanding activity and pharmacological properties. Here we tested Q203 and 
a pre-selected panel of IPA compounds for activity against Mycobacterium ulcerans, the 
causative agent of the neglected tropical skin disease Buruli ulcer (BU). We found 
several compounds with MIC values in the nanomolar range, outperformed however by 
Q203, which showed a MIC of <1 nM. Based on the promising in vitro activities, Q203 
and IPA-7 were selected for in vivo testing in a mouse foot pad model of established BU 
infection. Q203, but not IPA-7, had a striking activity when administered orally three 
times per week at 0.5 mg/kg for a period of four weeks. While a strong increase in foot 
pad thickness was observed for the controls and the IPA-7 treated mice during the four 
week treatment course, Q203 caused a complete regression of foot pad swelling. 
Furthermore, histopathological analyses revealed absence of typical hallmarks of BU 
histopathology, such as tissue necrosis and edema formation after completion of Q203 
treatment. These findings make Q203 a potent drug candidate for the treatment of BU. 
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Introduction 
A high-throughput phenotypic screen on macrophages infected with Mycobacterium 
tuberculosis carried out by Pethe et al. has led to the identification of two compounds 
belonging to the imidazo(1,2-α)pyridine amide (IPA) family [1–4]. Both molecules 
showed activity in the micromolar range against extra- and intracellular bacteria and 
were also found effective when tested on multi-drug resistant (MDR) clinical isolates. An 
extensive lead optimization program led to the selection of the IPA Q203, showing 
extracellular/intracellular MIC50 values of 2.7 nM and 0.28 nM, respectively [4,5]. Apart 
from its high in vitro potency, Q203 displayed desirable safety and pharmacokinetic 
profiles. Acute toxicity tests in mice indicated that concentrations up to 1000 mg/kg 
were tolerated without clinical signs of toxicity [4]. Pharmacokinetic studies in mice 
revealed a terminal half-life of nearly one day and a bioavailability of 90 %. In a mouse 
model of established tuberculosis, four weeks of treatment with Q203 at 0.4, 2 and 10 
mg per kg body weight reduced the bacterial load by 90 %, 99 % and 99.9 % [4]. 
Recently, another representative of the powerful IPA compound family [6,7], designated 
ND-09759, was shown to have activities in the nanomolar range [8] and to efficiently 
decrease the bacterial burden in lungs and spleens of M. tuberculosis infected mice.  
Similar to bedaquiline, a bactericidal diarylquinolone drug approved for clinical 
treatment of TB, members of the IPA family interfere with ATP synthesis. While 
bedaquiline binds to the F0-subunit of the mycobacterial ATP synthase and disturbs the 
proton gradient serving as an uncoupler [9–11], Q203 targets the b subunit of the 
electron transport complex ubiquinol - cytochrome c reductase (QcrB). Interaction with 
the Qp quinone binding site of the b subunit results in the exclusion of the substrate, and 
finally in an impaired ATP production [2,4,12]. As a major drawback, adverse effects 
such as nausea, headaches, arthralgia and arrhythmias have been described for 
bedaquiline, therefore its use is limited to patients suffering from MDR or XDR TB [13].  
Since the IPA compound family has good overall druggable properties and holds with 
the optimized IPA Q203 one of the currently most promising candidate drugs for the 
treatment of TB, we initiated a study in which we tested the activity of a selected panel 
of IPA compounds, including Q203, on M. ulcerans. Potent drugs against Buruli ulcer 
(BU) are urgently needed, since the currently recommended 8-weeks combination 
therapy with rifampicin and streptomycin entails disadvantages. Streptomycin requires 
daily intramuscular injections and has been shown to cause ototoxicity and 
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nephrotoxicity [14,15] while rifampicin may be prone to cause resistances [16]. Thus, 
the evaluation of TB candidate drugs for application in BU is an attractive approach for 
identifying potential new treatment options.  
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Results 
 
IPA compounds show potent in vitro inhibitory activity against M. ulcerans  
By performing resazurin-based medium-throughput screens as previously described 
[17], we tested a pre-selected panel of 85 published and/or commercially available IPA 
compounds for activity against two M. ulcerans strains isolated from Cameroonian BU 
patients. Based on the determined minimal inhibitory concentrations we grouped the 
compounds into activity categories (Supplementary Table 1, Appendix Chapter 3).  
20/85 (24 %) compounds were highly active with a MIC <0.1 μg/ml, with 8 of them 
having a MIC <0.01 μg/ml and a single compound - Q203 - even displaying a MIC <0.001 
μg/ml (Figure 1A and 1B).  
The SAR study of the IPA against M. ulcerans was found to yield largely similar results as 
the SAR study against M. tuberculosis [5]. Small residues like halogen, methyl or ethyl 
were tolerated on the imidazopyridine core, while the optimum activity of the 
substitution pattern depended on the amide residue. For the amide residue, p-
phenylbenzylamides, preferentially substituted with p-Cl, showed very high activities in 
the cell based assay. They were followed by p-(dialkylamino)benzylamides and p-
alkoxybenzylamides. Aliphatic, heterocyclic or branched amides had significantly 
reduced activities. Recently, pharmacokinetic data for the p-phenylbenzylamides were 
described, indicating some limitations due to their high lipophilicity and superior 
pharmacokinetic properties for the Q203 substitution pattern. The IPA compounds 
Q203 and IPA-7 were selected from the pool of the nine highly active compounds for 
more detailed profiling. 
MIC values for Q203 and IPA-7 were determined by performing resazurin-based 
metabolic activity assays with four M. ulcerans clinical isolates belonging to the classical 
lineage [18]. The strains tested included two low passage clinical isolates from 
Cameroon (S1013 and S1298), and one isolate each from Togo (S1014) and from 
Australia (S1251). The measured MIC values were in the range of 0.6 ng/ml (1 nM) for 
Q203 and 10 ng/ml (25 nM) for IPA-7 (Figure 2). The dose-response data showed a 
sharp threshold for Q203, while the curve progression was less steep for IPA-7.  
Next, we performed time-kill kinetic assays by cultivating strain S1013 in liquid broth 
medium in the presence of different concentrations of Q203 and IPA-7 (equivalent to 
0.25x, 1x, 2x, 4x, 8x and 16x the respective MIC) for different time periods (0, 3, 7, 14, 21 
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and 28 days), before plating the bacteria for CFU determination. After incubation of 
plates for 16 weeks at 30 °C, CFUs were enumerated and in vitro kill-kinetic curves were 
generated (Figure 3). The results of the kill kinetic assays confirmed the MIC and dose-
response data obtained with the metabolic activity assays (Figure 2). Q203 exerted 
strong bactericidal effects (4-log10 CFU/ml reduction, 99.99 % killing) when bacteria 
were exposed for at least 14 days to minimally 1x the MIC. For IPA-7, a reduction in 
bacterial numbers could also be observed after two weeks of drug treatment, but killing 
was less complete when bacteria were exposed to 1x or 2x the MIC concentration 
(Figure 3). 
 
 
Q203 shows potent in vivo activity against M. ulcerans 
To monitor the response to antibiotic treatment in vivo, we infected BALB/c mice by foot 
pad injection with M. ulcerans. Progression of the infection was followed by weekly 
measurements of the foot pad thickness using a caliper (Figure 4A). Five weeks after 
infection, when the mice started to show swelling of the infected feet (Figure 4A), the 
treatment was initiated by orally administering either rifampicin (10 mg/kg), Q203 (0.5 
mg/kg), IPA-7 (0.5 mg/kg) or a solvent control three times per week for a period of four 
weeks. A strong increase in foot pad thickness was observed for the controls and the 
IPA-7 treated mice during the four week treatment course (Figure 4A). Due to the severe 
progression of the infection, these animals had to be sacrificed after completion of the 
treatment. In contrast, a complete regression of the foot pad swelling was observed for 
the Q203 treated mice already 1.5 weeks after start of treatment (Figure 4A). The foot 
pad thickness of these mice returned to normal levels and did not increase again for the 
entire observation period of 10 weeks post treatment (Figure 4A). For rifampicin 
treated mice, the foot pad thickness reached a plateau after 2 weeks of treatment and 
started again to slightly increase after completion of treatment (Figure 4A). Responses 
to the suboptimal treatment with rifampicin (10 mg/kg three times a week instead of 
the recommended daily administration) varied strongly between animals 
(Supplementary Figure 1). The outcome of the different treatments is illustrated in 
Figure 4B where pictures of representative mice at the end of the treatment are shown. 
Histopathological analyses of foot pads taken at the end of the treatment revealed for 
the foot pads of the infected control animals (Figure 5A) and the IPA-7 treated mice 
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(Figure 5B) oedema formation and tissue necrosis, two typical hallmarks of BU 
histopathology [19,20]. Oedema formation and tissue necrosis were also present in foot 
pads of mice treated with rifampicin, however, to a much lower extent (Figure 5C). 
Strikingly, the foot pads of mice treated with Q203 looked almost identical to the non-
infected control foot pads (Figure 5, D1 and E1, respectively) and were completely 
devoid of oedema (Figure 5, D2) and tissue necrosis (Figure 5, D3).   
An IS2404-specific qPCR [21–23] was used to monitor the amounts of M. ulcerans DNA 
in the infected foot pads. In addition, tissue sections were stained with ZN to assess the 
integrity of AFBs. The qPCR analysis showed strongly increasing bacterial loads for the 
control mice and IPA-7 treated mice during the four week treatment period (Figure 6A). 
These findings are in line with the histopathological analyses, showing large 
extracellular clusters of solid-stained AFB for these mice (Figure 6, B1 and B2, C1 and 
C2, respectively). In the mice treated with rifampicin, bacterial multiplication was halted 
during the four weeks of treatment, but the amount of DNA started again to increase 
after completion of treatment (Figure 6A). As for the foot pad thickness values, a large 
in-group variance was observed at week 15 (Figure 6A). Compared to the controls and 
IPA-7 treated mice the bacteria were present in smaller extracellular clusters (Figure 6, 
D1) and presented as a mix of solid-stained and beaded AFB (Figure 6, D2). In Q203 
treated mice the amount of M. ulcerans DNA increased slightly during treatment, but 
dropped after completion of treatment (Figure 6A). Only small numbers of AFB were 
found in the tissue sections (Figure 6, E1), with the vast majority of these bacilli having a 
beaded, not solid-stained appearance (Figure 6, E2).  
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Discussion 
Screening of a panel of IPA compounds allowed for the identification of a series of 
derivatives with high in vitro activities (MIC < 0.01 μg/ml) against M. ulcerans, with 
Q203 ranking at the top (MIC < 0.001 μg/ml). Q203 represents the most active 
derivative of a lead optimization program for M. tuberculosis and it has been shown to 
have MIC50 values of 2.7 nM (in culture broth medium) and 0.28 nM (inside 
macrophages) [4]. While the majority of potent anti-tubercular agents are less active 
against M. ulcerans (N. Scherr, personal communication), Q203 displayed an even higher 
activity (MIC50 = 0.5 nM) against M. ulcerans. This was unexpected since Q203 is more 
than 5000 fold less effective against M. marinum (MIC50 = 3.5 μM) (Pethe et al., 2013), a 
close relative of M. ulcerans [24]. M. ulcerans has diverged from a common ancestor with 
M. marinum by uptake of a virulence plasmid and by drastic genome reduction [25]. 
Higher susceptibility to Q203 may thus be related to gene loss or inactivation. In the IPA 
lead optimization program that resulted in the development of Q203, the activity against 
M. tuberculosis was mainly improved through the introduction of a long and 
hydrophobic group at the R3 position [4]. This seems to be also relevant for an increase 
in potency against M. ulcerans, making Q203 an exceptionally active compound when 
compared with the in vitro activities of currently used BU drugs such as rifampicin (0.13 
μg/ml), streptomycin (0.25 μg/ml), ciprofloxacin (1 μg/ml), clarithromycin (0.25 μg/ml) 
and amikacin (1 μg/ml) [26–28]. To our knowledge, MIC values in the low nanomolar 
range against M. ulcerans have never been observed before.  
By using the BU mouse foot pad model, we evaluated the in vivo activity of Q203, IPA-7 
and rifampicin. As expected, three applications of rifampicin (10 mg/kg) per week for a 
period of four weeks were not sufficient to achieve complete cure. The high in vitro 
activity of IPA-7 did not translate into a good in vivo potency at the chosen regimen, 
which was however highly effective for Q203. Ten weeks after treatment completion, 
the group of Q203 treated animals was still devoid of relapses. Histopathological 
analysis showed after treatment with Q203 predominantly beaded and intracellular 
AFB, reconfirming the efficient killing of the bacteria. 
To the best of our knowledge, a complete cure of all mice infected with M. ulcerans has 
never been accomplished before by a one month treatment with a single antibiotic 
administered only 3 times per week. If clinical development of Q203 against M. 
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tuberculosis will be successful, this also holds great promises for the development of an 
alternative drug treatment regimen for M. ulcerans. 
 
Results Chapter 3 
 
102 
Acknowledgements 
We would like to thank Dr. Masato Murakami, Vincent Romanet, Caroline Stork, Ernesta 
Dammassa and Patricia Barzaghi Rinaudo from Novartis Basel for providing access to 
the lab equipment for histopathology as well as Peter Schmid for the Aperio scans of the 
foot pads.  
 
 
Author Contributions 
N.S., R. B. and G. P. conceived the study and wrote the paper; N.S. and R. B. performed the 
experiments; P.S., M.W., K.P., and G.P. provided technical advice and vital reagents and 
materials.  
 
 
Competing Financial Interests 
The authors have no competing financial interests. 
 
Results Chapter 3 
 
103 
Figures  
 
Figure 1: IPA compounds display very good in vitro activity against M. ulcerans.  
All 85 IPA compounds were tested in vitro by performing resazurin-based metabolic 
activity assays using two Cameroonian strains. The resulting MIC values were classified 
into six activity categories and presented in total numbers in the pie diagram (A). The 
chemical structures of the 9 IPA compounds with MIC values < 0.1 μg/ml are shown in 
(B). 
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Figure 2: In vitro dose-response curve of Q203 and IPA-7 against different M. 
ulcerans strains of the classical lineage.  
Metabolic activities of patient isolates originating from Cameroon (black circles and 
green squares), Togo (blue triangles) and Australia (red triangles) are displayed as 
mean values of duplicate samples. One representative of three independent experiments 
is shown.  
 
 
 
 
 
Figure 3: Time-to-kill kinetic assays of Q203 and IPA-7 against M. ulcerans. 
Cameroonian strain S1013 was incubated with different compound concentrations 
(multiples of the respective minimal inhibitory concentration) for 0, 3, 7, 14, 21 and 28 
days. Bacteria were then spread on 7H10 agar without compound and CFUs were 
counted after 16 weeks of growth at 30 °C. 
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Figure 4: Response to antibiotic treatment in M. ulcerans infected mouse foot 
pads.  
(A and B) Mice were infected with M. ulcerans into the left hind foot pad and the 
progression of the disease was followed by weekly measuring the foot pad thickness (A) 
and by taking pictures at the end of the treatment (B). After 5 weeks of infection, 
treatment was started by administering either rifampicin (blue squares), Q203 (red 
triangles), IPA-7 (green triangles) or solvent control (black circles) 3 times per week 
during a period of 4 weeks. (A) Mean values of the foot pad thickness (mm) are shown, 
and error bars represent the S.D. (B) Pictures of representative feet taken at the end of 
the treatment (week 9).  
 
Results Chapter 3 
 
106 
 
 
Figure 5: Absence of tissue necrosis and oedema formation in Q203 treated mice.  
HE stained histological sections of foot pads from representative control (A), IPA-7 (B), 
rifampicin (C), or Q203 (D) treated mice as well as of a non-infected control foot pad (E). 
Scans of whole foot pads (A1, B1, C1, D1 and E1) as well as pictures taken at the 
epidermis (A2, B2, C2, D2 and E2) and at the site of infection (A3, B3, C3, D3 and E3) are 
shown. Scale bars represent 5 mm (A1, B1, C1, D1 and E1), and 80 µm (A2, A3, B2, B3, 
C2, C3, D2, D3, E2 and E3).   
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Figure 6: Treatment with Q203 results in a strong reduction of the bacterial load 
and induces killing of AFB.  
(A) Bacterial load during the course of infection as determined by IS2404-specific qPCR. 
Individual animals are depicted, values are shown as log10 (genomes per foot pad) and 
mean values are linked by connecting lines. (B-E) Tissue sections of foot pads from 
representative control (B1 and B2), IPA-7 (C1 and C2), rifampicin (D1 and D2) and Q203 
treated (E1 and E2) mice stained with ZN for visualization of AFB. Scale bars represent 
200 μm (B1, C1, D1 and E1) and 10 μm (B2, C2, D2 and E2). 
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Supplementary Figure 1: Wide range of responses in mice treated with rifampicin.  
Mice treated with rifampicin showed a wide response range to the treatment, as 
illustrated by pictures taken at the end of the treatment (week 9). Scale bars represent 1 
cm. 
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Methods 
 
Bacterial strains, general growth conditions and reagents 
M. ulcerans strains S1012, S1013, S1047 and S1298 (isolated in 2010, 2011 and 2013 
from Cameroonian BU patients; also see [29]) were routinely propagated at 30 °C in 
BacT/Alert culture bottles supplemented with enrichment medium (bioMérieux). For in 
vitro compound testing, bacteria were grown either in liquid 7H9 medium or on 7H10 
agar, supplemented with 10 % (vol/vol) OADC. The M. ulcerans strain S1014 (Togo) was 
received from F. Portaels (ITM, Antwerp) and the Australian strain S1251 from J. Fyfe 
(VIDRL, Melbourne). 
Q203, used for initial screenings, was kindly provided by K. Pethe (Pasteur Institute 
Korea). For subsequent in vitro and in vivo experiments, re-synthesized Q203 was 
provided by K. Pethe (University of Singapore). The IPA screening panel encompassing 
85 IPA compounds was received from BASF SE, Ludwigshafen. 
 
 
Drug susceptibility assays 
Minimal inhibitory concentrations (MIC) were determined as described before [17] by 
performing resazurin-based metabolic activity assays in the 96-well plate format. 
Briefly, two-fold serial dilutions of compounds were set up in duplicates or triplicates in 
a volume of 100 μl. Then, 100 μl of a diluted M. ulcerans culture (OD=0.04) was added 
and incubated at 30 °C for 8 days in the presence of the compounds. Upon resazurin 
(0.125 mg/ml) addition, plates were transferred to 37 °C and incubated o/n. Compound 
activities were determined by fluorescence measurements (λ=540/588 nm). Unless 
otherwise stated, the determined MIC values refer to the actual measured minimal 
concentrations at which growth was still completely inhibited. The MIC values obtained 
were then classified into different activity categories.  
 
 
Kinetic survival assays 
Serial dilutions of compounds Q203 and IPA-7 (0.25, 1, 2, 4, 8 and 16 fold the 
corresponding MIC value) were set up in a volume of 100 μl. Then 100 μl of a diluted M. 
ulcerans S1013 (OD600=0.04) was added and bacteria were incubated at 30°C for 0, 3, 7, 
Results Chapter 3 
 
110 
14, 21 and 28 days in the presence of the compound. At every time point, bacteria were 
washed and 100 μl of undiluted, 1:100 or 1:1000 diluted bacterial suspension was 
plated on 7H10 agar. CFUs were assessed after 16 weeks of incubation at 30 °C. 
 
 
Infection of mice 
All mice were maintained in specific pathogen-free facilities at the Ecole Polytechnique 
Fédérale de Lausanne (EPFL, Switzerland) and the studies were performed under BSL-3 
conditions in eight weeks old female BALB/c mice (Harlan). For the infection of mice, 
the M. ulcerans strain S1013 was used [29]. For preparing the inoculum, the bacteria 
were cultivated for 6-8 weeks in Bac/T medium (Biomerieux, 251011), pelleted by 
centrifugation and resuspended in sterile PBS to a stock concentration of 125 mg/ml 
wet weight. The infection was performed by injecting 30 µl (about 6 x 103 bacilli) of an 
appropriate dilution of the stock solution in sterile PBS into the hind left foot pad of the 
mice. The course of infection was followed by weekly measurements of the foot pad 
thickness using a caliper.  
Mice were euthanized at treatment start (week 5), at the end of the treatment (week 9) 
and 6 weeks after completion of the treatment (week 15). Pictures of the feet were taken 
using a compact camera (WG-20, RICOH). Foot pads were aseptically removed for the 
determination of the bacterial load by quantitative RT-PCR or for histopathological 
analysis.  
 
 
Treatment of mice 
Treatment was started 5 weeks after infection when the first macroscopic signs such as 
foot pad swelling and reddening of the skin were observed. Treatment was given orally 
on three days per week during a period of four weeks (18 mice per treatment group). 
Q203 and IPA-7 were dissolved in 20 % D-α-Tocopherol polyethylene glycol 1000 
succinate (TPGS) (Sigma, 57688) / H20 containing 1 % Dimethyl Sulfoxide (Sigma, 
D2650) and administered at a concentration of 0.5 mpk. Rifampicin (Sigma, R3501) was 
dissolved in H2O and given at a concentration of 10 mpk. As a control, 20 % TPGS / H2O 
containing 1 % DMSO was administered.     
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Determination of the bacterial load by quantitative RT-PCR  
After euthanasia, mouse feet designated for quantification of M. ulcerans bacteria by 
qPCR were removed above the ankle, cleaned by 70 % EtOH, cut into 4 pieces and 
transferred to hard tissue grinding tubes (MK28-R, Precellys, KT03961-1-008.2). For the 
preparation of foot pad lysates, 750 µl sterile 7H9 medium was added and 
homogenization was performed using a Precellys 24-Dual tissue homogenizer (3 x 20 s 
at 5000 rpm with 30 s break). Afterwards, the lysate was transferred into a new tube 
and the remaining and still intact tissue was homogenized for a second time after 
addition of 750 µl of sterile 7H9 medium. The lysates were pooled and DNA was isolated 
from 100 µl of a 1/20 dilution of the pooled lysate as described by Lavender and Fyfe 
[21]. After DNA isolation, the bacterial load was determined by performing IS2404-
specific quantitative RT-PCR analysis as previously described [21]. Ct values were 
converted into genome numbers per foot pad by making use of the standard curve 
established by Fyfe et al. [22]. 
 
 
Histopathology 
Mouse feet used for histopathological analysis were removed above the ankle and fixed 
at room temperature during 48 hours in 10 % neutral-buffered Formalin solution (4 % 
formaldehyde, Sigma, HT501128-4L). The feet were decalcified in Formic Acid Bone 
Decalcifier (ImmunocalTM, StatLab, 1414A) for 6 days at room temperature and 
subsequently transferred to 70 % ETOH for storage. After dehydration and paraffin 
embedding, 5 μm thin sections were cut, de-paraffinised, rehydrated, and stained 
according to WHO standard protocols with Haematoxylin/Eosin (HE, Sigma, 51275-
500ML, J.T. Baker, 3874) to stain for connective tissue or Ziehl-Neelsen/Methylene blue 
(ZN, Sigma, 21820-1L and 03978-250ML) to stain for mycobacteria. The stained sections 
were mounted with the Eukitt® mounting medium (Fluka, 03989) and pictures were 
taken using a Leica® DM2500B microscope or an Aperio scanner.  
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General Discussion 
 
The WHO currently lists 17 diseases as neglected tropical diseases (NTDs), whereof BU 
belongs to one of four caused by bacteria. Altogether, these NTDs are responsible for 
substantial illness of more than one billion people worldwide and affect the world’s 
poorest population by impairing their physical and cognitive development and by 
limiting the productivity at the workplace, thereby making it difficult to earn a living 
[1,2].  
With the WHO’s acknowledgement of BU as a NTD in 1998, a new era of BU research 
was initiated and since then, the number of scientific reports on this devastating disease 
has strongly increased [3,4]. However, despite continuous research efforts, major 
aspects of the disease have remained mysterious such as the unidentified reservoir, the 
transmission of M. ulcerans or the mode of action of mycolactone. In addition to these 
open research questions, numerous aspects of BU care, such as early case detection or a 
more effective and well-tolerated treatment beyond the currently used R/S antibiotic 
combination therapy clearly need further improvement.  
Within the framework of this thesis, we have tackled some of the most relevant open 
research questions for the understanding of BU by studying the molecular pathways 
underlying the cytotoxic activity of mycolactone (Results Chapter 1) and by 
investigating the nature of protective immune responses against M. ulcerans infections 
(Results Chapter 2). Furthermore, important progress has been made towards a future 
treatment option by repurposing a highly active TB compound whose impressive anti-
BU activity could be demonstrated both in vitro and in vivo (Results Chapter 3).  
 
 
What has been learned about the molecular mechanisms underlying the cytotoxic 
activity of mycolactone and their impact on the pathogenesis of Buruli ulcer 
(Results Chapter 1)? 
Already 15 years ago it was demonstrated for the first time that mycolactone can induce 
apoptosis in cultured L929 fibroblasts and J774 macrophages as well as in the skin of 
guinea pigs [5]. However, five years later, results of another study published by the same 
group suggested that mycolactone-exposed cells might rather undergo a mix of 
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apoptosis and necrosis [6]. Since then, no substantial progress in the understanding of 
the molecular mechanisms underlying mycolactone-induced cell death has been made 
and despite the major importance of this issue for the pathogenesis of BU, the cellular 
receptor responsible for triggering these pathways has still not been identified [7].  
By using a set of selective inhibitors for apoptosis, programmed necrosis (necroptosis) 
and autophagy, we could show that mycolactone-exposed L929 fibroblasts exclusively 
die by apoptosis without an involvement of necroptosis or autophagy. These results 
could be reconfirmed in a follow-up quantitative real-time PCR (qPCR) screening 
approach for the most prominent genes involved in the regulation of apoptosis, 
necroptosis and autophagy, in which the pro-apoptotic Bcl-2 interacting mediator of cell 
death (Bim) was identified as a potential candidate gene responsible for mycolactone-
induced apoptosis. Subsequent analyses showed that Bim was highly up-regulated by 
mycolactone at mRNA as well as at protein levels in several cell types including L929 
fibroblasts, Jurkat T cells and J774 macrophages. It is important to mention that the up-
regulation of Bim protein levels was never observed before 24 hours of mycolactone 
treatment and that this up-regulation always directly preceded the induction of 
apoptosis in all cell types analyzed. To test whether Bim represents indeed the key 
regulator of mycolactone-promoted apoptosis, we silenced this gene by RNA 
interference and found that this results in an almost complete protection of 
mycolactone-induced apoptosis. Encouraged from the outcome of our promising in vitro 
studies we decided to perform an in vivo validation of our results by making use of an 
experimental BU mouse model. To that end, Bim-deficient mice were infected with M. 
ulcerans and the course of infection was compared to wild-type control animals. In 
contrast to the wild-type mice, Bim-deficient mice displayed a complete lack of tissue 
necrosis and oedema formation after five weeks of infection. Furthermore, Bim 
knockout mice were able to contain M. ulcerans infection and showed a significantly 
lower bacterial burden. A close vicinity of the remaining AFB to intact nuclei was 
indicative of the uptake of the bacteria by viable and functional phagocytes.  
Coagulative necrosis is a frequently used term in the BU field and describes the presence 
of extensive cell death and the pathogenesis of the disease due to tissue ischemia [8–11]. 
However, the de facto complete absence of tissue necrosis in M. ulcerans-infected Bim 
knockout mice and the detection of strong expression levels of Bim in clinical specimens 
of human BU patients suggest that the pathogenesis of BU is largely driven by the 
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induction of Bim-dependent apoptosis, raising the question whether coagulative 
necrosis is indeed involved in the pathogenesis of the disease. However, it should be 
emphasized that there might be discrepancies between the pathogenesis of BU in 
humans and mice, since a recently published study showed that mycolactone causes a 
depletion of endothelial cell thrombomodulin which is associated with the deposition of 
fibrin in BU lesions, a mechanism that might contribute to the formation of coagulative 
necrosis [10]. Yet, this study entirely relied on histopathological analyses without the 
demonstration of any mechanistic data and consequently it is not clear, whether these 
processes are indeed relevant for the initiation of the pathogenesis of the disease. 
 
After having identified Bim as the central mediator of mycolactone-induced apoptosis, 
we were wondering which molecular mechanisms might underlie its massive up-
regulation in mycolactone-exposed cells. Since the cellular effects of mycolactone 
reminded us of the mode of action of mTOR inhibitors, and since functional parallels 
between mycolactone and the natural mTOR inhibitor rapamycin have previously been 
postulated [7], we hypothesized that mycolactone might also act as an inhibitor of the 
mTOR pathway. In subsequent experiments we were not only able to demonstrate that 
mycolactone indeed has potent mTOR inhibitory activity, but we also found that the 
kinetics of mTOR inhibition caused by mycolactone and rapamycin were almost 
identical, suggesting that the two molecules might even share a similar mode of action.  
However, one major difference between the two compounds became evident. While the 
non-cytotoxic rapamycin was, as expected, primarily acting as an inhibitor of mTORC1, 
we found that mycolactone additionally possesses a very powerful mTORC2 inhibitory 
activity, leading to complete dephosphorylation and inactivation of the mTORC2-
targeted Akt kinase.  
The ultimate aim of the following experiments was to identify the molecular 
mechanisms linking the early mTOR inhibition with the subsequent up-regulation of 
Bim, finally resulting in Bim-promoted apoptosis. In search of potential factors we 
primarily focused on transcriptional regulators that are known to be activated in mTOR-
inhibited cells and which are able to directly induce the gene expression of Bim. One 
class of proteins that fulfilled both criteria was the so-called FoxO family of 
transcriptional regulators, a sub-family of the Forkhead family of transcription factors.  
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In mammalian cells, the FoxO family is comprised of four members: FoxO1, FoxO3, 
FoxO4 and FoxO6 [12]. While FoxO4 is mainly expressed in muscle, kidney and 
colorectal tissue, FoxO6 is primarily expressed in the brain and liver. In contrast, FoxO1 
and FoxO3 are expressed in nearly all tissues and therefore represented two promising 
candidate molecules for mediating the up-regulation of Bim [12]. By analyzing the 
expression levels of FoxO1 and FoxO3 in L929 fibroblasts, we found that predominantly 
FoxO3 was highly expressed in these cells. Therefore, we decided to silence this factor 
through RNA interference and evaluated the impact on cell viability. We found that 
knockdown of FoxO3 resulted in a decreased up-regulation of Bim and a significant 
protection from Bim-dependent apoptosis. The results of this experiment confirmed that 
FoxO3 constitutes the main factor linking mycolactone-induced mTOR inhibition and 
Bim up-regulation in mycolactone-treated cells. However, while knockdown of Bim 
resulted in an almost complete rescue of the phenotype, silencing of FoxO3 only partially 
protected the cells from mycolactone cytotoxicity, suggesting that also other FoxO family 
members might be involved in this process. 
 
After having demonstrated that the mTORC2-Akt-FoxO3-Bim axis represents the central 
pathway underlying mycolactone cytotoxicity, we aimed at characterizing the 
mechanism of mycolactone-mediated mTOR inhibition in more detail. Given that 
mycolactone and rapamycin share similar cellular effects such as the induction of an 
early cell-cycle arrest or the downregulation of various cytokines [7] as well as the 
observation of an almost identical kinetics of the mTOR inhibition induced by these two 
molecules it is tempting to speculate whether they might even share the same cellular 
receptor. 
In fact, by using an ELISA-based approach and biotinylated synthetic mycolactone 
derivatives with an unmodified, lower or upper side chain, respectively [13], we were 
able to show that mycolactone also binds to the intracellular 12kDa FK506-binding 
protein (FKBP12). To test whether mycolactone binding to FKBP12 is required for the 
cytotoxic activity of the molecule, we performed a competition experiment using FK506 
(Tacrolimus), an immunosuppressive drug binding to the conserved active site of 
FKBP12 [14–16]. Indeed, administration of a 10-fold molar excess of FK506 already 
resulted in a significant protection from mycolactone-induced apoptosis in L929 
fibroblasts, and a 1000-fold excess completely protected the cells. Based on the results 
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of these experiments we could draw two major conclusions. Firstly, mycolactone and 
rapamycin share a highly similar mode of action by binding to the same site of FKBP12. 
Secondly the existence of a secreted, so far unidentified factor required for the induction 
of mycolactone-induced apoptosis as previously speculated [17] can most likely be 
excluded. Hence, the recently published mechanism of mycolactone-mediated blockade 
of protein translocation to the ER, resulting in a nearly complete loss of all secreted and 
glycosylated proteins, is obviously relevant for mycolactone-induced 
immunosuppression by affecting the secretion of various cytokines [17]. However, this 
blockade is clearly not involved in the pathways constituting the molecular basis of 
mycolactone cytotoxicity. In addition, among all factors that are part of the mycolactone-
induced apoptosis pathway, Bim is the only protein that has to be de-novo synthesized. 
Since Bim is a non-glycosylated cytosolic protein, it is most likely not affected by the 
mycolactone-mediated inhibition of protein translocation [17].   
 
 
Could the new mechanistic insights into mycolactone cytotoxicity be used for the 
development of a novel therapeutic approach? 
The identification of the mTORC2-Akt-FoxO3-Bim axis as the central mechanism 
underlying mycolactone-induced apoptosis raises questions about the potential for 
therapeutic interventions affecting this pathway. Although we can conclude from the 
outcome of our in vitro and in vivo experiments that targeting Bim would be a promising 
strategy to treat BU, such a therapy would most likely be accompanied by strong side 
effects, since Bim is essential for apoptosis in various mature organ cell types, including 
osteoblasts, endothelial cells, epithelial cells and neurons [18]. Furthermore, Bim-
dependent apoptosis is absolutely critical for the maintenance and proper functioning of 
the immune system. For instance, it has been demonstrated that Bim deficiency results 
in an abnormal accumulation of myeloid and lymphoid cells as well as in an impaired 
development and function of B- and T-lymphocytes [19].  
The most promising approach to specifically interfere with the action of mycolactone 
might be an inhibition of the binding of the toxin to FKBP12. First of all, the competition 
experiments using FK506 (Tacrolimus) provided strong evidence that blocking of the 
conserved binding site of FKBP12 results in a nearly complete abolishment of the 
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cytotoxic activity of mycolactone. Furthermore, interfering with mycolactone binding to 
FKBP12 could additionally result in a reduction of the immunosuppressive activity of 
the toxin. Additional experiments are required to evaluate whether blocking the 
mycolactone/FKBP12 complex formation can also prevent the pathogenesis of BU in 
vivo. However, due to potential calcineurin-mediated side effects and the strong 
immunosuppressive characteristics of FK506 [20], a non-immunosuppressive analog 
such as FK1706 should be used in such an experimental setup [21].  
 
 
What is the significance of the mTORC2-Akt-FoxO3-Bim pathway for the 
immunosuppression mediated by mycolactone? 
In general, the immunosuppressive effects of mycolactone should be subdivided into 
two independent branches; a local and a systemic one. At a local level, the cytotoxic 
activity of mycolactone is responsible for the efficient killing of infiltrating immune cells 
and it has been demonstrated that M. ulcerans can proliferate for short time periods and 
at low multiplicity of infections (MOI) inside murine macrophages, until mycolactone 
causes apoptosis of the host cells, resulting in the release of the bacteria into the 
intercellular space [22]. For these processes, Bim-dependent apoptosis seems to be 
central as Bim-deficient mice showed only small numbers of acid-fast bacilli after 5 
weeks of infection. Furthermore, the bacteria were predominantly found in close vicinity 
of intact nuclei, indicative of the uptake by viable phagocytic cells, probably resulting in 
the destruction of the bacteria and the containment of the infection. In contrast, in wild-
type mice, the bacilli were found – as also typically observed in human BU lesions - in 
large extracellular clusters, suggesting that the host cells were killed during the early 
intracellular stage of the infection. 
On the other hand mycolactone additionally induces systemic immunosuppression and 
the functional parallels between mycolactone and the immunosuppressant rapamycin 
raised questions about the impact of the pathway underlying mycolactone-induced 
apoptosis on this systemic immunosuppression. In 1999, rapamycin was approved by 
the US Food and Drug Administration (FDA) for use in the prevention of kidney allograft 
rejection and nowadays, rapamycin and its derivative everolimus are still used for 
immunosuppressive treatment in solid organ transplantation [23].  
General Discussion 
 
120 
The mechanisms of rapamycin-mediated immunosuppression are multi-layered and 
highly complex. While the FK506 (Tacrolimus) / FKBP12 complex inhibits calcineurin 
phosphatase and the subsequent activation of the nuclear factor of activated T-cells 
(NFAT), thereby blocking the transcription of cytokines such as IL-2 and progression of 
the T-cell cycle from G0 to G1 [24], rapamycin / FKBP12 inhibits IL-2 signaling and other 
cytokine receptor-dependent signaling pathways via mTOR, a central downstream 
mediator of IL signaling, thus preventing the activation of T- and B-cells [25,26].  
Most likely, mycolactone also interferes with cytokine receptor-dependent signaling and 
the activation of T- and B-cells, since it showed even more potent mTOR inhibitory 
activity than rapamycin. This hypothesis is supported by observations from our lab 
showing that infection with mycolactone producing M. ulcerans bacteria leads to a 
complete suppression of humoral immune responses against the pathogen, an effect that 
is not observed during an infection with M. marinum, a close relative of M. ulcerans 
which is lacking the pMUM plasmid required for the production of mycolactone [27,28]. 
In addition to the interference with cytokine receptor signaling, mycolactone might act, 
like FK506, as a calcineurin inhibitor. In fact, NFAT-dependent inhibition of cytokine 
transcription might be involved in mycolactone-mediated immunosuppression, since it 
is well-known that the toxin is a potent suppressor of the expression of many cytokines, 
such as IL-2 in human T-cells in vitro and in BU patients [7,29–31]. 
Finally, in the past few years, research groups have provided us with a wealth of 
information demonstrating an important role for mTOR signaling in the regulation of 
innate immune responses by orchestrating a complex network of cellular and metabolic 
activities in myeloid cells. Activation of innate immune cells via Toll-like receptor (TLR) 
ligands, growth factors or cytokines triggers mTOR signaling, which is critical for 
shaping innate immune effector functions by controlling various cellular processes 
including cell migration, antigen presentation, T-cell stimulation or synthesis of 
inflammatory mediators such as cytokines, chemokines, prostaglandins and 
leukotrienes [32]. Despite major progress in the understanding of mycolactone-
mediated immunosuppression during the last few years [29], it is not clear to what 
extent these processes are also affected by mycolactone. Further studies should 
therefore aim at answering these open research questions, as they are crucial for a 
better understanding of the immunosuppression mediated by the toxin and for the 
pathophysiology of BU disease in general.  
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What is the impact of this work for the understanding of immunity and for the 
treatment of Buruli ulcer (Results Chapter 2 and 3)? 
Although knowledge about the mechanisms of mycolactone-mediated 
immunosuppression has considerably increased during the last decade, drawing 
conclusions on the type of immune effector functions relevant for defense against M. 
ulcerans has remained rather difficult [7]. The results of our experimental infection 
experiments with wild-type and IFNγ-deficient mice have indicated that the outcome of 
an infection with M. ulcerans may depend strongly on the induction of early cellular 
immune defense mechanisms. The absence of significant amounts of bacterial debris in 
IFNγ-deficient mice during the early intracellular stage of the infection was indicative of 
a reduced capacity of macrophages to kill intracellular M. ulcerans bacteria. As a 
consequence, a faster increase in the bacterial burden and an accelerated pathogenesis 
were observed. 
Beside a central role for innate immune effector mechanisms, there is mounting 
evidence for the generation of adaptive immune responses during M. ulcerans infection. 
For instance, it has been shown that sera of people living in BU endemic regions 
frequently contain M. ulcerans-specific antibodies, demonstrating that many individuals 
develop immune responses associated with exposure to M. ulcerans without developing 
clinical disease [33,34]. In line with this are the observation of a partial protection by 
Bacille Calmette-Guérin (BCG) vaccination in humans and mice [35–38] and reports on 
spontaneous healing of BU [39,40]. 
Clearance of M. ulcerans infections by the immune system might in particular be possible 
before large clusters of mycolactone-producing extracellular bacilli have formed. In 
advanced BU lesions, the high mycolactone concentrations seem to interfere efficiently 
with the activation of the immune system by the mechanisms described before.  
Immunosuppression seems to be reverted during treatment of BU [41]. 
Histopathological studies indicated that the production of mycolactone might decline 
early after start of R/S treatment, leading to a rapid onset of local cellular immune 
responses as characterized by a chronic leukocyte infiltration, the formation of defined 
granulomas and an efficient phagocytosis of extracellular bacteria [42,43]. In fact, we 
observed a massive cellular infiltration and a predominantly intracellular localization of 
AFB after 4 weeks of rifampicin treatment and to a lesser extent after Q203 treatment.  
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The reactivation of the immune system during R/S treatment might probably also be 
responsible for the strong reduction in relapse rates after the introduction of the R/S 
combination therapy in 2004 [44–46], in comparison to purely surgical treatment. 
However, although the recurrence rates could be reduced to around 2 % with the R/S 
treatment [45], it has also a number of disadvantages. First of all, the need for daily 
injection of streptomycin hinders decentralization of treatment in rural areas, where 
there is only limited access to health centers. The introduction of a solely oral treatment 
regimen is therefore one of the main goals of the WHO for the future treatment of BU 
[47]. In addition streptomycin may have severe side effects, such as nephrotoxicity and 
ototoxicity [47] and in a clinical trial, R/S treatment has led to hearing loss in more than 
25 % of the BU patients receiving this treatment [48]. 
In view of all these disadvantages, potent new drugs for treatment of BU are urgently 
needed. Since the IPA class of compounds showed potent activity against TB and had 
desirable safety- and pharmacokinetic profiles [49], we initiated a study in which we 
tested a selected panel of IPA compounds including the compound Q203 which was 
optimized for use as a TB drug, in vitro and in vivo on M. ulcerans. We found that Q203 is 
more active against M. ulcerans than for M. tuberculosis [49] and may thus have great 
potential for treatment of BU. While the strategy of repurposing compounds has many 
advantages, one disadvantage could be that use of a TB drug for BU treatment in a TB 
endemic region may be problematic, in particular when the duration of treatment 
required for BU therapy is shorter than for TB. This is the case for R/S treatment, which 
has raised concerns with respect to the potential enhancement of drug resistance 
development in M. tuberculosis in patients with co-infections, but also in cases where 
cutaneous TB is misdiagnosed as BU [50]. 
However, this potential disadvantage is outbalanced by all the positive aspects of Q203. 
Beside the striking activity against M. ulcerans, a phase 1 clinical trial for the treatment 
of pulmonary tuberculosis is currently in preparation for Q203 [51]. Approval of this 
compound for the treatment of TB would strongly facilitate subsequent clinical testing 
and introduction of it for BU therapy. In contrast, it would hardly be possible to find 
sufficient financial resources for an independent full drug development process for this 
neglected disease.  
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Conclusions 
 
In this PhD thesis, the molecular mechanisms underlying mycolactone cytotoxicity, a key 
factor in the pathogenesis of BU, were unraveled. In addition, by making use of the BU 
mouse foot pad model, the role of interferon-γ in immune defense against M. ulcerans 
was studied and the therapeutic potential of a novel tuberculosis drug candidate against 
BU was evaluated. The key findings of this thesis were: 
 
1. Mycolactone binds to the 12-kDa FK506-binding protein and acts as a potent 
mTOR inhibitor. Mycolactone-mediated inhibition of mTORC2 results in 
inactivation of Akt and dephosphorylation and activation of the Akt-targeted 
transcription factor FoxO3. Subsequent up-regulation of the FoxO3 target gene 
Bim leads to Bim-promoted apoptosis. 
2. Interferon-γ plays an important role during early host immune defense against M. 
ulcerans infection. Mice lacking this cytokine show a faster increase in bacterial 
burden and an accelerated pathogenesis. 
3. The tuberculosis drug candidate Q203 is highly active against M. ulcerans and 
may be suitable for replacing rifampicin as first line therapeutic option.  
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Supplementary Table 1 
 
Gene Symbol 0.5 h 3 h 12 h 24 h 
 9430015G10Rik 1.28 -1.02 1.11 -2.58 
 Abl1 1.25 1.06 -1.55 -1.16 
 Akt1 1.13 -1.13 -1.99 -2.49 
 Apaf1 1.17 -1.22 -1.04 -1.64 
 App 1.13 -1.07 -2.10 -1.27 
 Atg12 -1.21 -1.17 -1.27 -1.16 
 Atg16l1 1.14 1.12 -1.81 -2.21 
 Atg3 1.02 -1.03 -2.00 -2.01 
 Atg5 1.07 -1.10 -1.84 -2.56 
 Atg7 1.12 -1.07 -1.16 -1.27 
 Atp6v1g2 1.00 1.06 1.43 1.88 
 Bax -1.03 -1.19 -1.24 -2.75 
 Bcl2 -1.21 -1.30 -4.92 -7.72 
 Bcl2a1a -1.07 -1.10 -1.58 -1.86 
 Bcl2l1 1.08 -1.39 -3.70 -2.91 
 Bcl2l11 -1.22 -1.76 4.02 10.02 
 Becn1 -1.05 -1.05 -1.20 -1.42 
 Birc2 1.12 -1.41 1.12 1.38 
 Birc3 -2.67 -4.15 -4.08 -16.94 
 Bmf -1.03 -1.55 2.57 10.70 
 Casp1 1.03 -1.19 -1.16 1.23 
 Casp2 1.24 1.02 -1.45 -1.48 
 Casp3 1.10 -1.12 -1.87 -1.87 
 Casp6 1.19 -1.29 1.65 2.01 
 Casp7 1.01 1.00 -2.06 -2.19 
 Casp9 1.19 -1.24 1.25 1.96 
 Ccdc103 -1.41 -3.12 1.42 2.55 
 Cd40 1.02 1.26 -2.08 -4.99 
 Cd40lg 1.11 1.18 -1.19 -1.00 
 Cflar -1.02 -1.49 -2.73 -1.97 
 Commd4 1.04 -1.13 -1.07 1.05 
 Ctsb 1.13 -1.23 -1.23 1.45 
Ctss -4.04 -1.85 -3.40 1.28 
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 Cyld 1.05 -1.23 -1.43 -1.61 
 Defb1 -1.23 -1.85 -4.71 -5.82 
 Dennd4a -1.04 -1.01 -2.42 -2.72 
 Dffa 1.26 -1.02 -1.12 1.18 
 Dpysl4 -1.25 -1.30 1.02 -4.54 
 Eif5b -1.01 -1.22 -2.33 -3.04 
 Esr1 -1.10 -1.35 1.00 1.64 
 Fas 1.23 1.60 5.10 3.09 
 Fasl -2.34 -2.22 -2.91 -2.61 
 Foxi1 -1.26 1.06 -2.50 -2.96 
 Gaa 1.11 -1.12 -1.45 -1.14 
 Gadd45a 1.19 2.01 1.88 3.21 
 Galnt5 1.11 1.18 -1.19 -1.00 
 Grb2 1.13 -1.03 -1.47 -1.36 
 Hspbap1 -1.22 -1.38 -1.17 -1.40 
 Htt 1.06 -1.16 -2.03 -2.80 
 Ifng 3.43 -1.21 1.65 1.59 
 Igf1 1.08 -1.54 -2.53 2.31 
 Igf1r 1.01 -1.13 -1.50 -1.33 
 Ins2 -1.06 1.39 -1.25 -1.45 
 Irgm1 1.13 1.04 -1.48 1.22 
 Jph3 -1.85 -1.20 -1.76 -5.00 
 Kcnip1 1.96 1.30 -1.04 -1.21 
 Mag -1.32 1.09 -1.85 -2.56 
 Map1lc3a -1.03 -1.39 1.38 3.89 
 Mapk8 -1.06 1.01 -2.24 -3.06 
 Mcl1 -1.09 -1.37 -3.37 -4.23 
 Nfkb1 1.11 1.01 -2.07 -1.96 
 Nol3 1.16 -1.01 1.28 2.76 
 Olfr1404 1.12 1.15 -1.30 -2.61 
 Parp1 1.14 -1.07 -1.73 -2.87 
 Parp2 1.07 -1.19 -1.65 -4.06 
 Pik3c3 1.10 -1.17 1.26 1.06 
 Pvr -1.54 -1.42 -4.48 -8.53 
 Rab25 2.53 -1.17 -2.69 -2.14 
 Rps6kb1 1.10 1.02 -1.90 -2.69 
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S100a7a 1.79 1.44 -2.44 1.12 
 Snca 1.11 1.57 -1.20 -1.01 
 Spata2 -1.43 -1.11 -2.49 -3.11 
 Sqstm1 1.17 1.23 1.57 1.97 
 Sycp2 1.11 1.18 -1.19 -1.00 
 Tmem57 -1.18 -1.13 1.01 -1.16 
 Tnf 1.04 -1.47 -10.56 -9.24 
 Tnfrsf10b -1.03 1.21 -1.27 -2.42 
 Tnfrsf11b 1.11 1.18 -1.19 -1.00 
 Tnfrsf1a 1.05 -1.06 -1.27 -1.24 
 Traf2 -1.03 1.05 -1.77 -2.97 
 Trp53 1.17 -1.01 -1.59 -2.69 
 Txnl4b 1.24 -1.10 -1.28 -1.58 
 Ulk1 1.17 -1.07 1.99 2.21 
 Xiap -1.01 -1.27 -1.77 -1.65 
 
Supplementary Table 1: Results of a quantitative RT-PCR screen in L929 
fibroblasts.  
Expression levels of 84 key genes involved in the regulation of apoptosis, necrosis and 
autophagy were determined in L929 fibroblasts treated for 0.5, 3, 12 and 24 h with 80 
nM mycolactone. Values are displayed as fold change compared to DMSO control cells. 
One of two independent experiments, yielding similar results, is shown. 
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Synthesis of mycolactone derivatives 
 
General 
All non-aqueous reactions were carried out under argon atmosphere. All solvents used 
for reactions were purchased as anhydrous grade from Fluka. Solvents for extractions, 
flash column chromatography (FC) and thin layer chromatography (TLC) were 
commercial grade and distilled before use. Reactions were monitored by TLC using 
Merck TLC aluminum sheets (silica gel 60 F254). Visualization was achieved either by 
fluorescence quenching under UV light (λ=254 nm) or by staining with cerium sulfate / 
phosphomolybdic acid stain. FC was performed using Fluka silica gel 60 for preparative 
column chromatography (40-63 µm). Concentration under reduced pressure was 
performed by rotary evaporation at the appropriate temperature and pressure. NMR 
spectra were recorded on a Bruker AV-400 400 MHz and a Bruker DRX-500 500 MHz 
spectrometer at room temperature. Chemical shifts are reported as δ values (ppm). The 
solvent peaks were used as internal standards: Chloroform (δ 7.26), methanol (δ 3.31), 
or acetone (δ 2.05) for 1H spectra, and chloroform (δ 77.0), methanol (δ 49.0), or 
acetone (δ 29.84) for 13C spectra. Data are reported as follows: s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, br = broad signal. For inseparable isomers, 1H-NMR 
and 13C-NMR signals were assigned by HSQC and HMBC experiments. Infrared spectra 
(IR) were recorded on a Jasco FT/IR-6200 spectrometer. The absorption bands are 
given in wave numbers (cm-1). Optical rotations were measured on a Jasco P-1020 
polarimeter. Mass spectra were recorded on a Waters Micromass AutoSpec Ultima (EI-
Sector) or a Varian IonSpec Ultima (MALDI/ESI-FT-ICR) (both MS service of Laboratory 
of Organic Chemistry (LOC) at the ETH Zurich). Except when noted otherwise, high 
pressure liquid chromatography (HPLC) analyses were carried out using a Waters 
Symmetry column (C18, 3.5 µm, 4.6 x 100 mm). Preparative HPLC was carried out using 
Waters Symmetry columns (C18, 5 µm, 7.8 x 100 mm; C18, 5 µm, 19 x 100 mm). The 
absorbance of HPLC samples was recorded for wavelengths between 200 nm and 400 
nm. HPLC purity was determined by combining total absorbance from 200 nm to 400  
nm (“Max Plot”). 
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Truncated mycolactone analog 1 
 
 
Scheme S1: a) THF/H2O/AcOH 2:1:1, rt, 2.5 h, 90 %. b) sorbic acid, Cl3C6H2COCl, DIPEA, DMAP, THF, 2 h, 
rt, quant; c) HF·pyridine, THF/pyridine 6:1, rt, 2 h, 49 %. 
 
 
 
(6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6R)-2,2-di-tert-butyl-6-methyl-1,3,2-dioxasilinan-4-yl)-4-
methylhept-4-en-2-yl)-6-hydroxy-7,9-dimethyloxacyclododec-9-en-2-one (6). 
To a solution of TES-protected alcohol 51 (19.7 mg, 29 μmol) in THF (1.0 mL) were added H2O (0.5 mL) 
and HOAc (0.5 mL) at ambient temperature and the reaction mixture was stirred for 2½ h. Sat. aq. 
NaHCO3-solution was then added until no more gas evolved. EtOAc was added, the layers were separated, 
and the aq. layer was extracted with EtOAc (2 x 10 mL). The combined org. extracts were washed with 
brine, dried over MgSO4 and concentrated under reduced pressure. Purification of the residue by flash 
column chromatography (n-hexane/EtOAc 9:1) yielded 14.8 mg (90 %) of alcohol 6 as colorless oil. Rf (n-
hexane/EtOAc 2:1) = 0.53; [α]D25 = −36.2° (c = 0.47, CHCl3); 1H-NMR (400 MHz, CDCl3): δ 5.05 – 4.93 (m, 
3H), 4.18 – 4.08 (m, 1H), 3.69 (ddd, J = 11.3, 7.5, 1.8 Hz, 1 H), 3.54 – 3.47 (m, 1 H), 2.46 (dt, J = 14.2, 11.5 
Hz, 1H), 3.48 – 2.20 (m, 3H), 2.14 – 2.05 (m, 2H), 2.02 – 1.83 (m, 4H), 1.79 – 1.57 (m, 5H), 1.62 (s, 3H), 1.60 
(d, J = 1.2 Hz, 3H), 1.38 – 1.27 (m, 3H), 1.18 (d, J = 6.1 Hz, 3H), 1.04 – 0.92 (m, 6H), 1.00 (s, 9H), 0.98 (s, 
9H), 0.85 (d, J = 6.6 Hz, 3H); 13C-NMR (100 MHz, CDCl3): δ 175.2, 137.0, 132.6, 129.9, 123.1, 77.8, 77.2, 
71.0, 70.5, 45.4, 43.3, 41.7, 40.4, 35.0, 34.9, 34.8, 34.1, 30.0, 27.6 (3C), 27.2 (3C), 24.9, 22.7, 20.3, 19.6, 16.7, 
16.5, 16.1, 14.7; IR (neat):  3672, 2967, 2931, 2905, 2361, 2339, 1713, 1470, 1454, 1379, 1251, 1161,  
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(2E,4E)-((6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6R)-2,2-di-tert-butyl-6-methyl-1,3,2-dioxasilinan-4-
yl)-4-methylhept-4-en-2-yl)-7,9-dimethyl-2-oxooxacyclododec-9-en-6-yl)hexa-2,4-dienoate (7).  
To a solution of sorbic acid (3.1 mg, 28 μmol) in THF (1.0 mL) was added DIPEA (0.02 mL, 0.11 mmol), 
DMAP (17 mg, 0.14 mmol), and Cl3C6H2COCl (9 μL, 55 μmol). Immediately, the colorless solution turned 
turbid. Alcohol 6 (7.8 mg, 14 μmol) in THF (1.0 mL) was added. The white suspension was stirred at 
ambient temperature for 2 h. The reaction was quenched by adding sat. aq. NaHCO3-solution (5 mL), 
EtOAc (15 mL) and little water. The layers were separated and the aq. layer was extracted with EtOAc (2 x 
15 mL). The combined org. layers were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. Purification by flash column chromatography (n-hexane/EtOAc 20:1) yielded 9.6 mg 
(quant.) of ester 7 as an inseparable mixture of isomers (trans/cis 84:16) as slightly yellow oil. Rf (n-
hexane/EtOAc 9:1) = 0.48; [α]D25 = –18.64° (c = 2.40, CHCl3); 1H-NMR (400 MHz, CDCl3): δ 7.33 – 7.18 (m, 
1H), 6.29 – 6.01 (m, 2H), 5.76 (d, J = 15.7 Hz, 1H), 5.06 (d, J = 10.6 Hz, 1H), 4.95 (d, J = 9.5 Hz, 1H), 4.92 – 
4.82 (m, 1H), 4.80 – 4.68 (m, 1H), 4.19 – 4.06 (m, 1H), 3.69 (dd, J = 9.5, 7.7 Hz, 1H), 2.52 – 2.25 (m, 3H), 
2.16 – 1.87 (m, 7H), 1.85 (d, J = 5.8 Hz, 3H), 1.82 – 1.50 (m, 6H), 1.68 (s, 3H), 1.60 (d, J = 1.2 Hz, 3H), 1.39 – 
1.23 (m, 1H), 1.17 (t, J = 5.8 Hz, 3H), 1.00 (s, 9H), 0.98 (d, J = 6.7 Hz, 3H), 0.98 (s, 9H), 0.94 – 0.88 (m, 3H), 
0.85 (d, J = 6.7 Hz, 3H); 13C-NMR (100 MHz, CDCl3): δ 173.2, 166.6, 144.8, 139.1, 136.7, 132.7, 129.9, 129.8, 
122.6, 119.3, 78.8, 77.9, 76.0, 70.5, 45.6, 43.4, 41.7, 40.4, 35.5, 34.8, 31.9, 30.2, 29.7, 27.6 (3C), 27.2 (3C), 
24.9, 22.7, 20.4, 20.0, 19.6, 18.6, 16.7, 16.1, 15.7, 14.5; IR (film, CHCl3):   2962, 2931, 2857, 1729, 1712, 
1646, 1473, 1456, 1376, 1328, 1243, 1164, 1136, 1109, 998, 982, 940, 885, 826, 650; HR-ESI-MS calc. 
659.4701 for C39H67O6Si+, [M+H]+, found 659.4713. 
 
 
 
(2E,4E)-((6S,7S,12R,E)-12-((2S,6R,7R,9R,E)-7,9-dihydroxy-4,6-dimethyldec-4-en-2-yl)-7,9-
dimethyl-2-oxooxacyclododec-9-en-6-yl) hexa-2,4-dienoate (1).  
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To a solution of protected diol 7 (9.6 mg, 14.6 μmol) in THF (2.0 mL) and pyridine (0.34 mL) in a 10 mL 
Falcon tube was added HF·pyridine (ca. 70 % HF, 38 μL). The yellow solution was stirred at ambient 
temperature for 2 h. The reaction was quenched by adding sat. aq. NaHCO3-solution (10 mL) until the gas 
evolution ceased. Subsequently brine (2 mL) and EtOAc (15 mL) were added and layers were separated. 
The aq. layer was extracted with EtOAc (3 x 15 mL). The combined org. layers were dried over MgSO4 and 
concentrated under reduced pressure. Purification by flash column chromatography (n-hexane/ EtOAc 4:1 
to 3:2, 0.1 % MeOH) yielded 3.7 mg (49 %) of diol 1 as an inseparable mixture of isomers (2’E,4’E 
isomer/minor isomer 91:11). Rf (n-hexane/EtOAc 1:1) = 0.47; [α]D 25 = –40.3° (c = 1.10, CHCl3); 1H-NMR 
(400 MHz, acetone-d6, 2’E,4’E isomer):   7.24 (dd, J = 15.3 Hz, 10.0, 1H), 6.33 – 6.17 (m, 2H), 5.82 (d, J = 
15.3 Hz, 1H), 5.12 (d, J = 10.7 Hz, 1H), 5.04 (d, J = 9.8 Hz, 1H), 4.93 – 4.86 (m, 1H), 4.71 – 4.65 (m, 1H), 4.22 
– 4.16 (m, 2H, 2x OH), 4.00 – 3.92 (m, 1H), 3.54 – 3.47 (m, 1H), 2.55 – 2.44 (m, 1H), 2.44 – 2.33 (m, 2H), 
2.16 – 1.91 (m, 7H), 1.90 – 1.79 (m, 1H), 1.84 (d, J = 5.8 Hz, 3H), 1.74 – 1.62 (m, 3H), 1.71 (s, 3H), 1.64 (d, J 
= 1.3 Hz, 3H), 1.62 – 1.52 (m, 2H), 1.44 – 1.34 (m, 1H), 1.14 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H), 0.90 
– 0.87 (m, 6H); 13C-NMR (125 MHz, acetone-d6, 2’E,4’E isomer):  173.3, 166.7, 145.5, 139.9, 137.3, 133.4, 
131.2, 130.7, 123.9, 120.3, 79.3, 76.9, 76.3, 68.9, 46.4, 44.4, 43.8, 40.5, 35.9, 35.4, 32.8, 31.4, 29.8 (obscured 
by solvent signal), 24.6, 20.8, 20.4, 18.6, 17.1, 16.2, 15.9, 15.0; IR (film, acetone):   2952, 2929, 2889, 
2857, 1727, 1613, 1514, 1472, 1464, 1249, 1102, 1037, 1006, 836, 777; HR-ESI-MS calc. 519.3680 for 
C31H51O6+, [M+H]+, found 519.3671. 
 
Determination of HPLC purity: Purity of 1 was determined by HPLC (Water Symmetry C18 column, 3.5 
μm, 4.6 x 100 mm, injection: 10 μL, eluent: CH3CN/H2O 75:25 to 85:15, flow 1.0 mL/min).  
 
HPLC purification: 3.7 mg of 1 (HPLC purity >88 %) were purified by HPLC (Water Symmetry C18 
column, 19 x 100 mm, 5 μm, injection 1.0 + 0.1 mL MeOH, CH3CN/H2O 75:25 isocratic) yielded two 
product containing fractions. The fractions were combined, concentrated under reduced pressure and 
lyophilized overnight to yield 1.84 mg of 1 (trans/cis 84:13, HPLC purity >99 %). 
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C5 Biotin-tagged mycolactone analog 3 
 
 
Scheme S2: a) (1) CDI, THF, rt, 2 d; (2) H2O, rt, 45 min; (3) 1,2-bis(2-aminoethoxy)ethane, rt, 1 d, 81 %; b) 
HF·pyridine, THF/pyridine (4:1), rt, 2 h, 96 %; c) (+)-biotin, PyBop, DIPEA, DMF, rt, 30 min, 54 %.  
 
 
 
 (6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6R)-2,2-di-tert-butyl-6-methyl-1,3,2-dioxasilinan-4-yl)-4-
methylhept-4-en-2-yl)-7,9-dimethyl-2-oxooxacyclododec-9-en-6-yl-(2-(2-(2-aminoethoxy)ethoxy)-
ethyl)carbamate (8).  
To alcohol 6 (36 mg, 64 mol) in THF (4.0 mL) was added CDI (83 mg, 510 mol) at ambient temperature. 
The suspension was stirred at 40 °C for 1 d and subsequently at ambient temperature for 1 d. After 19 h, 
CH2Cl2 (2 mL) and additional CDI (4 x 21 mg, 510 mol) were added. When conversion was complete, 
water (28 L, 1.53 mmol) was added and the solution stirred for another 45 min. 1,2-bis(2-
aminoethoxy)ethane (162 L, 1.59 mmol) was added subsequently. The resulting milky suspension was 
stirred at ambient temperature for 1 d. Water (20 mL) and CH2Cl2 (20 mL) were added, the layers were 
separated and the aq. layer was extracted with CH2Cl2 (2 x 20 mL). The combined org. layers were washed 
with water (10 mL), dried over MgSO4 and concentrated under reduced pressure. Purification by flash 
column chromatography (CH2Cl2 to CH2Cl2/MeOH, 50:1 to 9:1) yielded 16 mg (34 %) of the product as a 
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colorless oil and 38 mg of a mixture of activated imidazolyl carbamate and the product. The mixture was 
dissolved in THF (2.0 mL) and 1,2-bis(2-aminoethoxy)ethane (97 L, 0.96 mmol) and a catalytic amount 
of DMAP were added. The colorless solution was stirred at ambient temperature for 1 d. Water (20 mL) 
and CH2Cl2 (20 mL) were added, the layers were separated and the aq. layer was extracted with CH2Cl2 (2 
x 10 mL). The combined org. layers were washed with water (10 mL), dried over MgSO4 and concentrated 
under reduced pressure. Purification by flash column chromatography (CH2Cl2/MeOH 50:1 to 9:1) yielded 
another 22 mg (47 %) of the product as a colorless oil to give a total of 38 mg (81 %) of amine 8. Rf 
(CH2Cl2/MeOH 4:1) = 0.16; []D25 = −26.7° (c = 0.53, CHCl3); 1H-NMR (400 MHz, CDCl3):  5.27 – 5.15 (m, 
1H), 5.02 (d, J = 10.2 Hz, 1H), 4.94 (d, J = 9.4 Hz, 1H), 4.86 (ddd, J = 11.7, 5.7, 2.9 Hz, 1H), 4.58 – 4.45 (m, 
1H), 4.20 – 4.06 (m, 1H), 3.75 – 3.47 (m, 9H), 3.41 – 3.29 (m, 2H), 2.88 (t, J = 5.2 Hz, 2H), 2.50 – 2.22 (m, 
3H), 2.18 – 1.45 (m, 19H), 1.32 (dt, J = 13.9, 11.2 Hz, 1H), 1.17 (d, J = 6.1 Hz, 3H), 1.02 – 0.87 (m, 24H), 0.83 
(d, J = 6.7 Hz, 3H); 13C-NMR (100 MHz, CDCl3):  173.2, 156.4, 136.7, 132.7, 129.8, 122.4, 79.4, 77.8, 75.9, 
73.3, 70.5, 70.3, 70.2, 70.1, 45.6, 43.4, 41.7 (2C), 40.7, 40.4, 35.5, 34.7, 32.0, 30.6, 29.6, 27.5 (3C), 27.2 (3C), 
24.9, 22.7, 20.3, 19.8, 19.5, 16.7, 16.0, 15.7, 14.4; IR (film, MeOH):  2961, 2931, 2858, 2357, 1722, 1524, 
1473, 1457, 1374, 1251, 1162, 1133, 1109, 1064, 1015, 982, 912, 886, 826, 650; HR-ESI-MS calc. 739.5287 
for C40H75N2O8Si+, [M+H]+, found 739.5280.  
 
 
 
(6S,7S,12R,E)-12-((2S,6R,7R,9R,E)-7,9-dihydroxy-4,6-dimethyldec-4-en-2-yl)-7,9-dimethyl-2-
oxooxacyclododec-9-en-6-yl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (9).  
To the protected diol 8 (16 mg, 22 mol) in THF (1.0 mL) and pyridine (0.26 mL) was added HF·pyridine 
(70 % in pyridine, 28 L, 1.08 mmol) at ambient temperature. The colorless solution was stirred at 
ambient temperature for 120 min. The reaction was quenched by adding sat. aq. NaHCO3-solution (ca. 10 
mL) until the evolution of gas ceased. CH2Cl2 (10 mL) was added and the layers were separated. The aq. 
layer was extracted with CH2Cl2 (3 x 5 mL). The combined org. layers were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification by flash column chromatography (CH2Cl2 to 
CH2Cl2/MeOH, 19:1 to 9:1 then 4:1) yielded 12.4 mg (96 %) of the diol 9 as colorless oil. Rf (CH2Cl2/MeOH 
4:1) = 0.06; []D25 = −14.5° (c = 0.42, MeOH); 1H-NMR (400 MHz, methanol-d4):  5.09 (d, J = 10.2 Hz, 1H), 
5.00 (d, J = 9.8 Hz, 1H), 4.93 – 4.83 (m, 1H, partly obscured by H2O signal), 4.50 – 4.39 (m, 1H), 4.01 – 3.90 
(m, 1H), 3.74 – 3.62 (m, 6H), 3.58 – 3.51 (m, 2H), 3.42 (ddd, J = 10.1, 7.7, 2.5 Hz, 1H), 3.36 – 3.25 (m, 2H, 
obscured by solvent signal), 3.16 – 3.09 (m, 2H), 2.60 – 2.33 (m, 3H), 2.21 – 1.79 (m, 8H), 1.72 – 1.57 (m, 
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11H), 1.49 (ddd, J = 14.0, 10.3, 7.4 Hz, 1H), 1.16 (d, J = 6.2 Hz, 3H), 1.01 – 0.87 (m, 9H); 13C-NMR (100 MHz, 
methanol-d4):   175.3, 159.1, 138.0, 134.2, 131.2, 123.9, 80.6, 77.6, 76.4, 71.4, 71.3, 71.2, 68.3, 67.9, 46.9, 
44.6, 44.3, 41.5, 40.8, 40.7, 36.4, 35.9, 33.5, 32.3, 29.9, 23.5, 21.0, 20.3, 17.2, 16.2, 15.9, 15.0; IR (film, 
MeOH):  3350, 2962, 2927, 1699, 1521, 1453, 1377, 1325, 1255, 1120, 1016, 941; HR-ESI-MS calc. 
599.4266 for C32H59N2O8+, [M+H]+, found 599.4263.  
 
 
 
(6S,7S,12R,E)-12-((2S,6R,7R,9R,E)-7,9-dihydroxy-4,6-dimethyldec-4-en-2-yl)-7,9-dimethyl-2-
oxooxacyclododec-9-en-6-yl-(2-(2-(2-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamido)ethoxy)ethoxy)ethyl)carbamate (2).  
To (+)-biotin (18 mg, 74 mol) in DMF (2.0 mL) were added DIPEA (43 L, 247 mol) and PyBop (51 mg, 
99 mol) at ambient temperature. The colorless solution was stirred at ambient temperature for 30 min. 
At this point all biotin had been consumed (TLC). The activated biotin (38 mol) in DMF (1.0 mL; 50 % of 
the above solution) was transferred dropwise to a flask charged with amine 9 (15 mg, 25 mol). The 
colorless solution was stirred at ambient temperature for 30 min. Sat. aq. NH4Cl-solution (5 mL), water 
(15 mL) and EtOAc (10 mL) were added, the layers were separated and the aq. layer was extracted with 
and EtOAc (3 x 10 mL). The combined org. layers were washed with sat. aq. NaHCO3-solution (2 x 3 mL) 
and brine, dried over MgSO4 and concentrated under reduced pressure. Purification by flash column 
chromatography (CH2Cl2 to CH2Cl2/MeOH, 96:4 to 93:7 then 90:10) yielded 11.1 mg (54 %) of amide 2 as 
colorless oil. Rf (CH2Cl2/MeOH 9:1) = 0.36; []D25 = +9.6° (c = 0.56, MeOH); 1H-NMR (400 MHz, methanol-
d4):  5.09 (d, J = 10.4 Hz, 1H), 5.00 (d, J = 9.7 Hz, 1H), 4.89 (ddd, J = 11.7, 5.0, 2.7 Hz, 1H), 4.54 – 4.41 (m, 
2H), 4.31 (dd, J = 7.9, 4.5 Hz, 1H), 4.00 – 3.87 (m, 1H), 3.66 – 3.58 (m, 4H), 3.58 – 3.50 (m, 4H), 3.42 (ddd, J 
= 10.2, 7.6, 2.5 Hz, 1H), 3.39 – 3.33 (m, 2H), 3.34 – 3.25 (m, 2H, partly obscured by solvent signal), 3.24 – 
3.18 (m, 1H), 2.93 (dd, J = 12.7, 5.0 Hz, 1H), 2.71 (d, J = 12.7 Hz, 1H), 2.57 – 2.33 (m, 3H), 2.23 (t, J = 7.4 Hz, 
2H), 2.16 – 1.42 (m, 26H), 1.16 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 6.7 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H), 0.89 (d, J 
= 6.7 Hz, 3H); 13C-NMR (100 MHz, methanol-d4):  176.1, 175.2, 166.1, 159.0, 138.0, 134.3, 131.2, 123.9, 
80.7, 77.6, 76.4, 71.3 (2C), 71.0, 70.6, 68.3, 63.4, 61.6, 57.0, 46.9, 44.6, 44.3, 41.6, 41.1, 40.8, 40.3, 36.7, 
36.4, 35.9, 33.5, 32.3, 30.0, 29.8, 29.5, 26.8, 23.5, 21.0, 20.5, 17.2, 16.2, 15.9, 15.0; IR (film, EtOAc):  3319, 
2930, 2871, 2360, 2338, 1695, 1540, 1454, 1374, 1332, 1312, 1253, 1160, 1129, 1093, 1016, 845, 558; 
HR-ESI-MS calc. 825.5042 for C42H73N4O10S+, [M+H]+, found 825.5045.  
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C20 Biotin-tagged mycolactone analog 2 
 
 
 
 
Scheme S3: a) a) (1) 41, t-BuLi (2.4 eq), MeO-9-BBN, Et2O/THF 1:1, −78 °C to rt, 45 min; (2) 101 (0.85 eq), 
Pd(dppf)Cl2 (0.1 eq), AsPh3, aq. Cs2CO3, DMF, rt, 19 h, 66 %; b) DDQ, CH2Cl2/water 5:1, rt, 2 h, 75 %; c) 
Ac2O, DIPEA, DMAP, CH2Cl2, rt, 30 min, quant.; d) THF/H2O/HOAc 3:1:1, rt, 6 h, 89 %. e) Cl3C6H2COCl, 
DIPEA, DMAP, rt, 16 h, 88 % (E-4’,5’/Z-4’,5’ 4.3:1); f) K2CO3, MeOH, rt, 180 min, 90 % (E-4’,5’/Z-4’,5’ 4:1). 
g) (1) CDI (12 eq), THF, rt, 5 h; (2) H2O, rt, 30 min; (3) 1,2-bis(2-aminoethoxy)ethane (25 eq), rt, 90 min, 
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87 % (E-4’,5’/Z-4’,5’ 3:1); h) (1) TBAF, THF, rt, 4 h; (2) NH4F, rt, 17 h, quant. (E-4’,5’/Z-4’,5’ 3:1); g) (+)-
biotin, DIPEA, PyBop, DMF, rt, 30 min, 63 % (E-4’,5’/Z-4’,5’/other isomers 63:29:8) 
 
 
 
(6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6S)-2,2-di-tert-butyl-6-(((4-methoxybenzyl)oxy)-methyl)-1,3,2-
dioxasilinan-4-yl)-4-methylhept-4-en-2-yl)-7,9-dimethyl-6-((triethylsilyl)oxy)oxacyclododec-9-en-
2-one (11).  
To a solution of alkyl iodide 4 [1] (80 mg, 0.16 mmol) and MeO-9-BBN (1.0 M in hexane, 0.41 mL, 
0.41 mmol) in diethyl ether (1.0 mL) in a 20 ml Schlenk flask was added t-BuLi (1.6 M in pentane, 0.24 mL, 
0.38 mmol) and THF (1.0 mL) slowly via syringe at −78 °C. The resulting yellow mixture was stirred at 
−78 °C for 10 min and was then allowed to warm to ambient temperature. It was stirred at ambient 
temperature for 45 min while it turned almost colorless. The solution was transferred into a solution of 
vinyl iodide 101 (75 mg, 0.13 mmol), Pd(dppf)Cl2 (11.5 mg, 16 μmol), AsPh3 (14.5 mg, 47 μmol), and aq. 
Cs2CO3-solution (3.0 M in H2O, 178 μL, 0.54 mmol) in DMF (1.0 mL) via syringe. The yellow suspension 
was stirred in darkness at ambient temperature for 19 h over which period it turned orange. H2O (20 mL) 
and Et2O (20 mL) were added, the layers were separated and the aq. layer was extracted with diethyl 
ether (2 x 20 mL). The combined org. layers were washed with brine (3 mL) and dried over MgSO4. The 
solvents were evaporated under reduced pressure. Purification by flash column chromatography (n-
hexane/EtOAc 50:1 to 20:1) yielded 72 mg (66 %) of coupling product 11 as colorless oil. Rf (n-
hexane/EtOAc 9:1) = 0.46; [α]D 25 =−17.89° (c = 0.66, CHCl3);1H-NMR (400 MHz, CDCl3):  7.26 (d, J = 8.6 
Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.00 – 4.95 (m, 2H), 4.84 (ddd, J = 11.7, 6.0, 3.0 Hz, 1H), 4.52 (s, 3H), 4.22 – 
4.15 (m, 1H), 3.80 (s, 3H), 3.75 (ddd, J = 11.5, 7.2, 1.6 Hz, 1H), 3.49 (dd, J = 10.0, 5.4 Hz,1H), 3.41 – 3.36 (m, 
1H), 3.33 (d, J = 10.0, 5.9 Hz, 1H), 2.53 – 2.31 (m, 3H), 2.12 (dd, J = 13.2, 4.2 Hz, 1H), 2.06 – 1.65 (m, 10H), 
1.66 (s, 3H), 1.59 (d, J = 1.0 Hz, 3H), 1.45 – 1.25 (m, 3H), 1.02 – 0.96 (m, 6H), 1.01 (m, 9H), 0.97 (s, 9 H), 
0.95 (t, J = 7.8 Hz, 9H), 0.83 (d, J = 6.8 Hz, 3H), 0.60 (q, J = 7.8 Hz, 6H); 13C-NMR (100 MHz, CDCl3):  173.5, 
159.1, 137.3, 132.8, 130.8, 129.6, 129.2, 129.1 (2C), 121.5, 113.8 (2C), 113.7, 77.8, 77.7, 75.7, 75.2, 73.5, 
73.0, 55.3, 45.4, 43.1, 40.4, 36.9, 35.9, 35.0, 33.5, 30.1, 27.5 (3C), 27.2 (3C), 22.8, 21.8, 19.7, 18.7, 16.5, 16.2, 
15.6, 7.0 (3C), 5.1 (3C); IR (film, CHCl3):  2956, 2933, 2875, 2857, 2359, 1727, 1513, 1472, 1464, 1458, 
1385, 1374, 1363, 1304, 1247, 1164, 1125, 1103, 1024, 985, 928, 825, 805, 783, 779, 762, 742, 724, 651; 
HR-ESI-MS calc. 832.5937 for C47H86NO7Si2+, [M+NH4]+, found 832.5946. 
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(6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6S)-2,2-di-tert-butyl-6-(hydroxymethyl)-1,3,2-dioxasilinan-4-
yl)-4-methylhept-4-en-2-yl)-7,9-dimethyl-6-((triethylsilyl)oxy)oxacyclododec-9-en-2-one (12).  
To a solution of PMB-protected alcohol 11 (72 mg, 88 μmol) in CH2Cl2/water (5:1, 6 mL) was added DDQ 
(27 mg, 119 μmol) at ambient temperature. The brown two-layer system was stirred at ambient 
temperature for 2 h. The reaction was quenched by adding sat. aq. NaHCO3-solution (10 mL) and little 
water. EtOAc (20 mL) was added and the layers were separated. The aq. layer was extracted with EtOAc (2 
x 10 mL), the combined org. layers were washed with water (3 mL), brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification by flash column chromatography (n-hexane/EtOAc 
100:7) yielded 46 mg (75 %) of primary alcohol 12 as colorless oil. Rf (n-hexane/EtOAc 9:1) = 0.38; [α]D 25 
= −28.5° (c = 0.84, CHCl3); 1H-NMR (400 MHz, CDCl3):   4.98 – 4.90 (m, 2H), 4.83 (ddd, J = 11.8, 5.7, 3.0 Hz, 
1H), 4.14 – 4.07 (m, 1H), 3.75 (ddd, J = 11.5, 7.8, 1.9 Hz, 1H), 3.58 – 3.51 (m, 1H), 3.47 – 3.36 (m, 2H), 2.53 
– 2.26(m, 3H + OH), 2.09 (dd, J = 13.0, 5.4 Hz, 1H), 2.04 – 1.57 (m, 10H), 1.66 (s, 3H), 1.60 (d, J =1.0, 3H), 
1.48 – 1.33 (m, 3H), 1.02 (s, 9H), 1.02 – 0.97 (m, 6H), 0.99 (s, 9 H), 0.95 (t, J = 7.8 Hz, 9H), 0.85 (d, J = 6.6 
Hz, 3H), 0.60 (q, J = 7.8 Hz, 6H); 13C-NMR (100 MHz, CDCl3):  173.6, 137.5, 133.2, 129.4, 121.4, 77.8, 77.7, 
75.4, 74.7, 67.6, 45.4, 43.4, 40.6, 35.9, 35.8, 34.8, 33.5, 33.4, 29.5, 27.5 (3C), 27.1 (3C), 22.8, 21.8, 19.7, 18.7, 
16.8, 16.1, 15.6, 14.5, 7.0 (3C), 5.1 (3C); IR (film, CHCl3):  2956, 2933, 2876, 2858, 1728, 1473, 1458, 
1385, 1249, 1165, 1128, 1103, 1087, 1067, 1024, 985, 949, 927, 826, 764, 738, 650; HR-ESI-MS calc. 
717.4916 for C39H74NaO6Si2+, [M+Na]+, found 717.4918. 
 
 
 
((4S,6R)-2,2-di-tert-butyl-6-((2R,6S,E)-6-((2R,7S,8S,E)-5,7-dimethyl-12-oxo-8-((triethylsilyl)oxy)-
oxacyclododec-4-en-2-yl)-4-methylhept-3-en-2-yl)-1,3,2-dioxasilinan-4-yl)methyl acetate (13).  
To a solution of primary alcohol 12 (46 mg, 66 μmol) in CH2Cl2 (2.0 mL) were added DIPEA (0.11 mL, 662 
μmol), acetic anhydride (19 μL, 199 μmol) and a catalytic amount of DMAP (ca. 2 mg) at ambient 
temperature. The reaction was stirred at ambient temperature for 30 min before additional CH2Cl2 (10 
mL) was added and the org. layer was washed with sat. aq. NaHCO3-solution (5 mL). The aq. layer was 
extracted with CH2Cl2 (2 x 5 mL). The combined org. layers were dried over MgSO4 and concentrated 
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under reduced pressure. Purification by flash column chromatography (n-hexane/EtOAc 25:1) afforded 
49 mg (quant.) of acetylated alcohol 13 as colorless oil. Rf (n-hexane/ EtOAc 9:1) = 0.56; [α]D25 = −19.1° (c 
= 0.83, CHCl3); 1H-NMR (400 MHz, CDCl3):  4.97 (d, J = 9.7 Hz, 2H), 4.87 – 4.80 (m, 1H), 4.24 – 4.16 (m, 
1H), 4.07 – 3.99 (m, 2H), 3.74 (ddd, J = 11.1, 7.4, 1.8 Hz, 1H), 3.38 (d, J = 9.3 Hz, 1H), 2.53 – 2.31 (m, 3H), 
2.12 (dd, J = 13.1, 4.4 Hz, 1H), 2.06 (s, 3H), 2.05 – 1.58 (m, 10H), 1.66 (s, 3H), 1.60 (d, J = 1.0 Hz, 3H), 1.50 – 
1.38 (m, 3H), 1.00 (d, J = 6.2 Hz, 3H), 1.00 (s, 9H), 0.99 (d, J = 3.6 Hz, 3H), 0.98 (s, 9H), 0.95 (t, J = 7.8 Hz, 
9H), 0.84 (d, J = 6.8 Hz, 3H), 0.60 (q, J = 7.8 Hz, 6H); 13C-NMR (100 MHz, CDCl3):   173.5, 170.9, 137.4, 
133.1, 129.4, 121.4, 77.8, 77.5, 75.6, 72.0, 68.6, 45.4, 43.2, 40.4, 36.2, 35.9, 35.0, 33.5, 33.5, 30.0, 27.5 (3C), 
27.0 (3C), 22.7, 21.8, 20.9, 19.7, 18.7, 16.6, 16.2, 15.7, 14.5, 7.0 (3C), 5.1 (3C); IR (film, CHCl3):  2956, 
2932, 2876, 2858, 1742, 1728, 1473, 1459, 1385, 1365, 1245,1163, 1131, 1109, 1084, 1069, 1040, 1024, 
985, 905, 825, 763, 742, 723, 651; HR-ESI-MS calc. 759.5022 for C41H76NaO7Si2+, [M+Na]+, found 759.5003. 
 
 
 
((4S,6R)-2,2-di-tert-butyl-6-((2R,6S,E)-6-((2R,7S,8S,E)-8-hydroxy-5,7-dimethyl-12-oxooxacyclo-
dodec-4-en-2-yl)-4-methylhept-3-en-2-yl)-1,3,2-dioxasilinan-4-yl)methyl acetate (14).  
To a solution of TES-protected alcohol 13 (49 mg, 66 μmol) in THF (2.0 mL) were added H2O (0.66 mL) 
and HOAc (0.66 mL) at ambient temperature.The reaction was stirred at ambient temperature for 6 h. 
Subsequently, sat. aq. NaHCO3-solution (20 mL) was added until the evolution of gas stopped. EtOAc (20 
mL) was added and the layers were separated. The aq. layer was extracted with EtOAc (2 x 10 mL). The 
combined org. layers were washed with sat. aq. NaHCO3-solution, brine, dried over MgSO4 and 
concentrated under reduced pressure. Purification by flash column chromatography (n-hexane/ EtOAc 
20:1 to 3:1, 0.5 % MeOH) yielded 37 mg (89 %) of secondary alcohol 14 as colorless oil. Rf (n-
hexane/EtOAc 2:1) = 0.37; [α]D 25 = −32.1° (c = 0.56, CHCl3); 1H-NMR (400 MHz, CDCl3):   5.06 – 4.93 (m, 
3H), 4.24 – 4.16 (m, 1H), 4.04 (d, J = 4.9 Hz, 2H), 3.71 (ddd, J = 11.3, 7.5, 1.7 Hz, 1H), 3.55 – 3.48 (m, 1H), 
2.46 (dt, J = 14.2, 11.5 Hz, 1H), 2.40 – 2.20 (m, 3H), 2.15 – 2.04 (m, 2H), 2.07 (s, 3H), 2.02 – 1.82 (m, 4H), 
1.77 – 1.51 (m, 5H), 1.61 (s, 3H), 1.60 (d, J = 1.2 Hz, 3H), 1.46 (dt, J = 13.8, 11.3 Hz, 1H), 1.37 – 1.27 (m, 1H), 
1.01 (d, J = 6.5 Hz, 3H), 1.01 (s, 9H) 0.98 (s, 9H), 0.95 (d, J = 6.8 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H); 13CNMR 
(100 MHz, CDCl3):   175.2, 171.0, 137.1, 133.0, 129.5, 123.0, 77.5, 76.7, 72.0, 70.8, 68.6, 45.4, 43.2, 40.5, 
36.1, 35.1, 31.5, 34.9, 34.2, 30.1, 27.5 (3C), 27.0 (3C), 22.7, 20.9, 20.4, 19.7, 16.6, 16.4, 16.2, 15.9, 14.8; IR 
(film, CHCl3):  2960, 2932, 2858, 1743, 1733, 1727, 1715, 1474, 1464, 1456, 1386, 1364, 1243, 1156, 
1134, 1107, 1041, 1012, 985, 962, 940, 905, 826, 793, 651; HR-ESI-MS calc. 623.4338 for C35H63O7Si+, 
[M+H]+, found 623.4339. 
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(2E,8E,10E,12S,13S,15S)-(6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6S)-6-(acetoxymethyl)-2,2-di-tert-
butyl-1,3,2-dioxasilinan-4-yl)-4-methylhept-4-en-2-yl)-7,9-dimethyl-2-oxooxacyclododec-9-en-6-
yl 12,13,15-tris((tert-butyldimethylsilyl)oxy)-4,6,10-trimethylhexadeca-2,4,6,8,10-pentaenoate 
(16). 
To a solution of acid 151 (98 mg, 0.14 mmol) in THF (2.0 mL) was added DIPEA (0.10 mL, 0.58 mmol), 
Cl3C6H2COCl (45 μL, 0.29 mmol) and DMAP (53 mg, 0.43 mmol) at ambient temperature. After a few 
seconds the bright yellow solution became turbid. After 10 min alcohol 14 (42 mg, 67 μmol) in THF (2.0 
mL) was added. The yellow suspension was stirred at ambient temperature for 16½ h protected from 
light. The reaction was quenched by adding sat. aq. NaHCO3-solution (10 mL) and EtOAc (15 mL), the 
layers were separated and the aq. layer was extracted with EtOAc (2 x 10 mL). The combined org. layers 
were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by 
flash column chromatography (1. n-hexane/EtOAc 12:1 to 4:1 to 4:1, 0.25 % HCOOH; 2. n-hexane/EtOAc 
25:1 to 9:1) yielded 76 mg (88 %) of ester 16 as an inseparable mixture of isomers (E-4’,5’/Z- 4’,5’ 4.3:1) 
as a yellow oil and 38 mg (39 %) of starting acid 14. Rf (n-hexane/EtOAc 9:1) = 0.35; Z-4’,5’ isomer: 1H-
NMR (400 MHz, acetone-d6):   7.93 (d, J = 15.3 Hz, 1H), 6.74 – 6.61 (m, 1H), 6.47 (d, J = 19.6 Hz, 1H), 6.34 
(s, 1H), 6.19 (d, J = 10.6 Hz, 1H), 5.93 (d, J = 15.3 Hz, 1H), 5.71 – 5.64 (m, 1H), 5.15 – 5.05 (m, 2H), 4.90 
(ddd, J = 11.8, 5.1, 2.8 Hz, 1H), 4.77 – 4.68 (m, 1H), 4.58 (dd, J = 9.2, 3.4 Hz, 1H), 4.36 – 4.27 (m, 1H), 4.09 – 
3.94 (m, 3H), 3.86 (ddd, J = 11.1, 7.6, 1.7 Hz, 1H), 3.82 – 3.75 (m, 1H), 2.59 – 2.29 (m, 3H), 2.29 – 1.77 (m, 
10H), 2.05 (s, 3H), 2.02 (s, 3H), 1.98 (d, J = 1.0 Hz, 3H), 1.94 (d, J = 1.0 Hz, 3H), 1.77 – 1.47 (m, 6H), 1.71 (s, 
3H), 1.67 (d, J = 1.04 Hz, 3H), 1.18 (d, J = 5.9 Hz, 3H), 1.06 (d, J = 6.6 Hz, 3H), 1.04 (s, 9H), 1.02 (s, 9H), 0.94 
– 0.87 (m, 33H), 0.37 −0.18 (m, 18H). 13C-NMR (100 MHz, acetone-d6):  173.3, 170.8, 166.9, 143.0, 141.8, 
140.0, 137.4, 135.7, 135.0, 135.0, 134.7, 134.3, 132.0, 130.2, 125.3, 123.8, 119.7, 79.2, 78.6, 76.2, 74.4, 
73.2, 72.2, 69.0, 66.8, 46.3, 44.3, 44.1, 41.4, 36.9, 36.0, 35.5, 32.9, 31.4, 29.6, 27.9 (3C), 27.6 (3C), 26.4 (3C), 
26.3 (3C), 26.3 (3C), 24.3, 23.3, 21.1, 20.8, 20.8, 20.5, 20.3, 18.7, 18.6, 18.6, 17.7, 17.0, 16.4, 15.9, 15.1, 13.9, 
−3.8, −3.9, −3.9, −4.1, −4.3, −4.4; E-4’,5’ isomer: 1H-NMR (400 MHz, acetone-d6):   7.37 (d, J = 15.5 Hz, 
1H), 6.74 – 6.61 (m, 1H), 6.48 (d, J = 14.5 Hz, 1H), 6.48 (s, 1H), 6.39 (d, J = 11.7 Hz, 1H), 5.89 (d, J = 15.5 Hz, 
1H), 5.71 – 5.64 (m, 1H), 5.15 – 5.05 (m, 2H), 4.90 (ddd, J = 11.8, 5.1, 2.8 Hz, 1H), 4.77 – 4.68 (m, 1H), 4.58 
(dd, J = 9.2, 3.4 Hz, 1H), 4.36 – 4.27 (m, 1H), 4.09 – 3.94 (m, 3H), 3.86 (ddd, J = 11.1, 7.6, 1.7 Hz, 1H), 3.82 – 
3.75 (m, 1H), 2.59 – 2.29 (m, 3H), 2.29 – 1.77 (m, 10H), 2.09 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.94 (d, J = 
1.0 Hz, 3H), 1.77 – 1.47 (m, 6H), 1.71 (s, 3H), 1.67 (d, J = 1.04 Hz, 3H), 1.18 (d, J = 5.9 Hz, 3H), 1.06 (d, J = 
6.6 Hz, 3H), 1.04 (s, 9H), 1.02 (s, 9H), 0.94 – 0.87 (m, 33H), 0.37 – −0.18 (m, 18H); 13C-NMR (100 MHz, 
Appendix 
 
143 
acetone-d6):  173.3, 170.8, 166.9, 151.2, 144.3, 140.3, 137.4, 136.2, 135.7, 135.4, 135.0, 134.3, 133.2, 
130.2, 125.3, 123.8, 117.5, 79.2, 78.6, 76.2, 74.4, 73.2, 72.2, 69.0, 66.8, 46.3, 44.3, 44.1, 41.4, 36.9, 36.0, 
35.5, 32.9, 31.4, 29.6, 27.9 (3C), 27.6 (3C), 26.4 (3C), 26.3 (3C), 26.3 (3C), 24.3, 23.3, 20.8, 20.8, 20.5, 20.3, 
18.7, 18.6, 18.6, 17.2, 17.0, 16.4, 15.9, 15.1, 14.4, 13.9, −3.8, −3.9, −3.9, −4.1, −4.3, −4.4; IR (film, acetone): 
 2955, 2931, 2895, 2857, 1740, 1728, 1707, 1650, 1604, 1509, 1472, 1463, 1442, 1386, 1362, 1304, 
1284, 1252, 1215, 1167, 1157, 1133, 1093, 1061, 1036, 985, 962, 938, 927, 835, 810, 807, 771, 759; HR-
ESI-MS calc. 1283.8763 for C72H131O11Si4+, [M+H]+, found 1283.8764. 
 
 
 
(2E,8E,10E,12S,13S,15S)-(6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6S)-2,2-di-tert-butyl-6- 
(hydroxymethyl)-1,3,2-dioxasilinan-4-yl)-4-methylhept-4-en-2-yl)-7,9-dimethyl-2-
oxooxacyclododec-9-en-6-yl-12,13,15-tris((tert-butyldimethylsilyl)oxy)-4,6,10-trimethyl 
hexadeca-2,4,6,8,10-pentaenoate (17).  
To a solution of acetylated alcohol 16 (76 mg, 59 μmol) in MeOH (4 mL) was added K2CO3 (41 mg, 296 
μmol) at ambient temperature. The solution was stirred at ambient temperature for 180 min. Aq. buffer 
solution (pH = 7.2, 10 mL) and EtOAc (15 mL) were added. The layers were separated and the aq. layer 
was extracted with EtOAc (1 x 5 mL). The combined org. layers were washed with brine, dried over MgSO4 
and concentrated under reduced pressure. Purification by flash column chromatography (n-hexane/EtOAc 
20:1 to 7:3) furnished 66 mg (90 %) of primary alcohol 17 as yellow oil as an inseparable mixture of 
isomers (E-4’,5’/Z-4’,5’ 4:1). Rf (n-hexane/EtOAc 4:1) = 0.58; Z- 4’,5’ isomer: 1H-NMR (400 MHz, acetone-
d6):  7.93 (d, J = 15.5 Hz, 1H), 6.72 – 6.62 (m, 1H), 6.53 – 6.29 (m, 2H), 6.19 (d, J = 10.7 Hz, 1H), 5.93 (d, J = 
15.5 Hz, 1H), 5.70 – 5.64 (m, 1H), 5.13 (d, J = 10.4 Hz, 1H), 5.07 (d, J = 9.9 Hz, 1H), 4.94 – 4.84 (m, 1H), 4.75 
– 4.69 (m, 1H), 4.58 (dd, J = 9.2, 3.4 Hz, 1H), 4.14 – 4.06 (m, 1H), 4.01 (dd, J = 12.3, 6.3 Hz, 1H), 3.90 – 3.73 
(m, 2H), 3.59 – 3.48 (m, 2H, OH), 3.47 – 3.40 (m, 1H), 2.61 – 2.36 (m, 3H), 2.22 – 1.77 (m, 19H), 1.77 – 1.52 
(m, 5H), 1.71 (s, 3H), 1.66 (d, J = 1.2 Hz, 3H), 1.44 (ddd, J =14.1, 11.4, 11.4 Hz, 1H), 1.17 (d, J = 6.0 Hz, 3H), 
1.05 (d, J = 5.3 Hz, 3H), 1.04 (s, 9H), 1.00 (s, 9H), 0.96 – 0.79 (m, 33H), 0.24 – −0.11 (m, 18H); 13C-NMR 
(100 MHz, acetone-d6):  173.3, 166.8, 143.0, 141.8, 140.0, 137.3, 135.7, 135.1, 134.7, 134.3, 133.9, 132.0, 
130.4, 125.2, 123.8, 119.7, 79.2, 78.8, 76.2, 76.2, 74.3, 72.1, 68.0, 66.7, 46.3, 44.3, 44.0, 41.4, 37.3, 36.0, 
35.4, 32.6, 31.3, 29.8, 28.0 (3C), 27.6 (3C), 26.4 (3C), 26.3 (3C), 26.3 (3C), 24.3, 23.4, 21.2, 20.8, 20.6, 20.3, 
18.7, 18.6 (2C), 17.7, 17.2, 16.3, 15.9, 15.0, 13.9, −3.7, −3.8, −3.9, −4.1, −4.2, −4.3; E-4’,5’ isomer: 1H-NMR 
(400 MHz, acetone-d6):  7.37 (d, J = 15.0 Hz, 1H), 6.72 – 6.62 (m, 1H), 6.53 – 6.29 (m, 3H), 5.89 (d, J = 15.7 
Hz, 1H), 5.70 – 5.64 (m, 1H), 5.13 (d, J = 10.4 Hz, 1H), 5.07 (d, J = 9.9 Hz, 1H), 4.94 – 4.84 (m, 1H), 4.75 – 
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4.69 (m, 1H), 4.58 (dd, J = 9.2, 3.4 Hz, 1H), 4.14 – 4.06 (m, 1H), 4.01 (dd, J = 12.3, 6.3 Hz, 1H), 3.90 – 3.73 
(m, 2H), 3.59 – 3.48 (m, 2H, OH), 3.47 – 3.40 (m, 1H), 2.61 – 2.36 (m, 3H), 2.22 – 1.77 (m, 16H), 2.09 (s, 
3H), 1.77 – 1.52 (m, 5H), 1.71 (s, 3H), 1.66 (d, J = 1.2 Hz, 3H), 1.44 (ddd, J =14.1, 11.4, 11.4 Hz, 1H), 1.17 (d, 
J = 6.0 Hz, 3H), 1.05 (d, J = 5.3 Hz, 3H), 1.04 (s, 9H), 1.00 (s, 9H), 0.96 – 0.79 (m, 33H), 0.24 – −0.11 (m, 
18H); 13C-NMR (100 MHz, acetone-d6):  173.3, 166.8, 151.2, 144.3, 140.3, 137.3, 136.2, 135.7, 135.3, 
134.9, 133.9, 133.2, 130.4, 125.2, 123.8, 117.4, 79.2, 78.8, 76.2, 76.2, 74.3, 72.1, 68.0, 66.7, 46.3, 44.3, 44.0, 
41.4, 37.3, 36.0, 35.4, 32.6, 31.3, 29.8, 28.0 (3C), 27.6 (3C), 26.4 (3C), 26.3 (3C), 26.3 (3C), 24.3, 23.4, 20.8, 
20.6, 20.3, 18.7, 18.6 (2C), 17.2, 17.2, 16.3, 15.9, 15.0, 14.4, 13.9, −3.8, −3.9, −3.9, −4.1, −4.3, −4.3; IR (film, 
acetone):  2956, 2929, 2857, 1709, 1614, 1472, 1386, 1252, 1156, 1131, 1093, 1065, 983, 960, 898, 835, 
774, 652; HR-ESI-MS calc. 1258.8923 for C70H132NO10Si4+, [M+NH4]+, found 1258.8931. 
 
 
 
(2E,8E,10E,12S,13S,15S)-(6S,7S,12R,E)-12-((2S,6R,E)-6-((4R,6S)-6-(12-amino-3-oxo-2,7,10-trioxa-
4-azadodecyl)-2,2-di-tert-butyl-1,3,2-dioxasilinan-4-yl)-4-methylhept-4-en-2-yl)-7,9-dimethyl-2-
oxooxacyclododec-9-en-6-yl-12,13,15-tris((tert-butyldimethylsilyl)oxy)-4,6,10-
trimethylhexadeca-2,4,6,8,10-pentaenoate (18).  
To a solution of primary alcohol 17 (15 mg, 12.1 μmol) in THF (1.5 mL) was added CDI (7.8 mg, 48 μmol) 
at ambient temperature. The solution was stirred at ambient temperature for 4¾ h. Additional CDI (2 x 
7.8 mg, 2 x 48 μmol) was added after 1 h and 2 h. Water (4.4 μL, 242 μmol) was added and the solution 
stirred at ambient temperature for 30 min. 1,2-bis(2-aminoethoxy)ethane (30 μL, 302 μmol) was added 
and the resulting turbid solution was stirred at ambient temperature for 90 min while it turned clear 
again. Water (10 mL) and CH2Cl2 (15 mL) were added, the layers were separated and the org. layer was 
extracted with CH2Cl2 (3 x 5 mL). The combined org. layers were washed with water (5 mL) and brine (3 
mL), dried over MgSO4 and concentrated under reduced pressure. Purification by flash column 
chromatography (CH2Cl2 to CH2Cl2/MeOH, 50:1 to 9:1) gave 15.2 mg (87 %) of amino carbamate 18 as an 
inseparable mixture of isomers (E-4’,5’/Z-4’,5’ 3:1) obtained as intensely colored yellow oil. Rf 
(CH2Cl2/MeOH/Et3N 90:10:1) = 0.17; Z-4’,5’ isomer: 1H-NMR (400 MHz, methanol-d4):  7.93 (d, J = 15.6 
Hz, 1H), 6.71 – 6.50 (m, 1H), 6.48 – 6.29 (m, 2H),6.13 (d, J = 11.3 Hz, 1H), 5.92 (d, J = 15.6 Hz, 1H), 5.73 – 
5.52 (m, 1H), 5.09 (d, J = 10.1 Hz, 1H), 5.03 (d, J = 9.7 Hz, 1H), 4.97 – 4.81 (m, 1H), 4.80 – 4.68 (m, 1H), 4.53 
(dd, J = 9.1, 3.4 Hz, 1H), 4.36 – 4.17 (m, 1H), 4.08 (dd, J = 11.1, 3.9 Hz, 1H), 4.03 – 3.91 (m, 2H), 3.89 – 3.70 
(m, 2H), 3.69 – 3.41 (m, 8H), 3.33 – 3.27 (m, 3H), 2.85 (t, J = 5.2 Hz, 2H), 2.62 – 2.29 (m, 3H), 2.17 – 1.42 
(m, 15H), 2.01 (s, 3H), 1.97 (s, 3H), 1.89 (s, 3H), 1.71 (s, 3H), 1.65 (s, 3H), 1.17 (d, J = 6.0 Hz, 3H), 1.10 – 
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0.96 (m, 3H), 1.03 (s, 9H), 1.01 (s, 9H), 0.96 – 0.81 (m, 33H), 0.16 – −0.05 (m, 18H); 13C-NMR (100 MHz, 
methanol-d4):  175.2, 168.6, 158.9, 144.3, 142.7, 140.2, 138.1, 136.1, 135.7, 135.3, 134.9, 134.6, 132.5, 
130.7, 125.5, 124.0, 119.3, 80.1, 79.1, 77.3, 74.8, 74.1, 72.6, 72.4, 71.6, 71.3, 71.1, 70.1, 67.4, 46.7, 44.9, 
44.3, 41.8 (2C), 41.7, 37.4, 36.4, 35.8, 33.5, 31.8, 29.7, 28.1 (3C), 27.7 (3C), 26.5 (3C), 26.5 (3C), 26.4 (3C), 
24.3, 23.7, 21.2, 21.0, 20.6, 20.4, 19.0, 19.0, 18.9, 17.7, 17.1, 16.3, 16.0, 15.1, 14.0, −3.8, −3.8, −3.9, −4.1, 
−4.2, −4.3; E-4’,5’ isomer: 1H-NMR (400 MHz, methanol-d4):  7.38 (d, J = 15.5 Hz, 1H), 6.71 – 6.50 (m, 1H), 
6.48 – 6.29 (m, 3H), 5.88 (d, J = 15.5 Hz, 1H), 5.73 – 5.52 (m, 1H), 5.09 (d, J = 10.1 Hz, 1H), 5.03 (d, J = 9.7 
Hz, 1H), 4.97 – 4.81 (m, 1H), 4.80 – 4.68 (m, 1H), 4.53 (dd, J = 9.1, 3.4 Hz, 1H), 4.36 – 4.17 (m, 1H), 4.08 (dd, 
J = 11.1, 3.9 Hz, 1H), 4.03 – 3.91 (m, 2H), 3.89 – 3.70 (m, 2H), 3.69 – 3.41 (m, 8H), 3.33 – 3.27 (m, 3H), 2.85 
(t, J = 5.2 Hz, 2H), 2.62 – 2.29 (m, 3H), 2.17 – 1.42 (m, 15H), 2.09 (s, 3H), 2.05 (s, 3H), 1.89 (s, 3H), 1.71 (s, 
3H), 1.65 (s, 3H), 1.17 (d, J = 6.0 Hz, 3H), 1.10 – 0.96 (m, 3H), 1.03 (s, 9H), 1.01 (s, 9H), 0.96 – 0.81 (m, 
33H), 0.16 – −0.05 (m, 18H); 13C-NMR (100 MHz, methanol-d4):  175.2, 168.6, 158.9, 152.4, 145.3, 140.6, 
138.1, 136.7, 136.1, 136.1, 135.3, 134.6, 133.5, 130.7, 125.5, 124.0, 117.1, 80.1, 79.1, 77.3, 74.8, 74.1, 72.6, 
72.4, 71.6, 71.3, 71.1, 70.1, 67.4, 46.7, 44.9, 44.3, 41.8 (2C), 41.7, 37.4, 36.4, 35.8, 33.5, 31.8, 29.7, 28.1 (3C), 
27.7 (3C), 26.5 (3C), 26.5 (3C), 26.4 (3C), 24.3, 23.7, 21.2, 20.6, 20.4, 19.0, 19.0, 18.9, 17.2, 17.1, 16.3, 16.0, 
15.1, 14.4, 14.0, −3.8, −3.8, −3.9, −4.1, −4.2, −4.3; IR (film, MeOH):  2956, 2928, 2856, 2360, 2344, 2328, 
1725, 1616, 1559, 1539, 1472, 1463, 1386, 1362, 1297, 1250, 1156, 1131, 1094, 1004, 982, 961, 938, 897, 
835, 773, 651; HR-ESI-MS calc. 1415.9662 for C77H143N2O13Si4+, [M+H]+, found 1415.9636. 
 
 
 
(2E,8E,10E,12S,13S,15S)-(6S,7S,12R,E)-12-((13S,15R,16R,20S,E)-1-amino-13,15-dihydroxy-16,18-
dimethyl-10-oxo-3,6,11-trioxa-9-azahenicos-17-en-20-yl)-7,9-dimethyloxooxacyclododec-9-en-6-
yl-12,13,15-trihydroxy-4,6,10-trimethylhexadeca-2,4,6,8,10-pentaenoate (19). To a solution of silyl-
protected pentol 18 (19.1 mg, 13.5 μmol) in THF (1.5 mL) was added TBAF (1 M in THF, 162 μL, 162 
μmol) at ambient temperature. The solution was stirred at ambient temperature for 2 h. Subsequently, 
NH4F (25 mg, 674 μmol) was added and the solution was stirred at ambient temperature for 17 h. Sat. aq. 
NH4Cl-solution (3 mL), water (5 mL) and CH2Cl2 (10 mL) were added, the layers were separated and the 
aq. layer was extracted with CH2Cl2/MeOH 100:1 (5 x 5 mL). The combined org. layers were washed with 
sat. aq. NH4Cl-solution (3 mL) and brine, dried over MgSO4 and concentrated under reduced pressure. 
Purification by FC (CH2Cl2/MeOH 20:1 to 10:1 to 4:1) gave 15.3 mg (quant) of pentol 19 as an inseparable 
mixture of isomers (E-4’,5’/Z-4’,5’ 3:1) obtained as strongly colored yellow oil. Rf (CH2Cl2/MeOH 4:1) = 
0.20; Z-4’,5’ isomer: 1H-NMR (400 MHz, methanol-d4):   7.91 (d, J = 15.6 Hz, 1H), 6.70 – 6.50 (m, 1H), 6.50 
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– 6.27 (m, 2H), 6.11 (d, J = 10.9 Hz, 1H), 5.94 (d, J = 15.6 Hz, 1H), 5.60 – 5.54 (m, 1H), 5.12 (d, J = 11.1 Hz, 
1H), 5.01 (d, J = 9.5 Hz, 1H), 4.95 – 4.89 (m, 1H, obscured by H2O signal), 4.78 – 4.69 (m, 1H), 4.43 – 4.29 
(m, 1H), 4.11 – 3.93 (m, 4H), 3.77 – 3.41 (m, 10H), 3.40 – 3.24 (m, 2H, obscured by solvent signal), 3.15 
(dd, J = 12.0, 6.9 Hz, 2H), 2.61 – 2.31 (m, 3H), 2.16 – 1.43 (m, 16H), 2.00 (s, 3H), 1.97 (s, 3H), 1.93 (s, 3H), 
1.71 (s, 3H), 1.65 (s, 3H), 1.23 – 1.11 (m, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.94 – 0.87 (m, 6H); 13C-NMR (100 
MHz, methanol-d4):   175.3, 168.6, 159.0, 144.4, 142.6, 140.0, 138.6, 138.0, 135.6, 135.0, 134.4, 133.6, 
132.6, 131.1, 125.8, 124.0, 119.3, 80.1, 77.5, 75.6, 75.1, 72.7, 71.3, 71.3, 71.0, 70.3, 69.6, 67.8, 67.5, 46.7, 
44.7, 42.0, 41.6, 40.7 (2C), 39.0, 36.4, 35.9, 33.4, 31.8, 29.9, 23.5, 21.2, 20.9, 20.4, 17.6, 17.2, 16.2, 15.9, 
15.0, 13.4; E-4’,5’-isomer: 1H-NMR (400 MHz, methanol-d4):   7.38 (d, J = 15.3 Hz, 1H), 6.70 – 6.50 (m, 
1H), 6.50 – 6.27 (m, 3H), 5.89 (d, J = 15.3 Hz, 1H), 5.60 – 5.54 (m, 1H), 5.12 (d, J = 11.1 Hz, 1H), 5.01 (d, J = 
9.5 Hz, 1H), 4.95 – 4.89 (m, 1H, obscured by H2O signal), 4.78 – 4.69 (m, 1H), 4.43 – 4.29 (m, 1H), 4.11 – 
3.93 (m, 4H), 3.77 – 3.41 (m, 10H), 3.40 – 3.24 (m, 2H, obscured by solvent signal), 3.15 (dd, J = 12.0, 6.9 
Hz, 2H), 2.61 – 2.31 (m, 3H), 2.16 – 1.43 (m, 16H), 2.08 (s, 3H), 2.05 (s, 3H), 1.93 (s, 3H), 1.71 (s, 3H), 1.65 
(s, 3H), 1.23 – 1.11 (m, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.94 – 0.87 (m, 6H); 13C-NMR (100 MHz, methanol-d4): 
  175.3, 168.7, 159.0, 152.3, 145.1, 140.4, 138.6, 138.0, 136.5, 135.9, 134.4, 133.6, 133.5, 131.1, 125.8, 
124.0, 117.1, 80.1, 77.5, 75.6, 75.1, 72.7, 71.3, 71.3, 71.0, 70.3, 69.6, 67.8, 67.5, 46.7, 44.7, 42.0, 41.6, 40.7 
(2C), 39.0, 36.4, 35.9, 33.4, 31.8, 29.9, 23.5, 21.2, 20.4, 17.2, 17.1, 16.2, 15.9, 15.0, 14.3, 13.4; IR (film, 
MeOH):  3339, 2970, 1697, 1647, 1559, 1456, 1302, 1270, 1251, 1159, 1131, 1089, 982, 652; HR-ESI-MS 
calc. 955.5866 for C51H84N2NaO13+, [M+Na]+, found 955.5874. 
 
 
 
 
(2E,8E,10E,12S,13S,15S)-(6S,7S,12R,E)-12-((19S,21R,22R,26S,E)-19,21-dihydroxy-22,24-dimethyl-
5,16-dioxo-1-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-9,12,17-trioxa-6,15-
diazaheptacos-23-en-26-yl)-7,9-dimethyl-2-oxooxacyclododec-9-en-6-yl 12,13,15-trihydroxy-
4,6,10-trimethylhexadeca-2,4,6,8,10-pentaenoate (3). 
To a solution of (+)-biotin (11.3 mg, 46 μmol) in DMF (2.0 mL) were added DIPEA (26.7 μL, 154 μmol) and 
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBop; 32 mg, 62 μmol) at 
ambient temperature. The colorless solution was stirred at ambient temperature for 20 min. The activated 
biotin (11.6 μmol) in DMF (0.5 mL; 25 % of the above solution) was transferred dropwise to a flask 
charged with amine 19 (7.2 mg, 7.7 μmol). The yellow solution was stirred at ambient temperature for 30 
min. Sat. aq. NH4Cl-solution (3 mL), water (10 mL) and EtOAc (10 mL) were added. The layers were 
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separated and the aq. layer was extracted with and EtOAc (3 x 5 mL). The combined org. extracts were 
washed with sat. aq. NH4Cl-solution (3 mL), sat. aq. NaHCO3-solution (3 x 2 mL) and brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification by flash column chromatography (CH2Cl2 to 
CH2Cl2/MeOH, 50:1 to 10:1 then 5:1) yielded 5.6 mg (63 %, HPLC purity: >79 %) of amide 3 as an 
inseparable mixture of isomers (E-4’,5’/Z-4’,5’/minor isomers 63:29:8) as a yellow oil. Rf (CH2Cl2/MeOH 
85:15) = 0.38; Z-4’,5’ isomer: 1H-NMR (400 MHz, methanol-d4):  7.92 (d, J = 15.6 Hz, 1H), 6.71 – 6.58 (m, 
1H), 6.49 –6.28 (m, 2H), 6.12 (d, J = 10.6 Hz, 1H), 5.94 (d, J = 15.6 Hz, 1H), 5.61 – 5.54 (m, 1H), 5.13 (d, J = 
10.4 Hz, 1H), 5.01 (d, J = 9.4 Hz, 1H), 4.96 – 4.80 (m, 1H), 4.79 – 4.67 (m, 1H), 4.49 (dd, J = 7.8, 4.9 Hz, 1H), 
4.35 – 4.25 (m, 2H), 4.16 – 3.91 (m, 4H), 3.68 – 3.42 (m, 10H), 3.41 – 3.28 (m, 4H), 3.26 – 3.14 (m, 1H), 2.93 
(dd, J = 12.8, 5.0 Hz, 1H), 2.71 (d, J = 12.7 Hz, 1H), 2.60 – 2.32 (m, 3H), 2.22 (t, J = 7.4 Hz, 2H), 2.18 – 1.89 
(m, 7H), 2.01 (s, 3H), 1.97 (s, 3H), 1.92 (s, 3H), 1.89 – 1.36 (m, 15H), 1.71 (s, 3H), 1.65 (s, 3H), 1.17 (d, J = 
6.1 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.96 – 0.82 (m, 6H); 13C-NMR (100 MHz, methanol-d4):  176.2, 175.3, 
168.7, 166.1, 159.0, 144.4, 142.6, 140.1, 138.3, 138.4, 135.5, 135.2, 134.4, 133.8, 132.6, 131.2, 125.7, 124.1, 
119.3, 80.1, 77.6, 75.6, 74.9, 72.6, 71.3, 71.3, 71.0, 70.7, 70.3, 69.7, 67.4, 63.4, 61.6, 57.0, 46.7, 44.7, 42.3, 
41.7, 41.1, 40.8, 40.3, 39.0, 36.8, 36.4, 35.9, 33.4, 31.8, 30.0, 29.8, 29.5, 26.9, 23.4, 21.2, 20.9, 20.4, 17.6, 
17.2, 16.3, 16.0, 15.1, 13.4; E-4’,5’ isomer: 1H-NMR (400 MHz, methanol-d4):  7.38 (d, J = 15.4 Hz, 1H), 
6.71 – 6.58 (m, 1H), 6.49 –6.28 (m, 3H), 5.89 (d, J = 15.4 Hz, 1H), 5.61 – 5.54 (m, 1H), 5.13 (d, J = 10.4 Hz, 
1H), 5.01 (d, J = 9.4 Hz, 1H), 4.96 – 4.80 (m, 1H), 4.79 – 4.67 (m, 1H), 4.49 (dd, J = 7.8, 4.9 Hz, 1H), 4.35 – 
4.25 (m, 2H), 4.16 – 3.91 (m, 4H), 3.68 – 3.42 (m, 10H), 3.41 – 3.28 (m, 4H), 3.26 – 3.14 (m, 1H), 2.93 (dd, J 
= 12.8, 5.0 Hz, 1H), 2.71 (d, J = 12.7 Hz, 1H), 2.60 – 2.32 (m, 3H), 2.22 (t, J = 7.4 Hz, 2H), 2.18 – 1.89 (m, 7H), 
2.08 (s, 3H), 2.05 (s, 3H), 1.92 (s, 3H), 1.89 – 1.36 (m, 15H), 1.71 (s, 3H), 1.65 (s, 3H), 1.17 (d, J = 6.1 Hz, 
3H), 0.99 (d, J = 6.6 Hz, 3H), 0.96 – 0.82 (m, 6H); 13C-NMR (100 MHz, methanol-d4):  176.2, 175.3, 168.7, 
166.1, 159.0, 152.3, 145.2, 140.5, 138.4, 138.4, 136.6, 135.8, 134.4, 133.8, 133.6, 131.2, 125.7, 124.1, 117.1, 
80.1, 77.6, 75.6, 74.9, 72.6, 71.3, 71.3, 71.0, 70.7, 70.3, 69.7, 67.4, 63.4, 61.6, 57.0, 46.7, 44.7, 42.3, 41.7, 
41.1, 40.8, 40.3, 39.0, 36.8, 36.4, 35.9, 33.4, 31.8, 30.0, 29.8, 29.5, 26.9, 23.4, 21.2, 20.4, 17.2, 17.1, 16.3, 
16.0, 15.1, 14.4, 13.4; IR (film, MeOH):  3323, 2928, 2361, 2338, 1700, 1555, 1454, 1256, 1159, 984, 846; 
HR-ESI-MS calc. 1181.6642 for C61H98N4NaO15S+ [M+Na]+, found 1181.6644. 
 
Determination of HPLC purity: Purity of 3 was determined by HPLC (Water Symmetry C18 column, 3.5 
μm, 4.6 x 100 mm, sample concentration: 1.0 mg/mL in MeOH, injection: 10 μL, eluent: H2O/CH3CN 90:10 
to 40:60, flow: 1 mL/min). 
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Supplementary Table 1 
 
μg/ml N (cpds)
< 0.001 1
0.001 - 0.01 8
0.01 - 0.1 11
0.1 - 1 20
1.0 - 10.0 14
> 10 31
total 85  
 
Number R1 R2 R3 R4 MIC range
Q203 (1) Cl H Et
2 Me H Me
3 H Me Me
4 Me H Me
5 Cl H Et
6 Br H Me
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7 Cl H Et
8 Cl H Et
9 Cl H Me
10 Me H Me
11 Br H Me
12 Cl H Me
13 Cl H Et
14 Me H Me
15 Br H Me
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16 H H Cl
17 H H Cl
18 H H Cl
19 Cl H Me
20 H H Cl
21 H H Cl
22 H H Me
23 Cl H Me
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24 H Me Me
25 H H Me
26 H H Cl
27 H H Me
28 H H Cl
29 H H Cl
30 Cl H Et
31 H H Cl
32 H Me Me
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33 H H Me
34 H H Cl
35 Br H Me
36 H H Me
37 H H Cl
38 H Me Me
39 H Me Me
40 H H Cl
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41 H H Me
42 H H Cl
43 H H Cl
44 H H Cl
45 H H Cl
46 Me H H
47 Me H H
48 Me H Me
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49 H H Me
50 H H Cl
51 H H Cl
52 H H Cl
53 H H Cl
54 H H Cl
55 Me H H
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56 H H Me
57 H H Cl
58 H H Cl
59 H H Cl
60 H H Cl
61 H H Cl
62 H Me Me
63 H H Me
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64 H H Me
65 H H p-Me-Ph
66 H H Cl
67 H H Cl
68 H H Cl
69 Cl H Me
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70 Me H m-Me-Ph
71 H H Cl
72 H H Cl
73 H H Cl
74 H H Cl
75 H Me Me
76 H H Cl
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77 H H Cl
78 H Me H
79 H H Me
80 H H Me
81 H H Me
82 H Me Me
83 H H Me
84
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Supplementary Table 1: List of tested IPA compounds ranked according to their 
activity against M. ulcerans.  
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